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1 Summary 
Cancer formation depends on the acquisition of multiple attributes via mutations of the genome to 
obtain replicative advantages of the tumor cells. Ras is a well-characterized small GTP-binding 
protein involved in signaling cascades regulating cell growth and proliferation. 25% of all human 
tumors contain a mutated form of Ras, making it an interesting target for cancer research. Ras 
activity is controlled via the bound G-nucleotide and the subcellular localization at the plasma 
membrane, achieved by posttranslational lipidation of the C-terminus of all four human isoforms of 
Ras. Correct subcellular compartmentalization of Ras is achieved by a cycle of constant 
de-palmitoylation catalyzed by Acyl Protein Thioesterase (APT), and re-palmitoylation at the golgi 
coupled to vesicular transport to the plasma membrane. Inhibition of APT disturbs this cycle, 
leading to entropy-driven random distribution of Ras over all cellular membranes resulting in a 
decreased local concentration at the plasma membrane and subsequently a reduced signaling 
activity of Ras.  
The suspected binding site of palmitoylated protein is a solvent-accessible hydrophobic tunnel 
where one wall is pre-formed by a “lid-loop”, a unique structural motif not described in the literature 
for other proteins so far. Different chemical classes of APT inhibitors have been described in the 
literature, but no structural data of APT-inhibitor complexes were available before. This thesis 
contains the first complex structures of S. cerevisiae APT with palmostatin B and palmostatin M 
and confirmed the hydrophobic tunnel as binding site of the aliphatic moiety. The β-lactone core of 
palmostatin inhibitors is covalently bound via a reversible ester to the active site serine. The 
activated epoxide of Cerulenin can also act as nucleophilic trap for the active site as seen in the 
structure of the covalent complex with human APT1. 2-Bromopalmitate (2BP) is a product mimetic 
of high similarity, and confirmed (as competitive inhibitor) binding inside the tunnel also for non-
covalently attached aliphatic fatty acids.  
The influence of the tunnel-forming lid-loop on substrate binding and catalytic activity of APT has 
not been described in the literature. APT belongs – like lipases and cutinases/esterases - to the 
family of α,β-hydrolases. The active site of lipases is covered by a flexible lid that is interfacially 
activated upon membrane attachment, while the active site of cutinases and esterases is open and 
accessible due to the lack of any covering loop. In this thesis, different lid-loop mutants of APT 
were crystallized and tested on biochemical activity. The proper formation of the wild type tunnel 
entrance was shown to be crucial for defined ligand binding and efficient catalysis as the tunnel 
entrance defines the insertion depth of the palmitate moiety, thus positioning the (thio-)ester at the 
active site serine. Mutations altering the shape of the tunnel entrance or increasing the flexibility of 
the lid-loop show less defined binding of 2BP (as seen in the crystal structures of the complexes 
with 2BP) that can serve as basis for a hypothetical unproductive binding mode of the test substrate 
PPTS. The lid-loop mutants having an altered tunnel entrance show a significantly reduced 
biochemical activity of about 25% compared to the wild type. A mutant lacking the complete lid-loop 
  Summary 
 2 
shows only 3% biochemical activity. Stopped Flow measurements corroborate that the tunnel 
formed by the lid-loop plays an essential role in defined binding of the palmitate moiety inside the 
hydrophobic tunnel. Lid-loop mutants also show a faster dissociation rate of the 2BP complex than 
the wild type of human APT1.  
Human APT1 forms a typical weak dimer in crystals (and potentially in solution), which blocks the 
potential secondary binding site for palmitoylated peptides and/or acyl chains. Attempts to free this 
binding site for structural investigation of a complex of human APT1 and a hexadecylated peptide 
were not fruitful so far. However, peptide binding could be shown indirectly via inhibition of 
biochemical activity of APT.  
APT crystallizes always with the lid-loop in the tunnel-forming conformation except for one structure 
of O. punctata APT that contains two of four monomers with an opened lid-loop. The potential of an 
opening lid-loop of APT (similar to the lid of lipases) was analyzed by comparing the available 
prediction of membrane insertion of different proteins, that predict APT to be weakly associated to 
membranes, a binding that is enhanced by the N-terminal palmitoylation of APT. Binding of the lid-
loop to the APT core protein is stronger than the membrane insertion of APT, but membrane 
binding strength could change if the lid-loop were in an open conformation. Thus, no reliable 
prediction on this hypothesis is possible at the moment.  
Combining activity assay data with the crystal structures, I conclude that for efficient substrate 
turnover the stability and shape of the entrance of the binding tunnel are of crucial importance. In 
contrast to lipases (where the lid regulates activity), the function of the lid-loop of APT is to form a 
stable tunnel to coordinate the substrate at the active site and thus stabilizing the transition state of 
catalysis. We therefore postulate that APTs are an individual structural and functional class 
between lipases and cutinases/esterases within the family of α,β-hydrolases.  
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2 Zusammenfassung 
Die Entstehung von Krebs ist abhängig vom Erwerben mehrerer vorteilhafter Fähigkeiten durch 
Mutationen des Erbguts. In 25% aller humanen Tumoren liegt eine Mutation von Ras vor, weshalb 
es ein interessantes Ziel in der Krebsforschung darstellt. Ras ist ein gut charakterisiertes kleines 
GTP-bindendes Protein, welches in verschiedenen Signalkaskaden zur Regulation von 
Zellwachstum und -teilung involviert ist. Die Aktivität von Ras wird durch das gebundene G-
Nukleotide sowie die subzelluläre Lokalisation an der Plasmamembran durch post-translationale 
Lipidierung der C-termini aller vier humanen Isoformen von Ras reguliert. Die korrekte subzelluläre 
Kompartmentalisierung wird durch einen konstanten Zyklus aus De-palmitoylierung durch Acyl 
Protein Thioesterase (APT) und Re-palmitoylierung am Golgi verbunden mit vesikulärem Transport 
zur Cytoplasmamembran gewährleistet. Inhibition von APT unterbricht diesen Zyklus und führt zu 
einen Entropie-getriebenen Verteilung von Ras über die gesamten Intrazellulären Membranen, was 
in einer verringerten lokalen Konzentration und damit verbunden geringeren Signalweiterleitung 
resultiert. APT-Inhibitoren verschiedener chemischer Klassen sind in der Literatur beschrieben, 
allerdings waren keine strukturellen Daten von APT - Inhibitor Komplexen verfügbar.  
Die vermutete Bindestelle von palmitoylierten Proteinen ist ein dem Lösungsmittel zugänglicher 
hydrophober Tunnel neben der katalytischen Triade, dessen Außenwand durch einen „lid-loop“ 
geformt wird, ein einzigartiges und in der Literatur noch nicht beschriebenes Strukturmotiv. Die 
Kristallstrukturenstrukturen von S. cerevisiae APT im Komplex mit Palmostatin B und Palmostatin 
M wurden in dieser Dissertation gelöst und bestätigen den hydrophoben Tunnel als Bindungsstelle 
der Fettsäure. Neben dem β-Lactone der Palmostatin Inhibitoren, welches kovalent durch einen 
reversible Ester an das katalytische Serin gebunden wird, zeigte die Struktur des Komplex mit 
Cerulenin das Potential von aktivierten Epoxiden als Falle für das nucleophile Serin. 
2-Bromopalmitat (2BP) ist ein Produkt Analoga von hoher struktureller Ähnlichkeit, welches die 
Bindung im Tunnel von (kompetitiven) nicht kovalent gebundenen aliphatischen Fettsäuren 
nachweist.  
Der tunnelformende lid-loop wurde noch nicht detailliert auf seinen Einfluss bei Substratbindung 
und katalytischer Aktivität in der Literatur beschrieben. APT gehört – wie auch Lipasen und 
Cutinasen/Esterasen – zur Familie der α,β-Hydrolasen. Während das aktive Zentrum von Lipasen 
durch einen „Deckel“ (engl. lid) abgeschirmt ist, welcher sich bei Membranenassoziation öffnet, ist 
das aktive Zentrum von Cutinasen und Esterasen frei zugänglich. In dieser Dissertation wurden 
verschiedene lid-loop Mutanten von humanen APT1 kristallisiert und auf biochemische Aktivität 
getestet. Ein korrekt gebildeter Tunneleingang ist essentiell für die Koordination von Liganden und 
effiziente katalytische Aktivität. Mutationen, welche die Form des Tunneleingangs oder die 
Flexibilität des lid-loop signifikant verändern zeigen eine verringerte Koordination von 2BP in den 
jeweiligen Komplex-Kristallstrukturen. Diese Strukturen erlauben auch einen hypothetischen nicht-
produktiven Bindungsmodus des Testsubstrats PPTS. Mutanten mit verändertem Tunneleingang 
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haben eine reduzierte biochemische Aktivität von ca. 25% verglichen mit dem human APT1 
Wildtyp, eine Restaktivität von lediglich 3% wurde bei einer Mutante ohne lid-loop gemessen. 
Stopped Flow Messungen bestätigen die Rolle des durch den lid-loop geformten Tunneleingang bei 
der Binding von 2BP im hydrophoben Bindungstunnel. Die Dissoziation von 2BP aus einem APT-
Komplex ist durch Mutation des lid-loop erhöht. 
Humanes APT1 bildet in Kristallen (und wahrscheinlich in Lösung) ein typisches schwaches Dimer, 
welches die potentielle sekundäre Bindungstelle für das Substratprotein und/oder weitere 
Fettsäureresten blockiert. Strukturelle Untersuchungen von humanem APT1 - Peptid Komplexen 
waren bis jetzt nicht erfolgreich, jedoch konnte die Bindung eines hexadecylierten Peptid indirekt 
durch die Inhibition der biochemischen Aktivität von APT nachgewiesen werden.  
Fast alle Kristallstrukturen von APT zeigen den lid-loop in den Tunnel-formenden Konformation, 
einzig eine Struktur von O. punctata APT enthält zwei von vier Monomeren mit geöffnetem lid-loop. 
Die Möglichkeit eines sich öffnenden lid-loop von APT (ähnlich zu dem lid von Lipasen) wurde 
analysiert durch Vergleich der Voraussage über Proteininsertion in Membrane sowie der 
theoretischen Bindungsstärke des lid-loop zu APT selbst. Die berechnete Interaktion des lid-loop 
mit dem Kern von APT ist stärker als die vorhergesagte Membraninsertion von APT, allerdings 
ändert sich die Insertion in eine Membran durch ein hypothetisches Öffnen des lid-loop, weshalb 
keine verlässliche Vorrausage getroffen werden kann. 
Die Daten der biochemischen Assay und Kristallstrukturen zeigen, dass der lid-loop durch die 
Bildung eines stabilen Tunnels mit definiertem Eingang eine für effiziente biochemische Aktivität 
essentielle strukturgebende Funktion hat, statt wie im Fall von Lipasen den Zugang zum 
katalytischen Zentrum zu regeln. Daher kann postuliert werden, dass APTs eine eigenständige 
strukturelle und funktionale Klasse – zwischen Lipasen und Cutinasen/Esterasen – innerhalb der 
α,β-Hydrolasen bildet.  
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3 Introduction 
3.1 Targeted chemotherapeutics in cancer therapy 
Modern cancer therapy relies on a combination of the three pillars of surgery, radiation therapy and 
chemotherapy. Conventional chemotherapy administering cytotoxic drugs has severe side effects 
due to the lack of selectivity. Knowledge about the cancer-causing and promoting malfunction of 
individual proteins can be used to specifically address these mutant versions of the protein, thereby 
focusing the destructive potential on the cancer cells. This approach is referred to as ‘targeted 
cancer therapy’ [1].  
The design of selective small molecular compounds targeting requires a detailed knowledge about 
structural and biochemical properties of the mutated protein as well as its role in the cellular 
signaling network. Due to the high abundance of mutations in the ras-gene and their strong effect in 
human cancer, the small GTP-binding protein Ras is one prominent target for cancer therapy. 
Extensive research in the past decades yielded considerable knowledge about Ras, but failed to 
produce an inhibitor. The following chapter provides a rough overview on the family of GTP-binding 
proteins, and a more detailed description of Ras is given in Chapter 3.3, followed by the 
introduction of APT in Chapter 3.4, which might provide an approach to indirectly target Ras activity 
in cancer.  
 
3.2 GTP-binding proteins 
Energy can be gained of all four nucleoside triphosphates (NTPs) by hydrolysis of the γ-phosphate, 
but unlike adenosine triphosphate (ATP) that is the cell’s currency in energy metabolism and a 
source of phosphate for protein phosphorylation[2], guanosine triphosphate (GTP) is mostly used as 
regulating co-factor of protein involved in signal transduction cascades. GTP-binding proteins 
(following referred to as G-proteins) can be found in all three kingdoms of life and contain a set of 
motifs responsible for GTP-specificity and binding. These motifs are highly conserved through all 
G-proteins, indicating a common ancestor. Guanine binding and specificity is set by G1-G5 motif, 
phosphate and metal binding by PM1-3 and the specificity by G1’-G3’ motif. G1/PM1 motif is the P-
loop GxxxxGKS/T, G2/PM2 is a Threonine in the switch I loop, G3/PM3 is a DxxG motif and G4/G2’ 
N/TKxD is largely responsible for the GTP specificity. A weakly conserved SAK is considered 
G5/G3’, but not present in all G-proteins. The conserved N-terminal 166 amino acids of Ras are 
considered the minimal G-binding fold[3], illustrated in Figure 1.  
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Figure 1: Minimal G-protein fold presented exemplarily on Ras (green) bound to GppNHp (yellow) and Mg2+ (blue 
sphere) (PDB ID 5p21), also shown as 2D topology (right). Switch 1 and switch 2 are coordinated by the γ-
phosphate of GppNHp in the active state. G1-5 motifs provide selectivity for guanine nucleotides. Figure taken 
from [3] and modified using Gimp[4].  
G-proteins function as a molecular switch. The active conformation is in the GTP-bound state, with 
the γ-phosphate bound by main-chain hydrogen bonds between G2 motif Threonine in the α1-β2 
loop (switch I) and G3 Glycine located in the β3- α2 loop (switch II). In this conformation the G-
protein can interact with downstream effectors leading to cell proliferation[5]. Both switch I and II 
undergo a structural change upon GTP γ-phosphate hydrolysis, termed the ‘loaded-spring’ 
mechanism that is conserved through all G-proteins[5,6]. Interaction of the γ-phosphate with the 
main chain amides instead of side chains might enable a stronger coordination and higher flexibility 
of the switch II due to the glycine, and additionally tolerates sequence variation for effector 
specificity[3].  
The intrinsic GTPase activity is usually rather slow in the range of 10-4-10-5 s-1, resulting in 
sustained signal transduction via binding of the GTP-form to downstream effectors until a GTPase-
Activating Protein (GAP) binds to the active small G-protein, thus enhances the intrinsic GTPase 
activity to 1-10 s-1, leading to GTP-hydrolysis and deactivation[3,7,8]. Some multimeric G-proteins 
trigger GTPase activity by dimerization. GDP release and GTP reloading is facilitated by Guanine 
Exchange Factors (GEFs) and the higher cellular concentration of GTP[9-11].  
 
Figure 2: Nucleotide-regulated cycle of G-protein activity. Ras belongs to the monomeric small G-proteins, which 
are activated by GEF-mediated GDP-GTP exchange. Hydrolysis of GTP is enhanced by complex-formation with a 
GAP. Image taken from [3].  
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The superclass of G-proteins can be divided into two large subclasses. The first SIMIBI (signal 
recognition, MinD, BioD) class contains signal recognition particle (SRP) GTPases, ATPases 
involved in protein localization and chromosome partitioning and a group of proteins with metabolic 
activity related to phosphate transfer. The latter subclass of G proteins, TRAFAC (designated after 
translation factors), contains those and proteins involved in signal transduction (for example the 
Ras-like superfamily), cell mobility and intracellular transport[3,12].  
The following chapter will describe the Ras protein, the prototypic member of the Ras superfamily. 
Mutations of Ras enhance cell growth and tumor formation in about 25% of all human cancer[13,14], 
making Ras an attractive target for cancer therapy.  
3.3 Ras, prototypic member of the Ras superfamily 
The Ras superfamily is a family of small GTP-binding proteins named after the prototypic member 
discovered in Rat sarcoma virus and contains about 150 proteins in humans, all being 20-25kDa of 
molecular weight as mostly consisting of the GTP-binding domain. Small G-proteins are monomeric 
in solution[15,16]. Also belonging to the Ras-subfamiliy are Rho (Ras homolog) involved in the control 
of the cytoskeleton[17], Ran (Ras involved in nuclear transport)[18], Rab (Ras-like protein in brain) 
and Arf/Sar1 (ADP ribosylation factor)[19].  
The three human RAS genes encode the four proteins H-Ras, N-Ras and the two splice variants K-
Ras4A and K-Ras4B. H-Ras and K-Ras were discovered in the 1960s by Harvey[20] and Kirsten[21] 
as the oncogene responsible for leukemia in sarcoma virus infected rats. N-Ras was identified in 
human neuroblastoma cells in 1982[22,23]. All Ras proteins contain the highly conserved minimal G-
binding fold (amino acids 5-166)[15,24,25] with a hypervariable C-terminal region. The G-binding fold 
contains switch I and switch II which change their conformation depending on the nucleotide 
bound[3,6] as described in chapter 3.2 before. The most common oncogenic mutation in Ras 
proteins at G12 blocks the interaction with its GAP that is necessary to deactivate the molecular 
switch by hydrolysis of bound GTP to GDP, thereby leaving Ras constitutively in its active state, 
which leads to uncontrolled cell growth[7]. This can be explained by analysis of the 
Ras•GDP•AlF3•RasGAP complex (PDB ID 1wq1, [26]) and RhoA•GDP•AlF3•GAP complex (PDB ID 
1tx4, [27]) structures, that show how the so-called “arginine finger” is inserted next to G12/G13 into 
Ras (G14/A15 in RhoA) next to the γ-phosphate, highlighting that any mutation to a residue with 
larger side chain would lead to a steric clash preventing acceleration of GTP hydrolysis. Fast 
GTPase activity without Arg-finger has been reported for Ran, were the Ran-intrinsic nucleophilic 
glutamine is correctly positioned for GTP hydrolysis upon formation of the ternary 
Ran•GppNHp•RanBP1•GAP complex (PDB ID: 1k5d/1k5g, [28]).  
The high percentage of human tumors containing mutations in one or more ras-genes indicates 
their strong oncogenic potential and significant role in tumorgenesis and cancer development[13]. To 
investigate their importance in fetal development and on overall survivability ras-deficient mice have 
been bred. N-Ras deficient mice have been found to be vital without any observed development 
defect, and adults of both sexes are fertile[29]. H-Ras deficient mice are vital, fertile, and show no 
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defects in neuronal development[30]. Crossbreeding of H-Ras and N-Ras deficient mice led to H-/N-
Ras double null mutants, which are also vital and show normal development[30]. However, K-Ras 
deficient mice die from liver defects and signs of anemia during embryonic development[31], 
showing that only K-Ras is essential for mice development. Despite the unaltered phenotype of a 
H-/N-Ras deficient mouse, tumors can be dependent e.g. on mutated H-Ras, as shown in mouse 
models[32].  
3.3.1 Post-translational acylation of Ras provides membrane affinity 
The hypervariable C-terminal region varies in sequence and lipid modification between the four 
human isoforms of Ras. All Ras proteins are post-translationally farnesylated and mono- (H-Ras, K-
Ras4A) or dually palmitoylated (N-Ras) at the hypervariable C-terminal region; only the splicing 
variant K-Ras4B is not palmitoylated, but instead contains a poly-lysine stretch next to the 
farnesylated cysteine to enhance membrane association[33-35].  
 
Figure 3: Human Ras-isoforms and their post-translational modifications. All four human Ras isoforms share a 
highly conserved GTP-binding core, but vary in sequence and lipid modification at the C-terminal hypervariable 
region. All Ras isoforms are farnesylated. Figure taken from[36].  
Ras farnesylation by farnesyl-protein transferases[37] and palmitoylation by DHHC9/GCP16 [38,39] 
happens at the golgi complex. Following the post-translational modification, Ras is shuttled through 
vesicular transport towards the membrane[40] where it acts as a molecular switch in signal 
transduction cascades regulating cell growth and proliferation. Entropy-driven diffusion of 
membrane associated Ras would lead to a random distribution of Ras trapped at all endo-
membranes, resulting in a decreased local concentration at the plasma membrane and a 
decreased signaling activity[41]. To circumvent this, the palmitoylated isoforms of Ras are proposed 
to be constantly de-palmitoylated by Acyl Protein Thioesterase (APT)[42], thereby detaching it from 
the membrane and enabling faster diffusion to the golgi, where Ras is re-palmitoylated and cycled 
back to the plasma membrane[41,43]. This constant cycle of de- and re-palmitoylation maintains a 
high local concentration of Ras at the plasma membrane necessary for correct signal transduction, 
and also presents a soft spot for modulating activity of indelible active mutated Ras and reverting 
cancerous phenotypes[44-46].  
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Figure 4: Palmitoylation cycle of Ras. Post-translational lipidation at the golgi includes a irreversible farnesyl 
thioether, and (depending on the Ras protein) up to two palmitoyl thioester groups (1). Ras is then transported 
via vesicular transport (2) towards the plasma membrane, where it acts as molecular switch regulated by the 
bound nucleotide. Membrane release and de-palmitoylation by APT (3) leads to trafficking of Ras towards the 
golgi, where re-palmitoylation initiates the restart of the cycle. Image created using Adobe Illustrator.  
While farnesylation is an irreversible lipid modification at cysteine residues via a thioether bond, 
palmitoylation via a thioester is reversible. Ras signaling activity is not only depending on the 
nucleotide bound to it, but also on its correct subcellular localization. Therefore, one approach to 
decrease Ras signaling activity caused by constitutively active mutants included farnesyl-protein 
transferase inhibitors to interfere with Ras maturation, but it has been shown that in cells treated 
with the farnesyl-protein transferase inhibitor tipifarnib Ras localization is rescued by geranyl-
geranylation[47].  
Ras extraction from the plasma membrane is not understood in detail. In its 
farnesylated/palmitoylated state, simple off-diffusion is unlikely due to the high membrane affinity of 
palmitoylated proteins[48,49].  There is no protein or mechanism for an active Ras extraction known 
so far, but it could be possible that APT itself is not only responsible for depalmitoylation but also 
membrane extraction of the palmitate membrane anchor of its substrates.  
3.4 Acyl protein thioesterase belongs to the family of α,β-hydrolases  
Acyl protein thioesterase (APT) belongs to the family of α,β-hydrolases. The α,β-hydrolase family is 
defined via its fold, that contains a three-layered (a/b/a) core with a central sheet of 8 β-sheets (of 
which β-sheet 2 is anti-parallel) in an order of 12435678, connected and surrounded by 6 α-helices 
(see Figure 5) [50,51]. Insertions and extensions of the α-helices form a variety of structural features 
of different sub-classes. The conserved catalytic triad consisting of a nucleophilic serine, basic 
histidine, and acidic aspartate; the reaction mechanism is described further below in Figure 7.  
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Figure 5: Left: Overview of a carboxyl esterase from Pseudomonas aeruginosa (PDB ID: 3cn9) as an example of 
the minimal fold of a α,β-hydrolase protein. The canonical fold contains a central sheet formed by 8 β-sheets 
shown in green, with β-sheet 2 being anti-parallel. The connecting α-helices are presented in yellow and labeled 
A-F from N- to C-terminus. Right: Structure of human APT1 contains a lid-loop (shown in red) formed by an 
extension of helix B. This lid-loop forms the hydrophobic binding tunnel next to the active site.  
The class of α,β-hydrolases contains 41 protein superfamilies according to the SCOP data base, 
among which are proteases, lipases, esterases, peroxidases, epoxide hydrolases and 
dehalogenases[51,52]. These classes are neither conserved in sequence nor function, but share the 
before mentioned conserved α,β-hydrolase fold, indicating a common ancestor[53].  
The active site of esterases is located on the surface close to a small binding pocket suitable to 
bind and be readily accessible for the specific substrate without rearrangements of the protein. 
Esterases hydrolyze a variety of short-chained (thio-) esters, but are unable to bind longer aliphatic 
chains[54].  
Lipases contain an additional loop that completely covers the active site and its surrounding 
hydrophobic patch. This loop opens upon binding to membranes and vesicles, thus revealing the 
active site to the substrate, typically long-chained mono-/di-/triglycerol esters[55]. Lipases contain a 
hydrophobic binding tunnel next to the active site that accommodates the long aliphatic chain of its 
substrate and stabilizes it during hydrolysis (compare PDB ID: 4lhe, [55,56]).  
 
Figure 6: Comparison of a monoglyceride lipase of Bacillus sp.[56] and carboxylesterase of Pseudomonas 
aeruginosa[57]. A: The large lid (red) of the lipase (green) completely covers the active site and surrounding 
hydrophobic patch. B: The active site of the esterase is accessible and not covered by a lid. A PEG molecule is 
bound in this structure in a shallow groove.  
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The reaction mechanism of a/β-hydrolases is depicted in Figure 7 in detail, showing the catalytic 
triad of APT consisting of serine, histidine and aspartate. The hydroxyl moiety of the active site 
serine is thought to be deprotonated by the histidine-aspartate diad, which acts as proton sink. The 
thus activated serine oxyanion (Figure 7, red) performs a nucleophilic SN2 attack on the thioester of 
e.g. palmitoylated Ras, forming a tetrahedral intermediate (Figure 7, yellow), which charged 
oxyanion is stabilized by hydrogen bonds via the backbone amides that form the oxyanion hole. In 
the following, the oxyester at the active site serine is formed with the thiol of the cysteine of Ras as 
leaving group, leaving the palmitoylated active site serine of APT (Figure 7, purple) as reaction 
intermediate. The deacylation of APT is performed in a similar mechanism, using a water molecule 
(Figure 7, blue) as nucleophile. This hydrolytic water is deprotonated by the histidine-aspartate 
dyad similar to the prior described formation of the reactive serine oxyanion, and subsequently 
attacks the serine palmitate ester. The oxyanion of the tetrahedral reaction intermediate is 
stabilized by the oxyanion hole, and the serine of APT poses the leaving group when palmitate is 
re-formed.  
 
Figure 7: Schematic reaction mechanism of APT with palmitoylated Ras as exemplary substrate. Histidine and 
aspartate of the catalytic triad act as electron sink and deprotonate the active site serine; the nucleophilic serine 
oxyanion (red) performs a SN2 attack on the palmitate thioester of e.g. Ras. The tetrahedral intermediate (yellow) 
is stabilized by the oxyanion hole (green), formed by backbone amides. The palmitate ester of the active site 
serine of APT is formed with Ras as leaving group. Regeneration of APT occurs in a similar mechanism, 
involving a water molecule (blue) as nucleophile that is activated in a same mechanism. APT is the leaving group 
of the tetrahedral intermediate upon formation of palmitate. Reaction scheme created using ChemBioDraw.  
3.4.1 Structural features of APT isoforms 
Acyl protein thioesterase (APT) contains the canonical α,β-hydrolase fold as well as the obligatory 
catalytic triad consisting of S114, H203 and D169. The positively charged oxyanion hole is formed 
by the backbone amides of L25 and F115 next to the active site serine. [58]. There are two known 
human isoforms sharing 66% sequence identity, which had been initially identified as 
lysophospholipases, hence named LYPLA1/2[59,60], but it was shown to be responsible for the 
majority of the cytosolic protein de-acylation activity[42]. A related protein, lysophospholipase-like 1 
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(LYPLAL1, also referred to as APT1L), sharing about 33% sequence identity with APT1, had been 
discovered in genome-wide association studies to influence body fat distribution and waist-hip-
ratio[61]. Structural characterization of the protein revealed significant differences in the topology of 
the substrate binding site resulting in the specificity for shorter esters as substrates despite the 
sequence homology (PDB ID 3uov)[62]. Notably, LYPLAL1 is unable to hydrolyze esters with long 
chains.  
APT1 and APT2 are rather promiscuous with regard to their substrates, among which are e.g. H/N-
Ras[41,42,45], α-subunit of trimeric G-proteins (Gα)[42], endothelial nitric-oxide synthase (eNOS)[63], 
RGS4[42] or SNAP-23[64]. However, some specificity has been reported, as GAP43 is 
depalmitoylated only by APT2[65], and Caveolin, a small transmembrane protein palmitoylated at the 
cytoplasmatic C-terminal end, is not depalmitoylated by APT1[63]. Deacylation of the secreted 
hunger peptide octanoyl-ghrelin and lysophosphocholine present in the serum by APT was 
suggested[66,67], opening the question if APT is secreted or leaked out of the cell into the serum.  
Further investigation are required to elucidate if both or only one of human APT1 and APT2 are 
involved in Ras cycle regulation, and a more detailed understanding of substrate and inhibitor 
binding is required to for further inhibitor development[68].  
APT1 contains a hydrophobic substrate-binding tunnel next to the catalytic serine formed by a 
flexible extension of helix B that was proposed to bind the palmitoyl moiety during hydrolysis. 
Initially it was not clear if this tunnel binds the palmitate moiety, as in monomer B of the published 
crystal structure (PDB ID 1fj2, [58]) the tunnel is obstructed by L73 and F176. However, in all 
structures solved in our group, the binding tunnel is pre-formed and solvent accessible[69]. The 
dimer packing of the published structure of human APT1 (PDB ID 1fj2) pushes L73 inwards, thus 
closing the tunnel. Human APT1 crystallizes as a conserved dimer (or multiples of this dimer), and 
the published structure of human APT1 (PDB ID 1fj2) forms a rotated version of the dimer 
compared to the structures solved in our group, most likely due to the larger cloning artifact of 
construct of the published structure[69]. The structures of human APT1 and APT2 were crystallized 
by Marco Bürger[69] and are shown below in Figure 8. 
 
Figure 8: Human APT1 (left) and APT2 (right) presented as ribbon. Both structures were solved by Marco 
Bürger[69]. The tunnel (highlighted by the circle) is pre-formed by the lid-loop (red) next to the active site serine of 
the catalytic triad.  
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In LYPLAL1, this tunnel is permanently obstructed by a conserved arginine, thereby rendering the 
protein unable to bind and cleave long-chained esters like palmitoylated proteins or 
lysophospholipids as initially assumed, and limits the range to shorter substrates, (PDB ID 3uov, 
[62]) comparable to the structurally related carboxylesterase from Pseudomonas aeruginosa (PDB 
ID 3cn9, [57]). Palmitoyl protein thioesterase 1/2 (PPT1/2), although closely related by sequence, is 
located in lysosomes and does not regulate spatial distribution of palmitoylated proteins[70]. As 
described further below, PPT1 lacks the hydrophobic tunnel, and binds palmitate in a surface 
exposed groove. To our knowledge (communications with Ingrid Vetter), revealed that a pre-formed 
and solvent-accessible hydrophobic tunnel like in APT is a unique feature of APT that has not been 
reported for other proteins so far, and it also has not been explicitly mentioned as such (due to the 
closed tunnel) by the authors of the original article[58].  
The shape of the binding tunnel varies slightly between human APT1 and APT2, as shown in 
Figure 9. In the absence of ligands, some flexible side chains like F176 and R144 in human APT1 
can move into the tunnel and narrow its exit.  
 
Figure 9: Comparison of the shape of the hydrophobic binding tunnel of human APT1 and APT2. Both structures 
were solved by Marco Bürger and presented in[69]. The surface around the active site and tunnel entrance is 
conserved, but the shape of the binding tunnel slightly differs. The tunnel exit can be narrowed by flexible side 
chains in the absence of a ligand bound to the tunnel.  
The residues forming the hydrophobic tunnel are highly conserved between APT1 and APT2, the 
only significant difference is R144 located at the exit of the tunnel in APT1, which corresponds to 
H142 in APT2[69]. Furthermore, two residues in the hinge region at the start and end of the lid-loop 
are altered, namely I70+I71 / L70+M71 of human APT1 / APT2, and S77+Q78 / A77+P78 in human 
APT1 / APT2, which could affect the flexibility of the lid-loop. For further details, refer to[69].  
Human APT contains three tryptophan residues. One tryptophan residue (W140/W142 in human 
APT1/2) is located inside the hydrophobic binding tunnel, forming parts of its inner wall. The second 
tryptophan (W32 in human APT1/2) is located at a solvent exposed shallow groove next to the 
active site that is expected to bind the substrate protein. The third tryptophan (W67) is part of the 
hydrophobic core of the protein, excluded from the solvent. The position of the three tryptophans in 
the structure is shown in Figure 10.  
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Figure 10: Highlighting the structural features of human APT1 and APT2. Both isoform contain three tryptophan 
residues. W140 form the inner wall of the hydrophobic tunnel formed by the flexible lid-loop (red). W32 is located 
in the shallow groove (yellow) predicted to bind the substrate protein. W67 is buried in the hydrophobic core of 
the protein and not accessible to solvent. The active site is highlighted in coral.  
Human APT1 forms a dimer in crystals (shown below in Figure 11), and analytical ultra-
centrifugation (AUC) has shown that this dimer is also formed in solution, with a KD of 2.8 µM, while 
human APT2 and Saccharomyces cerevisiae APT do not dimerize in solution, as confirmed by 
AUC[69]. The dimer of human APT1 is formed via the hydrophobic patch next to the active site and 
is observed in three different crystal forms, being rotated by about 2˚ within crystals of different 
space groups and unit cells[69]. It is unknown if the dimerization has a biological role as regulator of 
activity, e.g. at high local concentrations at the membrane in cells.  
 
Figure 11: Dimer of human APT1[69]. In both monomers, the lid-loop (red) and catalytic triad (orange) are buried in 
the dimer interface. Parts of the putative binding groove (yellow) close to the active site are also covered by the 
second monomer of the dimer, presented with transparent surface (grey) on top.  
The closest human relative to APT/LYPLA family are PPT1/2[71]. Both protein acyl thioesterases are 
responsible for the de-palmitoylation activity in vivo, but are spatially separated: PPTs are part of 
the lysosomal degradation machinery[70], while APTs are present in the cytosol[42]. Both APT and 
PPT cleave long chain thioesters from proteins, but PPT1 binds the palmitoyl moiety on a 
conspicuous surface groove (PDB ID: 1eh5, [72]) while APTs contains a pre-formed hydrophobic 
binding tunnel next to the active site. A comparison of the structures shows significant differences 
in the insertions at B and D α-helices, connecting β-sheets 4 to 5, and 6 to 7, respectively. These 
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insertions form the binding site for palmitate moiety of substrate proteins. In APT1, insertion B 
contains the lid-loop forming the outer wall of the substrate binding tunnel and is longer than the B 
α-helix in PPT1, while the insertion at the D α-helix of PPT1 is vastly extended and forms the 
surface exposed palmitate-binding groove (see Figure 12).  
 
Figure 12: Structural comparison of APT1 and PPT1. Insertion B (red) of APT1 (left, PDB ID 1fj2, [58]) contains the 
flexible lid-loop that forms the hydrophobic tunnel next to the active site (blue sticks). In PPT1 (right, PDB ID 
1eh5, [72]), insertion B is shorter and palmitate (red) is bound by the extended insertion D (cyan).  
3.4.2 Boron-based inhibitors of acyl protein thioesterase  
The identification of APT as a regulator of Ras subcellular localization[41,42] started the search for an 
inhibitor to modulate Ras activity. Clinical inhibitors of other serine hydrolases utilized a boronic 
acid moiety as nucleophilic trap for the active site serine[73]. Therefore, commercially available 
boronic acids have been tested for APT inhibition, and some have been found to have sub-µM 
potency[46]. Due to the covalent binding at the active site serine, boronic and borinic acids have 
slow off-rates and show long-lasting inhibition of APTs. One borinic acid has been shown to inhibit 
APT potently enough to reduce N-Ras dependent ERK-phosphorylation and partially revert the 
phenotype of MDCK-F3 cells[46]. The boron-based inhibitors lack isoform-specificity but showed no 
cell toxicity, indicating that they do not target essential proteins[46]. Complex structures of boronic 
acids with yeast APT have been solved in the course of my master thesis[74], proving the feasibility 
of obtaining inhibitor complexes of yeast APT.  
3.4.3 β-lactone containing palmostatin B and palmostatin M 
A second chemical class of potent inhibitor of APTs had been identified from a synthesized 
compound collection based on a central β-lactone that was inspired by lipstatin and 
tetrahydrolipstatin (also known as orlistat, Figure 13), the natural substrate and a commercial 
inhibitor of gastric lipase[44,75,76]. The first generation contained an aliphatic tail intended to mimic the 
acyl chain of natural substrates and replaced the thioester of the natural substrate by a central 
β-lactone core that acts as nucleophilic trap for the active serine[77]. An aromatic head group was 
connected to the β-lactone core via a short linker, and of the four different enantiomers palmostatin 
B (see Figure 13) proved to be the most potent. Further optimization replaced the bulky head group 
with a flexible sulfonyl-propylene-dimethylamino group (Figure 13). This head group mimics 
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lysophospholipid, a substrate of APT identified earlier[78]. The central β-lactone core and aliphatic 
tail were kept unchanged compared to palmostatin B[77]. However, structural proof of this binding 
mechanism is not available so far.  
 
Figure 13: Palmostatin M and palmostatin B, sharing a common β-lactone core inspired by tetrahydrolipstatin 
(also known as orlistat). Figure taken from[46].  
3.4.4 Cerulenin shares some features with palmostatin M  
Cerulenin is a antifungal small molecule produced by Cephalosporium caerulens. Cerulenin inhibits 
the multienzyme complex Fatty Acid Synthase (FAS) and interferes with malonyl-CoA binding and 
metabolism[79,80]. FAS is upregulated in many precursors of invasive types of cancer[81]. It has been 
suggested that Cerulenin affects protein acylation[82], and it shares some structural and functional 
similarities with palmostatin M as shown in Figure 14.  
 
Figure 14: Comparison of Cerulenin and palmostatin M and proposed structure of the covalent complex with the 
active site serine of APT. The chemical groups expected to address the same functional groups of the protein 
are highlighted in the same colours. Image created using ChemBioDraw13 and modified using Gimp[4].  
Both the electrophilic β-lactone of palmostatin M and the epoxide of Cerulenin can act as a trap for 
the nucleophilic serine of the active site, leading to a covalent adduct, which is an irreversible ether 
in case of Cerulenin. The β-keto-function next to the opened expoide could bind the protein similar 
to the opened β-lactone of palmostatin M, although there is one additional carbon atom in case of 
the Cerulenin adduct formed upon attack at C3. The unsaturated tail of Cerulenin both at C7 and 
C10 in trans-configuration, which is restrained in flexibility compared to the saturated tail of 
palmostatin M, but might be able to bind inside the hydrophobic tunnel of APT. For this reasons, 
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Cerulenin was also studied as a covalent inhibitor of APT in this thesis. Different studies showed 
covalent binding of Cerulenin at both C2[83,84] and C3[85] of the epoxide.  
3.4.5 2-Bromopalmitate as product mimic and inhibitor of APT 
2-Bromopalmitate (2BP) is the α-brominated palmitic acid (shown in Figure 15), and commonly 
used to inhibit Protein Acyl Transferases (PAT) during in vivo experiments[86]. Its striking similarity 
with the product of de-palmitoylation reactions has led to investigations that showed its inhibitory 
effect on APT activity[87]. The kinetic data obtained indicated an un-competitive mode of action on 
APT using palmitoyl-CoA as substrate[87]. This data and conclusion is surprising, since due to the 
remarkable similarity with the product it is unclear why 2BP should not address the same binding 
site as the palmitate moiety of a palmitoylated protein.  
Besides in crystallographic studies, 2BP was used in the course of this thesis for biochemical and 
biophysical experiments. A important advantage of this compound is the better solubility in aqueous 
solutions compared to palmitate.  
 
Figure 15: Structure of 2-Bromopalmitate (2BP). The bromine-substituted carbon in α-position to the carboxylic 
acid is chiral, and 2BP is supplied by Sigma Aldrich as racemic mixture. Figure created using ChemBioDraw 13.  
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4 Goal of this study 
Ras is a small GTP-binding protein that plays an important role in signal cascades controlling cell 
growth and proliferation, and tumor-growth promoting mutants of Ras can be found in 25% of all 
human tumors. Ras activity is regulated by the bound G-nucleotide and the sub-cellular localization 
at the plasma membrane. Membrane localization is achieved by post-translational lipidation of the 
C-terminus, and properly maintained by a constant cycle of de-palmitoylation by acyl protein 
thioesterase (APT) and re-palmitoylation at the Golgi coupled to vesicular transport to the 
membrane. Direct approaches to inhibit Ras activity in cancer were not successful so far. Inhibition 
of APT disrupts this cycle and reduces the local Ras concentration and thus the Ras activity in 
cancer.  
APT inhibitors of different chemical classes have been described in the literature, but structural 
data is missing. Therefore, different APT – inhibitor complexes will be structurally investigated by x-
ray crystallography to identify their exact binding mode to provide a starting point for further rational 
drug design. APT contains a pre-formed hydrophobic tunnel next to the active site which outer wall 
is formed by a lid-loop. It is unknown if the lid-loop is involved in substrate binding, and if the shape 
and stability of the lid-loop is related to biochemical activity. To address these questions, mutants of 
human APT1 containing an altered lid-loop will be structurally characterized on the formation of the 
hydrophobic tunnel and compared to the effect on biochemical activity. The shallow groove is a 
potential secondary binding site for the natural substrates, palmitoylated proteins and/or further acyl 
chains, but has not been verified yet, thus co-crystallization with lipid-modified peptides will be 
pursued.  
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5 Results 
5.1 Crystal structures of APT in complex with inhibitors  
5.1.1 Crystal structure of yeast APT serves as model for structural investigation of 
inhibitors of human APT1 
Different structures of human APT1 obtained by Marco Bürger in the course of his doctoral thesis 
revealed an active site blocked by crystal contacts[69]. Efforts to obtain structural data of any 
inhibitor in complex with either human APT1 or APT2 have failed so far[88]. To overcome this 
problem the homolog in yeast (sharing 36% sequence identity to human APT1) had been subjected 
to screening for crystallization conditions, resulting in well-diffracting crystals. The first structure of 
yeast APT was solved by Marco Bürger and refined in the course of my master thesis[74]. A second 
structure that crystallized under optimized conditions in a different space group and diffracted to 
higher resolution is presented here and is used for further comparisons.  
The best diffracting apo crystal of yeast APT was obtained in hanging drops from optimized 
conditions initially set up to obtain a complex structure with the inhibitor palmostatin B via co-
crystallization (Figure 16). The crystal structure was solved as described in Chapter 7.4 of Material 
and Methods. The crystallographic statistics are shown in Table 1. First, the high-resolution 
structure is analyzed in this chapter, followed by a comparison with the previously presented 
structures of yeast APT[69,74] and human APT1[69]. 
 
Figure 16: Crystals of yeast APT apo. The best-diffracting crystal of yeast APT grew in 30% PEG4000, 0.1 M 
Li2SO4 and 0.1 M Tris pH 8.5. The condition also contained 5 µM palmostatin B. Crystals grew within 14 days in 
hanging drops. Image taken using an Olympus DP21 camera attached to an Olympus CX-60 microscope.  
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Table 1: Crystallographic statistics of the yeast APT apo structure. Values for the highest shell are given in 
parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 yeast APT 
apo 
yeast APT 
apo[74]  
yeast APT 
apo 
yeast APT 
apo[74] 
Data collection   Refinement   
Space group P21 21 21  P42 21 2 Resolution (Å) 45.61-1.44 (1.48-1.44) 
19.98-2.20 
(2.26-2.20) 
Cell 
dimensions 
  Number of 
Reflexes 
396851 
(9484) 
50658 
(3407) 
    a, b, c (Å) 
44.70, 45.94, 
91.22  
145.86, 
145.86, 96.84 Rwork 
17.13 
(29.7) 
20.9 (25.7) 
    α, β, γ (°) 90, 90, 90  90.0, 90.0, 
90.0 Rfree 
20.66 
(29.7) 
26.7 (30.1) 
Resolution (Å) 45.61-1.44 
(1.48-1.44)  
48.62-2.2 
(2.26-2.2)  
Number of 
Atoms 
  
Monomers / au 1 4     Protein 1822 7037 
Wave length 
(Å) 
0.97857 0.977 
    Ligand/Ions 
6 4 
CC 1/2 100 (55.6) (no value)     Water 167 165 
I / σ(I) 24.6 (1.59) 11.56 (3.23) B-factor (Å2)   
Completeness 
(%) 
96.3 (71.7) 99.72 (99.97) 
    Protein 
22.4 62.4 
Redundancy 11.85 (5.24) 3.80 (4.00)     Ligand 34.5 83.0 
 
    Water 33.2 54.1 
RMSD   
    Bond length 
(Å) 
0.0239 0.022 
    Bond angle (°) 2.40 2.142 
Ramachandran 
(%) 
97.88 / 
2.12 / 0 
95.83 / 3.84 
/ 0.33 
Clashscore 3 14.04 
Rotamer outlier 
(%) 
3.06 13.77 
Molprobity score 1.77 2.81 
 
The asymmetric unit of the high-resolution crystal structure contains one molecule of yeast APT 
with an active site accessible to the solvent. Yeast APT does not form a dimer in solution as 
observed in human APT1[69]. The lid-loop is part of a crystal contact to one neighboring molecule. 
The Figure 17 illustrates the crystal contact that leaves the active site accessible. The active site 
contains a glycerol molecule soaked into to the crystal by the cryo solution. Although the 
crystallization condition contains 5 µM palmostatin B, which is expected to bind at the active site, 
palmostatin B is washed out of the active site due to insufficient concentration in the cryo solution.  
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Figure 17: Accessible active site of yeast APT. The lid-loop (cartoon in red) is involved in a crystal contact with a 
neighbor molecule (left, dark green).  
The hydrophobic tunnel, that accommodates the substrate palmitoyl moiety, is pre-formed by the 
lid-loop. In yeast APT, the surface of the hydrophobic tunnel is formed by the side chains of I74, 
W77, P79 and F81 located in the lid-loop, and F72, F145, V175, V176, and L180 of the core 
protein. The orientation of these side chains is shown in the Figure 18. 
 
Figure 18: The hydrophobic tunnel of yeast APT with relevant residues labeled and shown as sticks. Amino acids 
of the lid-loop are colored red. The glycerol molecule bound at the active site is shown as grey sticks.  
The different environments in the crystal of the two datasets allow a comparison of the flexibility of 
parts of the protein. The structure solved in P42 21 2 contains four monomers (A-D) per asymmetric 
unit with different contacts to the neighbor molecules: in monomer B, D78 and S80 are close to 
K101 of the neighboring molecule, and P79 of the tip is located close to M172. In monomer C a salt 
bridge between E76 and D78 is formed with K101 of a symmetry molecule, and P79 at the tip of the 
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lid-loop is packed to P133 and W134 of a symmetry molecule. The most prominent changes are 
found on the side chain of W77, with rotation of up to 180˚ even though no direct contact of this 
residue could be observed, indicating that the different conformations of the indole side chain are 
potentially energetically comparable. The electron density is not as well defined as for the other 
side chains of the lid-loop. The lid-loop is quite similar in the four monomers with an rmsd of 0.50 to 
0.92 Å for 10 Cα atoms. The largest movement of the lid-loop of about 1 Å is observed at the tip, 
measured at the Cα of P79 between monomer C, where the lid-loop is involved in crystal contacts, 
and monomer D, where the lid-loop is located at a solvent channel and not influenced by crystal 
contacts.  
 
Figure 19: Comparison between both structures of yeast APT. The high-resolution structure solved in space 
group P21 21 21 is shown in green with a red lid-loop, the side chains are highlighted as sticks. The four 
monomers of the structure are superimposed on the high-resolution structure and colored dark green, with a 
dark red lid-loop and side chains as stick model. Most prominently, the orientation of the indole of W77 varies.  
Taken together, the conformation of the lid-loop of yeast APT in this crystal is only slightly 
influenced by the crystal packing.  
In the following part, the high-resolution structure of yeast APT is compared with human APT1. The 
overall structure of yeast APT is similar to human APT1, with an rmsd of 1.38 Å over 211 Cα 
atoms. Upon close inspection of the active site of yeast APT, the hydrophobic binding tunnel 
displays an unusual shape. While human APT1, and in fact all other APT structures solved by our 
group[69], have a straight hydrophobic tunnel with the exit on the opposite site of the protein, the 
tunnel of yeast APT turns by nearly 90˚ and exits on the side of the protein. This is caused by a 
different amino acid sequence of the lid-loop, which is shown below in Figure 20.  
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Figure 20: Structural alignment of the lid-loop sequence of APTs from different organisms. Alignment is based 
on the structures solved by Marco Bürger[69]. The lid-loop of yeast APT has an insertion of one amino acid, 
leading to repositioning of the conserved proline (not in D. melanogaster). The following negatively charged 
residues aspartate and glutamate (76 and 79 in human APT1) are replaced by an aliphatic phenylalanine and a 
valine residue in yeast APT. Structure based sequence alignment created using Chimera[89].  
The structure-based sequence alignment of the lid-loop shows an insertion in the sequence of 
yeast APT, thus displacing the almost completely conserved P74 (numbering according to human 
APT1) further to the tip of the lid-loop. The sequence following the proline (SFSKV) is not 
conserved in yeast and lacks the negatively charged D76 and E79 (Figure 20). Instead, in yeast 
APT these positions are occupied by larger aliphatic residues, of which F81 blocks the tunnel 
approximately at the middle of the tunnel (Figure 21). The conserved L73, located at the entrance 
of the tunnel next to the active site, is replaced by a larger W77 of the yeast APT lid-loop.  
 
Figure 21: Detailed view on the active site and tunnel of yeast APT. The catalytic triad consists of S119, H207 and 
D174. A glycerol molecule binds next to the active serine. F81 blocks the straight tunnel leading away from the 
active site, thus redirecting the tunnel to exit in front of P79. The side chain of W77 is tilted upwards, so that the 
tunnel is not formed completely, resulting in a deep hydrophobic groove.  
In this crystal structure, the conformation of W77 at the tunnel entrance results in formation of a 
groove instead of a tunnel, as it is found in our structures of APTs from other organisms. The indole 
side chain is in 3.7Å distance to the side chains of I74 and A62, i.e. the range of van-der-Waals 
contacts. The shorter side chain of A62 (corresponding to L58 of human APT1) leaves space for 
the indole ring of W77 to move towards A62, while simultaneously the short V175 on the lower part 
cannot reach to W77, resulting in a gap between W77 and V175. In human APT1 however, the 
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corresponding amino acids are three leucines, L58 directs L73 downwards where it is in closer 
range to L171, thus forming the round entrance of the linear hydrophobic tunnel. The role of these 
three leucines of human APT1 is further investigated in Chapter 5.2.2, 5.2.3 and 5.2.4. 
 
Figure 22: Comparison of the lid-loops of yeast APT (shown in green with the lid-loop highlighted in red) and 
human APT1 (blue). A: The indole side chain of yeast APT W77 is rotated towards A62 and I74, resulting in a gap 
between W77 and V175. B: In human APT1, L58, L73 and L171 form a round entrance of the straight binding 
tunnel, whereas in yeast the tunnel is blocked by F81. The glycerol molecule at the active site of the yeast APT 
structure is not shown for clarity.  
A shallow groove next to the active site could be a binding site for the peptide of palmitoylated 
proteins, or for a second palmitoyl-moiety or for the farnesyl modification. The residues forming the 
groove are conserved in close proximity to the active site, but then diverge with increasing distance, 
as illustrated for yeast APT in Figure 23.  
 
Figure 23: Conservation of the shallow groove next to the active site of yeast APT. Conserved residues are 
colored in magenta, less conservation is shown as a gradient from white to cyan. The conservation is based 
comparisons of the structures of human APT1/2, X. tropicalis APT1/2, D. melanogaster APT1 and yeast APT 
solved by Marco Bürger[69] and reveals highly conserved regions at the active site and at the tunnel entrance. 
The shallow groove is a secondary binding site for e.g. peptide of a palmitoylated protein. The conservation is 
high in close proximity to the active site, but becomes more variable with increasing distance from the active 
site. Image created using Chimera[89] and annotated using Gimp[4].  
A more detailed comparison between human APT1 and model yeast APT is shown in Figure 24. As 
mentioned above, the residues close to the active site are conserved, namely F118 and W30 (yeast 
APT numbering). T209 and L214 in yeast APT correspond to S205 and M210 in human APT, 
keeping the electrostatic properties of the side chains comparable. Interestingly, the position of the 
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bulky F32 residue in yeast is occupied by A35 in human APT. Y36 of yeast APT corresponds to I39 
in human APT, with the polar hydroxyl group of Y36 pointing to the charged end of the groove, 
which is formed by E215 and R40 in yeast APT. In human APT, E215 of yeast APT corresponds to 
A210 that lacks a polar side chain, which is compensated by the side chain of Q207 next to it. The 
R40-containing helix of yeast APT is shortened in human APT1 by one turn, leaving the space of 
R40 to be occupied by K214 in human APT1. The hydroxyl group of T209/S205 is not completely 
conserved, but can be found in several APTs.  
 
Figure 24: Detailed comparison between yeast APT and human APT1. Yeast APT is represented in green, with 
the side chains forming the shallow groove highlighted in yellow. Human APT is colored in blue, with the 
corresponding side chains highlighted as sticks. Close to the active site, the groove is conserved and 
hydrophobic, with increasing distance the surface becomes more polar.  
Despite the minor structural differences between yeast APT and human APT1, yeast APT is useful 
as a model to structurally investigate inhibitor binding: First, the crystal packing of yeast APT leaves 
the active site solvent-accessible in contrast to the previously solved structures of human APT1. 
This allows soaking of ligands into the crystals. Second, the aliphatic tail of inhibitors is flexible 
enough to bind inside the bent hydrophobic tunnel of yeast APT. Third, although the binding groove 
is only partially conserved among APTs, small molecule ligands could address the conserved 
residues close to the active serine. 
5.1.2 Crystal structure of the yeast APT – palmostatin B complex 
Palmostatins are non-isoform-specific APT inhibitors that have been characterized and investigated 
in previous publications[44,45,90]. As described in Chapter 3.4.3, Palmostatins are based on a β-
lactone core acting as a nucleophilic trap coupled to an aliphatic tail to mimic the palmitoyl moiety 
of posttranslationally modified proteins, plus different head groups. Inhibition of biochemical activity 
of yeast APT by palmostatins with a sub-µM IC50 has been shown before[74]. The significantly higher 
IC50 of palmostatin B and yeast APT compared to human APT1 and APT2 (800 nM compared to 
5.4 nM and 19 nM, respectively) indicates that some stabilizing interaction is not possible in yeast 
APT.  
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Figure 25: Inhibitory effect of palmostatin B and palmostatin M on yeast APT, human APT1 and APT2. IC50 values 
were determined as described in [74] using XLfit. Palmostatin B is significantly less potent on yeast APT 
compared to both human isoforms. Graph created using Microsoft Excel.  
Palmostatin B was co-crystallized with yeast APT under optimized conditions similar similar to the 
crystallization condition of the apo structure of yeast APT. Macro-seeding of complex crystals to 
drops containing fresh protein-inhibitor complex in solution considerably increased the diffraction 
quality of crystals. The harvested crystals were transferred to drops on cover slips containing dried-
out palmostatin B (DMSO of stock solution was evaporated). The cryo solution contained reservoir 
solution plus 10% glycerol and additional fresh 2.5mM palmostatin B, in which the crystal was 
soaked only for less than a minute. Fresh palmostatin B is essential in the cryo solution, as the 
covalent complex has a short half-life due to hydrolysis of the ester.  
Data collection and structure solution via molecular replacement using the yeast APT apo structure 
is described in Chapter 7.4. The crystals of space group P21 21 21 diffracted to 1.7Å at the 
synchrotron.  
 
Figure 26: Crystals of yeast APT in complex with palmostatin B. The right crystal grew around a macro-seeded 
crystal, still visible in yellow. The left crystal appeared after 3 hours and grew slowly for 7 days when it was 
isolated and used for data collection. The condition #89 from Classics screen contains 30% PEG 4000, 0.1 M 
Li2SO4, and 0.1 M Tris pH 8.0 - 8.5. Crystals were grown in hanging drops on glass slides in 24-well plates and 
photographed using an Olympus DP21 attached to an Olympus CX-60 microscope with polarization filter. Scale 
bar inserted using Gimp[4]. 
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Table 2: Crystallographic statistics of yAPT - palmostatin B complex. Values for the highest shell are given in 
parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
yAPT – 
Palmostatin B   
Data collection  17 Jun 2012 Refinement   
Space group P212121 Resolution (Å) 
45.1-1.7 (1.74-
1.7)  
Cell 
dimensions   
Number of 
Reflexes 80522 (6234) 
    a, b, c (Å) 
44.34    45.26    
90.21 Rwork 18.8 (36.5) 
    α, β, γ (°) 90.00 90.00  
90.00 Rfree 23.2 (32.3) 
Resolution (Å) 45.1-1.7 
(1.74-1.7) Number of Atoms   
Monomers / au 1     Protein 1756  
Wave length 
(Å) 0.9785      Ligand/Ions 27  
CC 1/2 99.7 (61.5)      Water 132  
I / σ(I)  9.1 (1.6) B-factor (Å2)   
Completeness 
(%) 
89.2 (93.8)     Protein 25.8 ± 10.1 
Redundancy 2.3 (2.3)      Ligand 47.5 ± 16.7 
 
    Water 38.6 ± 12.2 
RMSD   
    Bond length (Å) 0.019 
    Bond angle (°) 1.88 
Ramachandran (%) 97.37 / 2.63 / 0.0 
Clashscore 9.92 
Rotamer outlier (%) 3.73 
Molprobity score 2.08 
 
Interestingly, the asymmetric unit of yeast APT in complex with palmostatin B contains only one 
monomer. The crystal packing is identical to the apo yeast APT structure in the same space group 
P21 21 21 and comparable unit cell dimensions, obtained under similar conditions that was used for 
macro-seeding to obtain the inhibitor complex. In human APT1, the crystals always contained a 
dimer that buried the hydrophobic patch around the entrance of the binding tunnel, close to the 
active site. In contrast, yeast APT structures do not show similar contacts in the crystals. Instead, 
the active site is accessible, and the lid-loop is part of crystal contacts, as shown in Figure 27. This 
corresponds to a relatively low B-factor, the Cα atoms of the lid-loop have an average B-factor of 
29.88 Å2, which is not significantly increased compared to the protein main chain overall B-factor of 
23.50 Å2. The buried interface of human APT1 dimers ranges from 1659 to 2415 Å2 ([69], PDB ID 
1fj2) whereas the largest buried surface in yeast APT is 605 Å2.  
  Results 
 28 
 
Figure 27: Crystal contacts of the yeast APT - palmostatin B complex. No extended interfaces are formed in the 
crystal, similar to the structure of yeast APT apo that crystallized in the identical space group with similar unit 
cell parameters. The active site remains accessible, and the lid-loop is involved in crystal contacts.  
A comparison of the palmostatin B complex and the high-resolution structure of the apo form of 
yeast APT described in Chapter 5.1.1 reveals a nearly identical structure with an rmsd of 0.25Å 
over 226 amino acids. Yeast APT apo and the complex with palmostatin B crystallized in the same 
space group P21 21 21 and a similar unit cell. Binding of palmostatin B causes only marginal 
differences in the lid-loop and overall structure (Figure 28). 
 
Figure 28: Comparison of the yeast APT the apo structure (dark green) and in complex with palmostatin B 
(green). The lid-loop of the complex (red) is not changed in its conformation compared to the apo structure (dark 
red), with the side chains being oriented identical in both structures.  
Since both the palmostatin B complex and the high-resolution structure of the apo form of yeast 
APT crystallized in a very similar unit cell and same space group, the complex was compared to the 
older structure of the apo form of yeast APT crystallized in P42 21 2[69,74]. This apo form of yeast 
APT containing four monomers per asymmetric unit, was used for comparison to investigate the 
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influence of crystal contacts. Due to the different environment of the four monomers, monomers A 
and D possess lid-loops exposed to a solvent channel, unaffected by crystal contacts. In contrast, 
the individual lid-loops of monomers B and C are both part of different crystal contacts.  
The four monomers each have an overall rmsd between 0.44 to 0.54 Å over 224 to 225 amino 
acids. The local rmsd of the lid-loops only are increased to 0.75 to 0.98 Å, indicating a larger 
flexibility of the loop than the rest of the core protein, but no significant change upon binding of 
palmostatin B.  
 
Figure 29: Comparison of the four monomers of the previous structure of yeast APT in apo form refined to 2.2 Å 
[master thesis] with yeast APT in complex with palmostatin B. The conformation of the lid-loop (dark red) slightly 
varies insignificantly between the four monomer (A-D) of the asymmetric unit of yeast APT apo (dark green) and 
the palmostatin B complex (green/lid-loop in red). The different rotamers of W77 observed in the apo structure of 
yeast APT are the most prominent changes, but also indicate certain flexibility at this position.  
Well-defined electron density was visible for the aliphatic tail, as well as for the β-lactone moiety of 
palmostatin B (Figure 30). The β-lactone core of palmostatin B acted as a nucleophilic trap as 
designed,[44] and was found to be covalently bound to the active site serine. The aliphatic decanoic 
tail is located inside the hydrophobic tunnel next to the active site. However, the aromatic head 
group lacks a well-resolved electron density despite the high resolution of the diffraction data, 
indicating a weak, statistically disordered binding of the head group corresponds to multiple 
conformations.  
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Figure 30: Yeast APT in complex with Palmostatin B. Palmostatin B (grey sticks) is bound covalently via an ester 
bond resulting from the nucleophilic attack of S119 on the β-lactone core of Palmostatin B. The well resolved 
electron density shows the opened β-lactone covalently attached to S119. The hydrophobic tail occupies the 
hydrophobic binding tunnel formed by the flexible lid-loop (shown in red). The head group is probably mostly 
oriented close to L23 at the tunnel entrance, but the lack of well-defined electron density indicates multiple 
binding modes. Electron density shown as blue mesh scaled to 1 δ.  
The active site serine itself is covalently linked to the hydrolyzed β-lactone core, forming an ester 
bond (Figure 31). The oxyanion hole formed by the backbone amides of L23 and Q120 stabilizes 
the transition state of the tetrahedral intermediate of the attacked β-lactone (in case of the a 
palmitoylated protein, the palmitoylate thioester), and forms H-bonds with the ester of the resulting 
stable covalent complex. The newly formed hydroxyl group of the opened β-lactone forms a 
hydrogen bond with Nε of H207 of the catalytic triad. G24 and D63 are in close vicinity to the 
methylethers of the head group that is placed in accordance to the geometric restrains due to the 
weak electron density. A 2D representation of the interaction of palmostatin B with yAPT generated 
with LigPlot+[91] is shown in Figure 31.  
 
Figure 31: 2D representation of the interactions of palmostatin B with yeast APT. The aliphatic tail is bound in the 
hydrophobic tunnel. The active site serine opened the β-lactone; the resulting ester is stabilized by the backbone 
amide of L23 and Q120 that forms the oxyanion hole. The head group is positioned according to geometric 
restraints due to the lack of clean electron density; therefore the interactions shown here is representative of 
one of multiple possible orientations of the head group. Figure generated with LigPlot+[91]. 
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Two positions of water molecules at the active site in the palmostatin B complex with the apo form 
of yeast APT are compared in Figure 32. Water molecule 1 is coordinated by the side chain of D25 
and the carbonyl oxygen of L23, and present in both crystals. In the apo form, a second water 
molecule is coordinated by Nε2 of H207 and the first water molecule; this second water molecule is 
activated through de-protonation by H207 and regenerates APT by attacking the palmitoyl-serine 
ester reaction intermediate (see Figure 7 for detailed information). Strikingly, the exact position of 
this water molecule is occupied by the hydroxyl group of the opened β-lactone in the palmostatin B 
complex, as illustrated in Figure 32. This impedes hydrolysis of the covalent complex, and enables 
the observation of the covalently bound palmostatin B by x-ray crystallography.  
 
Figure 32: Comparison between water coordination next to the active site serine in the palmostatin B complex 
(A) and apo form (B) of yeast APT. Palmostatin B forms hydrogen bonds via the ester to the oxyanion hole 
backbone amides of L23 and Q120, similar to the glycerol molecule found in the apo form. The apo form contains 
two water molecules, the first being coordinated by the carbonyl oxygen of L23 and the carboxylic acid side 
chain of D25, and the enzyme regenerating water that is coordinated by the first water and activated by H207. In 
the palmostatin B complex, the first water is also present but moved by 0.7Å, but the exact position of the 
regenerating water is occupied by the hydroxyl resulting from the opened β-lactone of palmostatin B, thereby 
slowing down hydrolysis of the palmitoyl-serine ester.  
The interaction of palmostatin B with APT can be divided in the three parts of the ligand: the β-
lactone core is bound by the active site and coordinated by the oxyanion hole, the aliphatic tail is 
located inside the hydrophobic tunnel, and the head interacts with amino acids close to the active 
site. The individual amino acids are shown above in Figure 31. Amino acids interacting with the β-
lactone core and the head group are conserved between yeast and human APT (Figure 33).  
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Figure 33: Superimposition of human APT1 apo and the yeast APT - palmostatin B complex. The amino acids 
interacting with the head and core of palmostatin B are conserved and shown as sticks. The lid-loop forming the 
hydrophobic tunnel is not conserved and the tunnel differs in shape, but the aliphatic tail of palmostatin B is 
flexible enough to fit into either a bent or linear tunnel.  
In summary, conditions could be found for successful soaking of yeast APT crystals with the 
covalent inhibitor palmostatin B. Clear electron density for the inhibitor revealed a binding in the 
hydrophobic tunnel and covalent attachment to the active site serine. The head group apparently 
does not interact with the protein. Therefore, an inhibitor with a larger head group was investigated 
as described in the following.  
5.1.3 Crystal structure of the yeast APT - palmostatin M complex 
Palmostatin M was designed as the next generation of β-lactone based inhibitors (see Figure 13). 
The search for a common motif in shape and charge of two of APTs natural substrates; 
lysophospholipids and palmitoylated H-Ras C-terminus, resulted in the long and flexible head group 
of palmostatin M that should address the same hydrogen bond network as the natural substrates 
(see Chapter 3.4.3). Indeed, the modified head group increased affinity for human APT and in vivo 
potency in cells[77].  
Crystallization screens were set up as described in Material and Methods. Several PEG-containing 
conditions resulted in well-diffracting crystals, but many structures solved from these crystals 
lacked evidence of binding of palmostatin M, or had very low occupancy of the inhibitor. Refinement 
of the condition that already resulted in well-diffraction crystals of apo yeast APT and the yeast APT 
palmostatin B complex worked also for the complex of yeast APT and palmostatin M. Crystals were 
grown in drops (containing 0.2 M LiSO4, 0.1 M Tris-HCl pH 8.0 and 32% PEG 4000) placed on 
palmostatin M dried on glass plates (1 µl of 10mM stock, DMSO of stock solution was left to 
evaporate). The best-diffracting crystal was isolated in a thin liquid film directly from the drop 
without transfer to a cryo solution. Diffraction data was collected and the structure was solved via 
Molecular Replacement and refined to a resolution of 2.4 Å as described in Material and Methods. 
The crystallographic statistics is summarized in Table 3. Interestingly, the crystals of the yeast APT 
- palmostatin M complex now belong to space group P42 21 2 containing four monomers per 
asymmetric unit, in contrast to the palmostatin B complex that belongs to space group P21 21 21 and 
one monomer per asymmetric unit obtained under similar crystallization conditions, but similar 
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space groups and unit cell to one of the apo form of yeast APT (compare Table 3 to Chapter 5.1.1, 
Table 1).  
 
Figure 34: Crystallization drop of yeast APT in complex with palmostatin M. The drop (containing yeast APT 
(1.2 mM) mixed at 1:1 ratio with reservoir solution containing 0.2 M Li2SO4, 0.1 M Tris-HCl pH 8.0, and 32% PEG 
4000) was placed on palmostatin M dried on a glass cover slip. Clean, single crystals were isolated for x-ray 
diffraction data collection in a thin liquid film directly from the drop without cryo solution. Crystals photographed 
using an Olympus DP21 camera attached to an Olympus CX-60 microscope with polarization filter. Scale bar 
inserted using Gimp[4].  
Table 3: Crystallographic statistics of the complex of yeast APT and palmostatin M. Values for the highest shell 
are given in parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier. 
 
yAPT – 
palmostatin M  
 
Data collection  26 Oct 2012  Refinement   
Space group P 42 21 2 Resolution (Å)  48.38-2.4 
Cell 
dimensions  
Number of 
Reflexes  356262 (25851) 
    a, b, c (Å) 
 145.6, 145.6, 
96.8 Rwork  17.7 (25.7) 
    α, β, γ (°) 90.0, 90.0, 
90.0 Rfree  24.6 (35.5) 
Resolution (Å) 
48.38-2.4 
(2.46-2.40) Number of Atoms   
Monomers / au 4     Protein  7036 
Wave length 
(Å) 
 0.9786     Ligand/Ions  146 
CC 1/2  99.8 (83.4)     Water  441 
I / σ(I)  13.6 (2.3)  B-factor (Å2)   
Completeness 
(%) 
 100 (99.9)     Protein 53.1 ± 16.5 
Redundancy  8.6 (8.6)     Ligands 79.0 ± 26.0 
 
    Solvent 50.5± 8.3 
RMSD   
    Bond length (Å) 0.014 
    Bond angle (°) 1.58 
Ramachandran (%) 96.48 / 3.52 / 0 
Clashscore 2.54 
Rotamer outlier 2.67 
Molprobity score 1.59 
 
The crystal indexed in P42 21 2 contained four monomers per asymmetric unit, with similar packing 
to the yeast APT apo structure crystallizing in the same space group. Similarly to this apo crystal 
form, all monomers have an active site accessible by solvent channels, and two of four monomers 
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(C+D) have the lid-loop located at a solvent channel not influenced by crystal contacts, while the 
lid-loop of monomer A and B is part of different crystal contacts as shown in Figure 35. The 
different environment might have influence on the conformation of the head group of palmostatin M, 
as shown later in detail in this chapter. 
 
Figure 35: Exemplary view of the crystal packing of yeast APT - palmostatin M complex. All four monomers have 
the active sites accessible through solvent channels of the protein. The lid-loop of monomers A(dark 
green)/B(light green) is part of crystal contacts to symmetry mates (grey) and thus could reduce its flexibility, 
shown here for monomer A.  
The structure was refined to a resolution of 2.4 Å and contained positive difference electron density 
ranging from the active site serine both upwards to the protein surface and down into the 
hydrophobic tunnel, which could be unambiguously fitted to Palmostatin M. Similar to palmostatin 
B, the β-lactone core is covalently bound as an ester to the nucleophilic hydroxyl of the active site 
serine. The aliphatic tail binds inside the hydrophobic tunnel. The distinctive flexible head group of 
palmostatin M is bound to the protein surface in close proximity of the active site. Its orientation 
varies between the four monomers of the asymmetric unit. Three of the four monomers (A-C) 
contain palmostatin M in a conformation with the head group located in front of W77 of the lid-loop, 
although in monomer C the electron density is quite weak. However, the electron density of 
palmostatin M bound in monomer D is the best defined for the whole inhibitor, including the head 
group. Here, the head group forms a charged interaction with the backbone amide oxygen of L23 
instead. The sulfonyl group is coordinated by the amide of N63 in all four monomers, but whilst in 
three monomers (Figure 36, grey) the flexible amine is located in front of the side chain indole of 
W77, the head group of the fourth palmostatin M (turquoise) in chain D electrostatically interacts 
with the oxygen of the backbone amide of L23. However, the electron density is weaker for the 
head group than for the covalently bound core and aliphatic tail, demonstrating the flexibility of the 
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head group and statistically disordered binding. A superimposition of the four monomers with a 
focus on palmostatin M is shown in Figure 36.  
 
Figure 36: Superimposition of all four chains of yeast APT - palmostatin M complex. The opened β-lactone core 
and aliphatic tail are identically bound in the four monomers. The head group of three molecules (grey) shows 
relatively weak electron density in front of W77, whereas the tertiary amide of the head group of the fourth 
molecule (turquoise, monomer D) shows a well defined density and seems to form a charged interaction with the 
backbone carbonyl oxygen of L23.  
As shown in Figure 36, monomer D contains palmostatin M bound with its head group in front of 
L23. In this monomer, the electron density is the best defined, suggesting that this orientation of the 
head group is more stable. A reason for the different binding modes is the crystal packing. In 
monomer A, the space in front of L23 is blocked by the N-terminal end of monomer C, as shown in 
Figure 37A. This prevents the binding of the palmostatin M head group at the amide backbone of 
L23, as it would clash with the neighbor’s N-terminus. The space in front of L23 in monomer B is 
limited by Q39 of monomer C to a narrow gap only allowing to accommodate three water molecules 
(Figure 37B), blocking the amide oxygen of L23 by crystal contacts as binding site of the head 
group of palmostatin M. The active site and lid-loop of monomer C are positioned next to a solvent 
channel, resulting in enough space for palmostatin M to bind in front of L23, and the electron 
density indicates a mix of both conformations of the head group bound next to L23 and W77.  
 
Figure 37: A: L23 of monomer A is blocked by the N-terminus of monomer C, thus preventing binding of the 
palmostatin M head group at this position. B: Narrow gap between L23 of monomer B and Q39 of monomer C. 
The head group of palmostatin M is bound at the indole ring of W77.  
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An analysis of the interactions of yeast APT with palmostatin M is shown for both conformations of 
the head group, taking chain A as example for the head group bound in front of W77, and chain D 
containing palmostatin M in the second conformation of the head group where the tertiary amide of 
the head group forms a charged interaction with the carbonyl of L23. The analysis of the interaction 
was carried out using LigPlot+[91] and is shown in Figure 38. 
 
Figure 38: Analysis of the binding mode of palmostatin M to yeast APT. In all four monomers, palmostatin M is 
covalently bound by S119 via the opened β-lactone with aliphatic tail inside the tunnel. The sulfonyl moiety of the 
flexible head group is coordinated by N63 in all four monomers. Three of the four monomers (A,B,C) have 
evidence to bind palmostatin M in the mode as observed in chain A (left), with the head group folding onto the 
lid-loops W77. Monomer D (right) contains palmostatin M with the head group in a different orientation bound 
close to L23. Structure analyzed using LigPlot+[91].  
The comparison with the apo structure of yeast APT crystallized in the same space group and very 
similar unit cell shows the induced fit of palmostatin M binding on the lid-loop. Both monomers (A 
and B) whose lid-loop is involved in crystal contacts show only minor outwards movement of the lid-
loop by less than one Ångstrom compared to the apo structure (measured at the Cα of P79) 
caused by palmostatin M binding inside the tunnel (see Figure 39A). A stronger influence by 
Palmostatin M binding is observed on the lid-loop of monomer C and D. In these monomers of the 
complex structure, the Cα of P79 is moved by nearly 2 Å compared to the apo structure (see Figure 
39B). The lid-loop of the latter monomers C and D is located next to a solvent channel and forms 
no contacts to neighbor molecules. Other parts of yeast APT like the L23 or the A62 containing 
loops are not affected in their conformation by binding of palmostatin M. The minor movements of 
the lid-loop upon ligand binding corroborate the rigidly pre-formed binding tunnel. This is illustrated 
in the following Figure 39.  
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Figure 39: Comparison of the effect of palmostatin M on the lid-loop. Panel A shown a monomer of yeast APT 
(green, lid-loop in red) in complex with palmostatin M (grey) superimposed with yeast APT apo. The lid-loops of 
both structures are part of crystal contacts, which might lead to a slightly biased conformation. The monomer 
superimposed in panel B has the lid-loop located next to a solvent channel, enabling induced fit movements of 
the tip in the case of the palmostatin M complex.  
A superimposition of a monomer of yeast APT - palmostatin M complex and apo form of human 
APT1 has an rmsd of 1.27Å over 209 Cα and is shown in Figure 40. The active site residues, L23, 
and N63 are conserved between yeast and human. The amino acids of the lid-loop, and thus the 
surface at this side of the tunnel entrance is not conserved. It remains unclear if the head group of 
palmostatin M would prefer the same or a different orientation in human APT1. As noted above, it is 
probably impossible to get the structure of human APT1 in complex with palmostatin M since the 
active sites are not accessible in all available crystal forms, at least of the wild type (see also 
Chapter 5.3). 
 
Figure 40: Superimposition of yeast APT (green) in complex with palmostatin M (grey) and human APT1 (blue). 
The lid-loop of yeast and human APT is colored in red and dark red, respectively. Interesting amino acids 
interacting with palmostatin M are highlighted as sticks, the residue numbers are shown in the respective color. 
The L23 and N63 residues, interacting with the head group of palmostatin M in yeast APT, are conserved, in 
contrast to the residues of the lid-loop.  
As the head group of palmostatin M was designed to target the same binding site as 
lysophosphocholine (see Introduction Chapter 3.4.3), it can only be speculated that this structure 
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represents the likely binding mode of a lysophosphocholine molecule. However, due to the lack of 
structures available of a lysophosphocholine in complex with APT, the confirmation of the binding 
mode is not possible at this time.  
In summary, both inhibitors B and M of the palmostatin class bind covalently at the active site 
serine via the β-lactone core and the aliphatic tail is tightly coordinated inside the hydrophobic 
tunnel. Merely the head group differs and provides the likely reason for improved affinity and in vivo 
activity of palmostatin M, as it is longer and more flexible to provide additional interaction with the 
protein. Interestingly, the head group of palmostatin M seems to interact with the conserved part of 
the surface. 
 
5.1.4 Crystal structure of human APT1 in complex with Cerulenin  
Cerulenin was discovered as antifungal antibiotic that inhibits fatty acid metabolism by covalently 
binding to FAS[79] (see Chapter 3.4.4) that is upregulated in many invasive cancers[81]. It has been 
also suggested that Cerulenin inhibits protein acylation[82]. Palmostatin M and Cerulenin share 
some structural features (see Figure 14), a hydrophobic tail next to an electrophile, and potential for 
a comparable hydrogen network coordination of their respective head groups. Consequently, we 
wondered whether Cerulenin could also serve as an inhibitor of APT where the activated epoxide 
would serve as nucleophilic trap for the catalytic serine of APT. High resolution crystal structures of 
beta-ketoacyl-ACP synthase II (FabF) in non-covalent and covalent complex with Cerulenin had 
been reported recently (PDB ID 4ls7 / 4ls8, [85]). In this case, Cerulenin is attached to the active site 
cystein where the covalent bond is formed to the carbon C3 of the inhibitor, in contrast to the 
previously proposed C2 carbon (Figure 14).  
An attack on the epoxide by the nucleophilic serine of APT results in an irreversible ether, and 
depending on affinity, reactivity and incubation time, equilibrium could be completely shifted to the 
covalent complex prior to crystallization. This provides an advantage for crystallographic 
approaches since crystal growth is usually slower (hours to weeks) than the the hydrolysis of 
reversible complexes like in the case of palmostatin B and M. Human APT1 wild type (1.3 mM) and 
Cerulenin (up to 9-fold molar excess) were mixed in gelfiltration buffer (see Chapter 7.2.11) and 
incubated at 20˚C for 400 min. Complex formation was monitored via ESI-MS as described in 
Chapter 7.2.13. An equimolar human APT1 - Cerulenin adduct could be observed nearly instantly 
(data not shown). After 400 min incubation of human APT1 wild type with a 6-fold molar excess of 
Cerulenin (8.4 mM), a maximum binding of three Cerulenin molecules per human APT1 protein is 
observed (Figure 41), but also showed that a significant fraction of unmodified protein remains in 
the sample. Using a simple 1,2-hexadecylpoxide lacking any electron-drawing groups next to the 
epoxide does not result in significant modification of APT (data not shown).  
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Figure 41: Formation of the covalent human APT1 – Cerulenin complex monitored via ESI LC-MS. After 400 min 
incubation of 1.3 mM human APT1 wild type with 8.4 mM Cerulenin at 20˚C, the apo form of human APT1 (peak A, 
m=24,310.0 Da) and the single (m=24,529.0 Da), dual (m=24,750.0 Da) and triple (m=24,974.0 Da) adduct with 
Cerulenin are observed (peaks B, C, D). LC-MS data analyzed using Xcalibur (ThermoFisher) and MagTran[92] and 
the figure prepared using Gimp[4].  
Encouraged by the expected stable ether bond adduct at the active site serine, Cerulenin was co-
crystallized with human APT1. Three different molar ratios (1:3, 1:6, 1:9; 1.3 mM of human APT1 to 
3.9 mM, 7.8 mM and 11.7 mM Cerulenin, respectively) of the human APT1 - Cerulenin complex 
were subjected to screening yielding reasonably diffracting crystals, which were isolated directly 
from the screening plate. Diffraction data to a resolution of 2.5 Å was collected at SLS in Villigen, 
CH and the structure was solved via MR using the apo form of human APT1 wild type as template. 
The statistics of the structure are summed up in Table 4.  
 
Figure 42: Crystallization drop of human APT1 in complex with Cerulenin. The drop contained human APT1 (1.4 
mM) and Cerulenin (4.5 mM). Screening condition G1 / #73 of Core1 screen containing 20% PEG 3350 and 0.18 M 
tri-ammonium citrate. Crystals grew within one week and were isolated directly from the screening plate. Image 
taken by Formulatrix Imager. 
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Table 4: Crystallographic statistics of the refinement of the human APT1-Cerulenin complex. Values for the 
highest shell are given in parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
- Cerulenin   
Data collection  16Apr 2014 Refinement   
Space group P 42 21 2 Resolution (Å) 
 45.6-2.5  
(2.57-2.5) 
Cell dimensions    Number of Reflexes  990309 (38294) 
    a, b, c (Å) 
91.15 91.15 
255.53 Rwork 20.7 (33.6) 
    α, β, γ (°) 90.00 90.00  
90.00 Rfree 24.0 (41.3) 
Resolution (Å) 45.6-2.5 
(2.57-2.5) Number of Atoms   
Monomers / au 4     Protein  6756 
Wave length (Å) 0.91887      Ligand/Ions  112 
CC 1/2  100 (64.2)     Waters  67 
I / σ(I)  21.2 (1.65) B-factor (Å2)   
Completeness (%)  100 (100)     Protein 64.7 ± 18.3 
 
    Ligand 88.7 ± 20.3 
    Waters 61.1 ± 15.0 
RMSD   
    Bond length (Å) 0.0154 
    Bond angle (°) 1.82 
Ramachandran (%) 96.19 / 3.59 / 0.22 
Clashscore 8.39 
Rotamer outlier 3.24 
Molprobity score 2.10 
 
As expected, human APT1 is covalently modified with Cerulenin at the active site, and the aliphatic 
tail is bound in the substrate binding tunnel. The crystal structure of human APT1 in complex with 
Cerulenin contains four monomers per asymmetric unit. The four monomers are arranged in such a 
way that the largest interface is not related to the dimer observed for the apo form of human APT1 
(Figure 43A). Closer inspection of the residues located in the new interface reveals a strong 
difference electron density at the thiols of C168 and C206, which are exposed on the surface, 
indicating a covalent modification by Cerulenin. The binding of Cerulenin would clash with 
monomer B of the apo form dimer. In addition, Cerulenin contains a long hydrophobic tail, and thus 
forms a new hydrophobic patch, which supports the formation of this interface. The modification of 
the surface exposed cysteines was observed in all crystals obtained from different human APT1 – 
Cerulenin ratios, varying from 3:1, 6:1 and up to 9:1, all resulting in crystals of comparable 
diffraction and electron density quality. The comparison of the new interface of the Cerulenin 
complex to the human APT1 apo dimer is depicted in Figure 43B.  
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Figure 43: A: Content of the asymmetric unit of the human APT1 – Cerulenin complex. The four monomers do 
not form a contact comparable to the dimer of human APT1 apo form. B: Interface of the human APT1 – 
Cerulenin complex (dark blue, surface) compared to the human APT1 apo dimer (light blue, ribbon, from[69]). Two 
monomers of each structure were superposed highlighting the differing position of the respective second 
monomer of the structure. Cerulenin is bound to the active site serine with the hydrophobic tail inside the 
binding tunnel. Both cysteine residues located on the protein surface are covalently modified by Cerulenin as 
well and contribute to the new interface in the crystal.  
Cerulenin binds at the active site with the tail in the binding tunnel. The aliphatic chain is half as 
long as palmitate, the acyl moiety of the natural substrate, and stretches from the entrance of the 
binding tunnel between L73 and L171 to the middle of the tunnel marked by W140. A diffuse 
electron density is observed at the active site serine, indicating a mixture of two covalent binding 
modes and complicating precise model building. The electron density of the head group is not 
defined enough to clearly identify a preferred binding mode, but the binding mode via the ether 
formed at C3 fitted slightly better to the electron density (Figure 45A). Two hydrogen bonds 
stabilize the head group: the hydroxyl group resulting from the opened epoxide at C2 binds inside 
the oxyanion hole via H-bond to the backbone amide of L25. The amide head is coordinated via H-
bonds to Nε of H203 and the backbone carboxyl of L25 (see Figure 46). The activated epoxide of 
Cerulenin can be attacked on two chemically nearly identical positions, resulting in irreversible 
ethers (Figure 44). Both reactions are energetically comparable, and thereby lead to a mixture of 
both possible adducts and a diffuse electron density, if Cerulenin is not coordinated during the 
nucleophilic attack. 
 
Figure 44: Nucleophiles can attack the epoxide of Cerulenin at both C2 (right) and C3 (left) position, resulting in a 
mixture of two adducts. Image created using ChemBioDraw13.  
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The two Cerulenin molecules bound to the surface cysteines are not bound in one defined 
orientation in the interface between the two proteins, resulting in no or only weak electron density 
for the aliphatic tail. Cerulenin adducts at both surface exposed cysteines are less well described 
by electron density than at the active site (Figure 45B & C). The Cerulenin adducts in monomer A 
are shown in Figure 45 as an example and are compared to the published structure of the covalent 
FabF-Cerulenin complex (Figure 45D).  
 
Figure 45: Comparison of the Cerulenin adducts observed in at the active site of human APT1 (A), and at both 
surface exposed cysteines (B, C) at 2.5 Å resolution. The high-resolution structure of the biological target of 
Cerulenin, FabF, is shown in the inhibited state with Cerulenin covalently bound to its active site cysteine 163 (D, 
PDB ID 4ls8, 2.1 Å resolution). The Fo-Fc electron density is shown at 1σ.  
The lack of a preference for one binding mode results in a mixture and ambiguous electron density, 
which complicates building the adduct structure of the complex. Furthermore, the recently 
published high-resolution structure of Cerulenin covalently inhibiting its biological target FabF (PDB 
ID 4ls8) opens another question. The structure solved at a resolution of 2.1 Å shows a clear 
electron density of covalently bound Cerulenin, but the electron desity supports an adduct that is 
chemically difficult to explain. Cerulenin was attacked by the thiol of cysteine at C3 and is 
covalently bound. The epoxide oxygen, however, is not located at C2 as it would be expected 
according from the SN2 reaction. As stated in[85], the unambiguous electron density only supports 
the oxygen bound to the C3, resulting in a O,S-hemiketal. The authors suggest a more complex 
reaction mechanism with its natural target, involving a rearrangement after initial attack[85].  
The electron density of the human APT1 – Cerulenin complex is not defined enough to support a 
complex adduct that underwent this chemically challenging rearrangement. Therefore, the adduct 
bound at C3 (which fitted best into the electron density) containing the α-hydroxyl group was built in 
the structure of human APT1 - Cerulenin complex. An analysis of the interactions of Cerulenin 
bound at the active site is shown in Figure 46.  
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Figure 46: Interactions of human APT1 with the major conformation of Cerulenin covalently bound at its active 
site. The covalent adduct to the active site serine binds with the hydrophobic tail inside the binding tunnel. The 
short head group forms two hydrogen bonds, one between the hydroxyl group at C2 and the amide of L25, and 
another between the amide and Nε of H203. Interactions visualized using LigPlot+[91].  
Albeit Cerulenin is less well coordinated (possibly bound as a mixture of both adducts at C2 and 
C3) than both palmostatins (described in Chapter 5.1.2 and 5.1.3), the complex structure proves 
the feasibility of using activated epoxides as nucleophilic trap for APT. The reactivity must be 
significantly reduced to avoid unspecific modification of solvent-accessible thiols if one would want 
to use Cerulenin as serine hydrolase specific inhibitor.  
5.1.5 Crystal structure of human APT1 in complex with 2-Bromopalmitate  
2-Bromopalmitate (2BP) is the α-brominated derivative of APTs natural product palmitate. 2BP is 
widely used as inhibitor of palmitoylation in cell experiments in vivo in order to interfere with 
palmitoylation mediated subcellular localization of proteins. Recently, 2BP was published to be an 
inhibitor of human APT1 and 2, inhibiting depalmitoylation as well[87]. The mode of inhibition was 
described as “uncompetitive”, meaning that the inhibitor binds to the pre-formed enzyme-substrate 
complex. The above presented structures of yeast APT in complex with palmostatin B and 
palmostatin M, and co-purified tunnel-bound fatty acids in Xenopus tropicalis APT1 homolog[69], 
provided evidence for binding of long-chained aliphatic molecules inside the binding tunnel. Due to 
the nearly identical structure of 2BP with palmitate, an identical and thus competitive binding mode 
to palmitate inside the hydrophobic binding tunnel[69] was expected, which would at least partially 
contradict the idea of an uncompetitive inhibitor[87]. To resolve this contradiction, the complex of 
human APT1 and 2BP was co-crystallized and represents the first structure of human APT1 in 
complex with a non-covalent inhibitor. The binding site was verified via Stopped Flow 
measurements, described in Chapter 5.1.7.  
To prepare the 2BP complex, human APT1 was pre-incubated with a 3-fold molar excess of 2BP 
for 10min at 50˚C, as complex formation is facilitated at increased temperatures (Stefan 
Baumeister, private communication). The protein-inhibitor mixture was subjected to screening for 
suitable conditions as described in Material and Methods, covering a total of 768 conditions. 
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Crystals grew at several conditions, and a strong preference for conditions containing various 
PEGs of small to medium molecular weight at a pH range between 4.6 and 8.5 was observed. 
Significantly better electron density for 2BP corresponding to higher occupancy was observed at pH 
≥ 7.0. Large, single crystals also grew in one PEG-free condition containing 1.0 M (NH4)2SO4 and 
0.1 M Bicine, pH 9.0 and this crystal was isolated using perfluorated 4500 cryo oil to prevent ice 
formation upon freezing the crystal. As the monomeric structure of the human APT1 – 2BP complex 
is nearly identical in different crystals belonging to different space groups obtained under different 
conditions, only the best diffracting crystal is presented here which grew in screening condition 
Core1 B2 under a strong but easily removable skin. Diffraction data was collected as described in 
Material and Methods at X10SA at SLS, Villigen, (CH) using monochromatic x-rays of 0.9242 Å 
wavelength to provide anomalous data to support the position of the bromine atom.  
 
Table 5: Crystallographic statistics of human APT1 in complex with 2BP. Crystals were grown in JCSG Core1 
condition B2. Values for the highest shell are given in parentheses. Values for Ramachandran plot are given for 
favoured, allowed and outlier.  
 
human APT1 
+ 2BP    
Data collection  Refinement  
Space group  P21  Resolution (Å) 
 46.37 - 1.6 (1.64 
- 1.6) 
Cell dimensions   Number of Reflexes  1733591 (128472) 
    a, b, c (Å) 
 72.59 62.08 
114.67 Rwork  17.6 (28.3) 
    α, β, γ (°) 
 90.00 
106.13 90 Rfree  21.2 (34.7) 
Resolution (Å)  45.87 -1.6 
(1.64 - 1.60) Number of Atoms   
Monomers / au  4     Protein  6866 
Wave length (Å)  0.92045     Ligand/Ions  247 
CC 1/2  99.9 (75.4)     Water  1276 
I / σ(I)  19.93 (1.70) B-factor (Å2)  
Completeness (%)  98.3 (97.3)     Protein  21.5 ± 8.2 
Redundancy  6.94 (6.99)     Ligands  30.0 ± 9.6 
 
 
  
    Solvent  35.6 ± 9.1 
RMSD  
    Bond length (Å)  0.0244 
    Bond angle (°)  2.23 
Ramachandran (%)  97.14 / 2.86 / 0.0 
Clashscore  7.74 
Rotamer outlier  1.19 
Molprobity score  1.64 
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Figure 47: Crystals of human APT1 in complex with 2-bromopalmitate, grown in Core1 B2 containing 0.1 M 
HEPES at pH 7.5 and 20% PEG 8000. The complex was pre-incubated prior to setting up the crystallization plate. 
Crystals appear within 12 hours and grow for eight days. Photograph taken using Formulatrix Rock imager.  
The best-diffracting crystal of human APT1 in complex with 2BP contains 4 monomers per 
asymmetric unit, forming two dimers similar to each other (rmsd of 0.43Å over 443 amino acids) 
and relatively similar to the apo form of human APT1 (Figure 48A, rmsd of 0.55 Å over 219 amino 
acids). The second monomer of the two dimer of the human APT1 - 2BP complex is rotated by 4.1˚ 
and 6.9˚ compared to human APT1 apo protein crystallized in P1[69]. The active site and the 
entrance to the binding tunnel is blocked in the dimer interface in this crystal similar to the apo form 
of human APT1 (not shown), and 2BP is bound inside the binding tunnel of human APT1, similar to 
the co-purified palmitic acid in complex with X. tropicalis APT1 previously described[69]. The 
conformation of the lid-loop and side chains forming the tunnel entrance are not changed, minor 
movements (in the range observed between multiple monomers of one crystal) can be observed for 
the lid-loop as induced fit by binding of 2BP (Figure 48B).  
 
Figure 48: A: Comparison of the dimer formed by human APT1 in complex with 2BP (blue) and the apo form of 
human APT1 (grey). The active site residues and 2BP are shown as sticks, the lid-loop is highlighted in red. B: 
Superimposition of human APT1 in complex with 2BP (light blue) and crystallized in the apo form (dark blue) 
Only minor changes in conformation of the lid-loop (light / dark red respectively) or the side chains forming the 
tunnel entrance (light / dark green) are observed upon binding 2BP (turquoise) inside the tunnel.  
Overall, twelve peaks of the anomalous electron density map were found in the asymmetric unit. 
Two peaks are located at the head group of 2BP next to the active site of each monomer, and two 
further peaks are found in both dimer interface. Their intensities given in I/σI are listed in the 
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following table. The intensity ratio between major and minor conformation shows a preference for 
2BP to bind in the major conformation with the carboxyl head coordinated by the oxyanion hole.  
Table 6: Intensities of the peaks of the anomalous map for bromide, given in I/σI.  
Intensity [I/σI] Major  Minor Interface AD / BC 
Monomer A 28.5 7.0 21.0 
Monomer B 25.8 7.3 14.0 
Monomer C 25.2 8.1 15.6 
Monomer D 27.8 10.2 10.7 
 
The anomalous signal was calculated from the data set collected at the high-remote edge of 
bromine (0.92045Å) at X10SA at SLS and was used to verify the presence and the position of the 
bound 2BP (and to exclude a co-purified fatty acid). Two peaks of the anomalous map were 
observed in the forked electron density of 2BP close to the active site serine (Figure 49), indicating 
that 2BP binds in two orientations. Comparing the intensity of the signals, one is about 3- to 4-fold 
stronger than the other. Consequently, the stronger and weaker signals were assigned to two 
conformations termed major and minor conformation, respectively. The electron density of both 
signals is shown in Figure 49.  
 
Figure 49: Human APT1 co-crystallized with 2BP. Human APT1 is shown in blue with the catalytic triad 
highlighted as sticks, and the lid-loop shown in red. 2BP is shown as turquoise sticks. Electron density of the 
anomalous signals of the α-bromide of 2BP is shown scaled to 5.0 σ. 2BP is shown in the major conformation, 
fitting the α-bromide into the strongest anomalous electron density, and the carboxylate bound in the oxyanion 
hole. In the minor conformation, the α-bromide binds inside the oxyanion hole.  
The electron density of 2BP is very well defined due to the high resolution (1.6 Å) and occupancy. 
This allows a differentiation between both enantiomers of 2BP present in the racemic mixture 
obtained from Sigma Aldrich. The electron density supports fitting of R-2BP in the major 
conformation, with the carboxyl head group forming hydrogen bonds to the backbone amides of 
L25 and Q115 of the oxyanion hole, and as the amide head of Q115 and S114 (Figure 50). A water 
molecule coordinated by H203 and the backbone amide of L25 forms a H-bond to the carboxyl 
head of 2BP. The bromine of 2BP is located close to the side chain of L171, which forms the lower 
part of the tunnel entrance. I70, G72, L73 are located in the lid-loop and form with F176, L179, 
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T180, and W140 the hydrophobic tunnel, in which the aliphatic chain of 2BP is bound (Figure 50). 
R144 is located at the rear exit of the binding tunnel, and the aliphatic part of its side chain contacts 
with the tip of 2BP.  
 
Figure 50: Coordination of R-2BP in major conformation. The carboxyl head group is coordinated via H-bonds to 
the backbone amides of L25 and Q115, the side chain amide of Q115, the hydroxyl of S114, and a water molecule 
that itself is coordinated by imidazole side chain of H203 and the backbone amide of L25. The α-bromide is 
located close to L171 at the tunnel entrance. H-bonds are shown as dashed lines, the amino acids involved in 
hydrophobic interactions with 2BP are shown with a transparent surface. Image created using CCP4mg[93], 
LigPlot+[91] and labeled using Gimp[4].  
2BP is a chiral molecule, and the R-enantiomer fits well into the electron density in the major 
conformation described above. To fit 2BP in the minor conformation, satisfying the anomalous 
signal inside the oxyanion hole, the S-2BP enantiomer was used in order to remain in the same 
geometry at the Cα of 2BP. A cross-validation using the R-2BP in the minor and S-2BP in the major 
conformation including switched occupancies resulted in slightly higher Rfree and a worse fit into the 
electron density. In all monomers, 2BP is bound with 50% occupancy of R-2BP in the major, and 
30% occupancy of S-2BP in the minor conformation. Refining the 2BP molecules with higher 
occupancies resulted in negative difference electron density (2Fo-Fc) at the head group.  
 
Figure 51: Panel A shows R-2BP bound in the major conformation, and S-2BP bound in the minor conformation. 
This arrangement fits the electron density well, the Cα atoms of both 2BP are at the same position and cause no 
clashes. Panel B: R-2BP fitted in the minor reveals a worse fit into the electron density, and furthermore causes 
some clashes.  
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In addition to the two peaks of the anomalous map at the active site corresponding to the α-
bromide of 2BP in two conformations, two additional anomalous signals of perfectly round shape 
were detected in the dimer interface. In both similar dimers, these bromides are located next to and 
coordinated by the side chains of N59 and M64 of both monomers and a water molecule (Figure 
52). These signals can be explained by free bromide ions that are probably impurities from the 
synthesis of the compound, which was bought from Sigma Aldrich (~97% purity). An overview of 
the anomalous signals observed at the active site and in a dimer interface is given in Figure 52.  
The first structure of human APT1 (PDB ID 1fj2) was phased via SAD using sodium bromide added 
to the cryo protectant[58]. This structure contains 40 bromide ions per asymmetric unit, of which two 
bromide ions are found close to the active site. The positions of the bromide anions in the 
respective dimer interfaces differ between the published structure soaked with bromide (1fj2) and 
the 2BP – complex presented here, probably due to the different dimer interface. However, the 
oxyanion hole of human APT1 in the structure 1fj2 contains a bromide anion, and the same position 
is also occupied by the α-bromide of 2BP bound in the minor conformation (Figure 49).  
 
Figure 52: Position of bromide ions in the dimer interface of human APT1 co-crystallized with 2BP. The 
interacting amino acids N59 and M64 of both chains with the two bromide ions are highlighted as green sticks. 
2BP bound in the hydrophobic tunnel is presented in the major conformation.  
Summarized, the crystal structure of human APT1 in complex with 2BP revealed binding of 2BP 
inside the hydrophobic binding tunnel. The electron density of 2BP is well defined due to high 
resolution and occupancy and supported by the anomalous signal for the bromide. Binding of 2BP 
inside the tunnel means a competitive mode of inhibition. To exclude this binding mode as a 
crystallographic artifact, binding of 2BP to human APT1 was monitored via Stopped Flow, 
described in chapter 5.1.7.  
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5.1.6 Summary of APT – inhibitor complexes 
The structures of palmostatin B and palmostatin M bound to yeast APT provide structural insight 
into the interactions of both inhibitors on atomic scale. Since the amino acids involved in binding the 
core and head group are conserved, the binding mode could similar in human APT1 (Figure 40). 
The complex structure with Cerulenin showed that it is possible to covalently modify the active site 
serine in a complex of human APT1, and also demonstrated the potential of activated epoxides as 
nucleophilic trap for APTs. Cerulenin modifies surface-exposed cysteines as well, thus being less 
selective compared to palmostatin B and M. The complex of human APT1 and 2BP, being the first 
non-covalent inhibitor complex structure of human APT1, shows that 2BP binds inside the tunnel 
and acts as a competitive inhibitor of human APT1. The lid-loop of yeast APT and human APT1 
appears to be rather rigid in those structures and ligand binding has only minor effects on its 
conformation (Figure 48B). The pre-formed solvent-accessible hydrophobic binding tunnel is a rare, 
if not even unique feature of APTs among other α,β-hydrolases. Therefore, further investigations on 
the role of the lid-loop forming the tunnel and its influence on substrate binding and coordination 
during catalysis, and product release were conducted using several mutants with altered properties 
regarding length and flexibility of the lid-loop resulting in different length and shape of the binding 
tunnel as described in the following.  
5.1.7 Binding of 2BP to human APT investigated by Stopped Flow  
Binding of 2BP to human APT1 was to be further characterized by Stopped Flow measurements. 
The crystal structure of human APT1 in complex with 2BP shows 2BP exclusively bound inside the 
hydrophobic tunnel, as described in Chapter 5.1.5. The shallow groove on the surface of APT (see 
Figure 10) was found to bind PEG molecules in some crystals structure of human APT solved in 
our group [unpublished observation]. A closely related esterase has a PEG molecule bound in a 
similar position (see Figure 6, PDB ID 3cn9, [57]). Thus, the possibility that this position could 
present a second binding site for 2BP was investigated in Stopped Flow measurements.  
Human APT1 contains three tryptophan residues. A ligand binding assay based on the intrinsic 
fluorescence of tryptophan present in the wild type protein was established by Stefan Baumeister 
and is described in Chapter 7.6 of Material and Methods. As presented in the introduction in Figure 
10, two of the three tryptophan residues are located at positions of interest. The first, W140, forms 
the inner wall of the hydrophobic binding tunnel. The second tryptophan, W32, is located in the 
shallow groove next to the active site, which could accommodate a moiety of the natural substrate 
like e.g. the peptide of palmitoylated H-Ras. W67 is buried inside the protein. Mutants lacking either 
W32 or W140 were used in Stopped Flow experiments (as described in Material and Methods 
Chapter 7.6.1) to unravel the rate constants of 2BP binding at the two specified sites.  
As shown in Figure 53A, wild type APT (blue curve) containing tryptophan residues both in the 
tunnel and at the groove (and thus detects both binding events simultaneously) shows a fast initial 
decline that reaches a base line within 5 seconds with a very slow nearly linear decline over the full 
course of the measurement. The signal of 2BP binding inside the hydrophobic tunnel and at the 
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shallow groove can be split using mutants lacking the tryptophan at one binding site each. Human 
APT1 W32F detects only the signal of W140 in the tunnel (Figure 53, red curve) and shows a fast 
decline of the signal within 5 seconds, indicating fast binding of 2BP inside the tunnel. In contrast, 
human APT1 W140F should detect binding at the groove (Figure 53, green curve) and shows a 
very slow decline, not reaching equilibrium within 60 seconds. Since the fast binding of 2BP inside 
the tunnel is the stronger signal, the curves of 2BP binding to human APT1 wild type and W32F 
mutant have a very similar profile. The 2BP effect on W32 in the groove is slower by orders of 
magnitude compared to the tunnel binding. This signal is not necessarily caused by binding (only), 
it could also be caused by unspecific binding and/or be indicative of slow denaturation or unfolding 
of the protein as has been found at higher concentrations of 2BP (Stefan Baumeister, personal 
communication). This shows that the signal of 2BP binding to human APT1 wild type is dominated 
by the binding inside the tunnel, and thus the negligible effect of 2BP on W32 binding at the groove 
on the binding signal of the wild type was ignored in further experiments (see Chapter 5.2.14) for 
practical purposes.  
 
Figure 53: Panel A: The binding of 2BP (50µM) to human APT1 (5  µM) was assessed by Stopped Flow 
measurements. The wild type is shown in blue. The binding rates of 2BP inside the hydrophobic tunnel (W32F, 
red) and at the adjacent shallow groove (W140F, green) can be separated using mutants lacking the other 
tryptophan. As seen in the scaled data, equilibrium for binding inside the tunnel is reached in less than 5 
seconds, while binding inside the shallow groove is slower and not finished after 60 seconds. Data scaled and 
normalized and plotted using Microsoft Excel. Panel B: Overview of both binding sites of 2BP on human APT1 
wild type. Labels added using Gimp[4].  
Both binding signals of human APT1 wild type (Figure 53, blue) and the W32F mutant (Figure 53, 
red) contain two fast binding rate constants. A fit with a single exponential shows systematic 
deviations. In general, multi-exponential fits are dynamic and can be unstable if no parameter is 
initially known and both rates are within a comparable range. Attempts to deconvolute the binding 
rate constants failed as the rates determined could be varied by an order of magnitude still resulting 
in a fit of similar quality. Therefore, the 2BP binding curves were compared qualitatively. 
 The slow binding at the groove cannot be the cause for the two fast binding rates observed in 
human APT1 wild type and W32F mutant, since the W32 mutant lacks the tryptophan residue at the 
groove and thus does not detect 2BP binding there. An induced fit of 2BP inside the tunnel or a 
rearrangement of the lid-loop upon binding would be the first and most obvious suggestion for the 
two fast binding rates, but this was contradicted in another experiment where a lid-loop lacking 
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mutant also showed two fast binding rates (described in Chapter 5.2.14). Another possibility would 
be binding of 2BP to a monomeric and dimer species of APT since human APT1 forms a (weak) 
dimer that most likely needs to dissociate to enable 2BP binding inside the hydrophobic tunnel. A 
third possibility would be that binding of 2BP inside the tunnel could cause minor alterations of the 
protein structure and thus indirectly affect the fluorescence of W67 inside the protein (an known 
effect observed in intrinsic tryptophan fluorescence measurements called “tryptophan cross-talk”).  
As seen from the Stopped Flow results, the rate constant for binding of 2BP inside the hydrophobic 
tunnel is much faster than the binding rate at the groove observed in the W140F mutant. This is in 
agreement with a KD of ~1 µM for the specific binding site in the tunnel and a high second KD of 
about 100 µM for 2BP for rather (unspecific binding) at the second binding site observed in the 
tryptophan fluorescence binding assay [Stefan Baumeister, unpublished observation].  
5.1.7.1 Human	  APT1	  binds	  2BP	  when	  presented	  in	  DOCP	  vesicles	  	  
The biological substrates of human APT1 are attached to cellular membranes via a palmitoyl 
anchor. Therefore, it was tested if human APT1 is able to bind 2BP when incorporated in multi-
lamellar DOPC vesicles (vesicle preparation see Chapter 7.6.3). The measurement is shown in 
Figure 54 and reveals that the binding rate of 2BP incorporated in DOPC vesicles to human APT1 
(blue) is comparable to binding of free 2BP (green). In contrast, a suspension of mixed CHAPS - 
2BP micelles prevents binding of 2BP to human APT1 (data not shown), indicating that binding of 
2BP to CHAPS micelles is stronger than binding to human APT1 or DOPC vesicles.  
 
Figure 54: Comparison of the binding rates of human APT1 wild type (5 µM) and free 2BP (50 µM, blue) or 2BP 
(50 µM) presented in multi-lamellar DOPC vesicles (1 mM). Data plotted by Ingrid Vetter using GnuPlot[94] and 
annotated using Gimp[4].  
The similar binding rates of free 2BP and 2BP in DOPC vesicles is remarkable for the following 
reason: The association rate constant is dependent on the ligand concentration (unit: M-1 s-1). The 
protein and total 2BP concentration is similar in both measurements. In the presence of DOPC 
vesicles, 2BP is most likely randomly incorporated within the multiple layers of the DOPC vesicles 
since it has a high affinity for the lipids (2BP extraction from a complex with human APT1 by DOPC 
vesicles shown in Figure 55). Thus, the effective 2BP concentration on the accessible surface of 
the DOPC vesicles, and the fraction of free 2BP (depending on the equilibrium) has to be lower 
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than in the case of free 2BP. Therefore, the fact that the concentration-dependent binding rates are 
comparable indicates two possibilities: Either 2BP binding to human APT1 is enhanced when 
presented in vesicles, or the free 2BP concentration is in the saturation of the maximal binding rate 
in both cases.  
5.1.8 Dissociation of the human APT1 – 2BP complex investigated by Stopped Flow 
The dissociation of 2BP from a pre-formed complex with human APT1 wild type or selected 
mutants was measured via Stopped Flow as described in Chapter 7.6.2. To extract 2BP from its 
complex with human APT1, equilibrium was changed using high affinity 2BP binders injected via 
the second syringe. Three different 2BP binders were tested on their suitability to measure release 
of 2BP from human APT1 wild type complex. L-FABP, a tryptophan-free fatty acid binding protein, 
has a high affinity for fatty acids in the low nanomolar range (60 nM for palmitate, [95]) and was 
estimated to have a high affinity for 2BP due to the high similarity. The vesicle-forming lipid DOPC, 
and CHAPS, a detergent were tested as well. The dissociation rates of human APT1 wild type in 
complex with 2BP using the three competitors are shown in Figure 55 and are (as expected) 
depending on the specific competitor used to sequester 2BP. The significantly slowest dissociation 
of the human APT1 wild type – 2BP complex is observed when adding DOPC vesicles; the system 
does not reach equilibrium within the here presented time frame of 2 seconds (but does in 
approximately 10 seconds, data not shown). The initial extraction rates of L-FABP and CHAPS are 
comparable, but L-FABP exhibits a slower second phase (which will be discussed in the following 
part) than in the case of CHAPS. CHAPS as a detergent could potentially influence the protein 
structure itself or the lid-loop in particular to actively facilitate 2BP release apart from changing the 
equilibrium concentrations. No biological relevant connection between human APT1 and L-FABP is 
known that would imply an active ligand dissociation-activating mechanism. Therefore, L-FABP was 
chosen as competitor for further experiments like the comparison of the dissociation rate of 
selected human APT1 mutants presented in Chapter 5.2.15.  
 
Figure 55: Comparison of the dissociation rates of the human APT1 - 2BP complex using different competitors. 
The human APT1 – 2BP complex always contained 2.5µM protein and 10 µM 2BP. The release rate could depend 
on the binding rate and/or the affinity to the competing reagent.DOPC (purple) causes a slower dissociation rate 
constant of the human APT1 – 2BP complex compared to L-FABP (cyan) or CHAPS (blue) used as competitor. 
Data averaged, normalized, and plotted by Ingrid Vetter using gnuplot[94]. Labels were added using Gimp[4]. 
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The curve using 1% CHAPS as competitor can be reasonably well fitted using one apparent 
dissociation rate constant estimated to be in the range of koff = 30- 40 s-1 (see Figure 116 in 
Appendix). However, as both other competitors show two dissociation rates, it is possible that 
CHAPS affects the structure of the protein and thus actively enhances the dissociation rate and 
causes it to be monophasic. Using L-FABP, the data can be fitted estimating a first, faster apparent 
dissociation rate constant of koff = 50-65 s-1, and a second, slower rate constant of koff = 3 - 8 s-1 
(see Figure 117 in Appendix). The faster dissociation rate is about 2-fold higher than the single 
dissociation rate constant estimated for the experiment using 1% CHAPS, which is not a significant 
difference considering the quality of the fit and the resulting range of dissociation rate constants. 
The two dissociation rates are potentially caused by the two binding sites of human APT1, the 
faster dissociation rate might then results from 2BP unspecifically bound e.g. near W32 at the 
groove. The second slightly slower dissociation rate is probably caused by the more stable tunnel-
bound 2BP.  
 
The dissociation constant of a complex KD is defined as KD = koff / kon, [96], and is an expression of 
the affinity of a complex. Taking the KD of around 1 µM of 2BP for the binding tunnel (Stefan 
Baumeister, private communications) and the estimated koff in the range of 8 s-1 (diss. rate constant 
of 2BP from human APT1 when adding L-FABP) solving the above equation would result in a 
calculated kon of 8 x106 mol-1 s-1. This is multiple orders of magnitude higher than the association 
rate constants estimated from binding experiments. The 2BP concentration assumed in the kon 
measurement is the most likely cause of this discrepancy, as little is known about the effect of 
micelle formation and aggregation on the concentration of free 2BP. Also, potential adsorption of 
the hydrophobic 2BP to wall of the reaction vessel or unspecific binding on the protein surface 
affects the 2BP concentration. This hypothesis is corroborated by another observation: the binding 
rate constants kon estimated from several experiments of different 2BP concentrations can only be 
measured with very large errors and do not show concentration dependency (although kon has the 
unit of s-1 M-1 and thus is dependent on the ligand concentration). This indicates that the effective 
2BP concentration is comparable in these measurements, but significantly lower than the assumed 
input concentration of 2BP due to the before mentioned uncertain problems of micelle formation or 
aggregation.  
 
5.2 Analysis of the lid-loop forming the hydrophobic binding tunnel 
Lipases usually have a lid-domain covering the active site and the hydrophobic patch around it. 
Lipases are often interfacially activated by membranes and uncover the active site to enable 
catalysis. In contrast, esterases have a solvent accessible active site. APTs contain a loop that 
helps to form a structural motif that, to my knowledge, has not been observed within the family of 
α,β-hydrolases: a pre-formed solvent-accessible hydrophobic tunnel located next to the catalytic 
triad. The outer wall of this tunnel is formed by the lid-loop.  
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This raises the questions if the lid-loop is flexible, and if the flexibility of the lid-loop is linked to 
protein activity; how the binding tunnel is held in an open, solvent-accessible state; how its shape 
affects substrate binding; and if the tunnel is essential for substrate turnover. To address these 
questions, several lid-loop mutants have been subjected to activity assays, “Stopped Flow” 
measurements, and structural analysis.  
5.2.1 Design of different lid-loop mutants 
The conformation of the lid-loop is determined by polar contacts as well as hydrophobic van-der-
Waals interactions. The side chains of the residues S74, D76, S77, and Q78 (Figure 56) are facing 
the solvent and do not address the protein core. Side chains of I70 and I71, located at the N-
terminal hinge of the lid-loop, are buried in the inside or facing towards the C-terminal hinge, 
respectively, acting as anchors of the hinge. Of the remaining amino acids, G72 lacks a side chain, 
and P75 forms the tip of the lid-loop and is located close to F176, thus closing the outer wall of the 
tunnel. The side chain of L73 is located close to L171 and L58 (green sticks in Figure 56) in about 4 
to 4.5Å distance, within the range of van-der-Waals interactions, and probably helps to anchor the 
lid-loop. The side chains of these three leucines form a hydrophobic entrance of the binding tunnel 
and are conserved in higher animals. A detailed overview of the lid-loop is shown in Figure 56.  
 
Figure 56: Panel A: Amino acids of the lid-loop shown as sticks. Polar amino acids like S74, D76, S77, and Q78 
are facing with their side chains into the solvent. Notably, L73 is located at the tip of the lid-loop forming the 
tunnel entrance with L171 and L58 (all three highlighted in green) next to the active site. Panel B: Schematic view 
of the interactions that are suspected to keep the lid-loop in the wild type conformation.  
In order to explore the role of the different residues within the lid-loop, three types of mutants were 
created, addressing different properties of the lid-loop. Firstly, we investigated the effect of mutating 
the three leucines forming the outer part of the tunnel entrance by alanine and valine mutations 
(L171A, L171V, L58A, L73A).  
As second type of mutation, we explored the effect of an elongated lid-loop inspired by the APT-
related protein SOBER1 from A.thaliana [69] that has an extended lid-loop and is not able to 
hydrolyze long-chained substrates, by extending the lid-loop of APT with a Leu-Pro insert in 
between G72 and L73. 
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The third group of mutants contains lid-loop truncations of various lengths to investigate the 
influence of the lid-loop length on activity. Six distinct truncations were generated by deleting either 
two, four or six residues of the lid-loop (ΔG72L73, ΔL73S74, ΔS74P75, ΔI71-S74, ΔL73-D76, ΔI71-
D76).  
5.2.2 Crystal structures and biochemical activity of human APT1 L171A and L171V 
mutants 
Human APT1 L171V and L171A mutants were assayed on their activity against the fluorescent 
substrate PPTS (see Chapter 7.5.1). Figure 57 shows their activity compared to human APT1 wt. 
Human APT1 L171V shows a slightly increased activity compared to the wild type, with a kcat, of 3.9 
± 0.32 s-1 and a KM of 3.79 ± 1.09 µM. In contrast, human APT1 L171A has a marginally reduced 
activity of kcat of 2.70 ± 0.20 s-1 and a KM of 2.84 ± 0.77 µM.  
These changes, however, are not a significant alteration of the activity profile, as indicated by the 
errors of kcat and KM of the averaged data points of duplicate measurements.  
 
Figure 57: Activity assay of human APT1 wild type, L171A, and L171V using PPTS as substrate. Plotted is kcat 
versus the substrate concentration. The activity did not significantly change by the mutations compared to the 
wild type. Data averaging of the duplicate measurements and error calculation was done with Microsoft Excel, 
the plot was fitted with Origin Pro.  
Table 7: Kinetic parameters of human APT1 wild type, L171A and L171V mutants on PPTS used as test substrate. 
 Vmax [µmol s-1] kcat [s-1 x104] KM [µM] kcat / KM [µM-1 s-1 x104] 
L171V 195 ± 16 3.90 ± 0.32 3.79 ± 1.09 1.03 
wild type 170.5 ± 11 3.41 ± 0.22 3.38 ± 0.77 1.01 
L171A 135 ± 10 2.70 ± 0.20 2.84 ± 0.77 0.95 
 
Both mutants were subjected to screening for conditions suitable for crystallization. The 
crystallization drops and conditions in which the best-diffracting crystals grew are shown in Figure 
58. Crystals were isolated directly from screening plates and diffraction data collected at SLS, 
Villigen, Switzerland, as described in Material and Methods.  
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Figure 58: Crystals of human APT1 L171A (left) and L171V (right). Crystals of the L171A mutant grew in condition 
D12 of PACT screen from Qiagen, containing 0.1 M Tris pH 8.0, 20% PEG 6000, and 0.01 M ZnCl2. Crystals of 
L171V grew in Core2 E4, containing 0.1 M MES pH 6.0, 1.0 M LiCl, and 10% PEG 6000. Crystals of both mutants 
grew within 13 days. Photographs taken using Formulatrix Rock Imager and scale bar inserted using Gimp[4].  
The structures of both hAPT1 L171A and L171V mutants were solved by molecular replacement 
using human APT1 wild type as template and belong to space group P21 with 4 monomers per 
asymmetric unit and P1 containing 2 monomers per asymmetric unit, respectively. The 
crystallographic statistics for both L171 mutants are presented in Table 8.  
Table 8: Crystallographic table of human APT1 L171A and L171V. Values for the highest shell are given in 
parentheses. A molecule of MES is bound to human APT1 L171V. Values for Ramachandran plot are given for 
favoured, allowed and outlier.  
 
human APT1 
L171A 
human APT1 
L171V  
human APT1 
L171A 
human APT1 
L171V 
Data collection     Refinement     
Space group P21 P1 Resolution (Å)  48.53-2.20 (2.26-2.20) 
38.01 -1.28  
(1.31-1.28) 
Cell dimensions     Number of Reflexes  239761 (16921) 323611 (8311) 
    a, b, c (Å) 
76.88, 55.50, 
101.55 
38.5, 40.9, 
71.9 Rwork 23.15 (30.5) 18.33 (26.2) 
    α, β, γ (°) 90.0, 112.1, 
90.0 
102.1, 95.6, 
106.2 Rfree 28.03 (32.2) 20.43 (25.5) 
Resolution (Å) 
48.52-2.20 
(2.26-2.20) 
38.01-1.28 
(1.31-1.28) Number of Atoms     
Monomers / au 4 2     Protein  6685  3474 
Wave length (Å)  0.91639 0.92019     Ligand/Ions  -  12 
CC 1/2 99.3 (73.0) 99.8 (68.3)     Water  143  705 
I / σ(I) 6.99 (1.94) 9.5 (1.77) B-factor (Å2)     
Completeness 
(%) 
99 (99.76) 82.3 (32.3)     Protein 44.0 ± 13.6 13.0 ± 6.0 
Redundancy 3.05 (2.92) 1.86 (1.67)     Ligand - 22.6 ± 4.4 
 
    Water 42.0 ± 12.5 28.7 ± 8.9 
RMSD     
    Bond length (Å) 0.013 0.0271 
    Bond angle (°) 1.552 2.37 
Ramachandran (%) 
97.40,  
2.37,  
0.23 
98.27, 
1.73,  
0.00 
Clashscore 8.70 7.22 
Rotamer outlier (%) 5.36 2.08 
Molprobity score 2.14 1.64 
  Results 
 57 
Both mutations of L171 do not cause any significant changes within the overall structure of human 
APT1. The 1.94 Å structure of the apo form of human APT1 belonging to space group P1[69] is used 
as reference. The L171A mutant monomers have an average rmsd of 0.48 Å2 over 219 Cα 
compared to the wild type and form a dimer similar to the wild type (rotated by 6.3 to 7.1˚), despite 
the different crystallization conditions and space group. The conformation of the lid-loop does not 
differ from the wild type lid-loop in any of the four monomers (see Figure 60 for details). The 
structure of human APT1 L171V belongs to the same space group (P1) as the apo form of human 
APT1 wild type with a similar unit cell [69]. The two monomers have an average rmsd of 0.39 Å 
compared to the wild type. Again, the conformation of the lid-loop is not altered in the mutant. The 
dimer is nearly identical (rotated by 1˚) compared to the wild type, and only the loop region 
containing T28/G29/H30 is present in an alternative conformation, which has been observed in 
various structures of APT, sometimes within different monomers of one crystal. 
 
Figure 59: Comparison of human APT L171A (green) and L171V (purple) mutants with the wild type (blue). The 
typical dimer is formed in the crystals of both mutants, being rotated by 6.3 to 7.1˚ for the L171A mutant, and 1˚ 
for the L171V mutant.  
The relative B-factors can be used as an indicator of flexibility when comparing different parts of a 
structure. The 1.94 Å resolution structure of human APT1[69] shows average B-factors of 17.6 and 
21.4 Å2 for the Cα atoms of the lid-loops of monomer A and B, respectively, and an overall B-factor 
of 12.5 Å2. In the four monomer of human APT1 L171A, the average B-factor of the Cα atoms of 
the individual lid-loops ranges from 38.8 to 48.3 Å2, and is not significantly increased compared to 
the average B-factor of the whole protein (41.2 Å2). The lid-loops are partially stabilized by neighbor 
molecules.  
The Cαs of the lid-loop in human APT1 L171V have an average B-factor of 13.5 and 17.1 Å2 in 
monomer A and B, respectively, which is set in relation to 11.4 Å2 of the whole protein and 
comparable to the wild type structure. In the P1 space group, the lid-loop is not obstructed or 
stabilized by crystal contacts but is exposed to a solvent channel. This means that the lid-loop of 
the wild type as well as the human APT1 L171V odes not show significant flexibility even if not 
constrained by a neighboring symmetry related molecule. The lid-loops of both mutants are 
compared to the wild type in the following Figure 60.  
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Figure 60: Superimposition of human APT1 wt (blue) with all crystallographically related monomers of the L171A 
(green) and L171V (purple) mutants. The representation is focused on L171. The conformation of the lid-loop is 
identical to the wild type, leaving the hydrophobic binding tunnel (perpendicular to the paper plane) unchanged 
in length and shape.  
Taken together, the crystal structures of both mutants show no significant difference in neither the 
shape of the lid-loop nor tunnel from the wild type, which corresponds to the similar hydrolytic 
activity for the long-chain PPTS substrate observed in the activity assays. Thus, it looks like there is 
no significantly stabilizing effect of the L73-L171 hydrophobic interaction on the conformation of the 
lid-loop.  
5.2.3 Crystal structure of human APT1 L58A mutant 
L58 is the second leucine located at the protein surface close to L73 of the lid-loop, and is located 
in the “foot-rest” loop (see Figure 56). An alanine mutant was designed to test for the stabilizing 
effect of L58 on the lid-loop.  
Human APT1 L58A was subjected to screening for crystals as described in Material and Methods. 
Crystals (Figure 61) were directly isolated from the screening plate, X-ray diffraction data was 
collected at X10SA at SLS, Switzerland. The crystal belongs to space group C2 and the structure 
was refined to 2.62 Å resolution as described in Material and Methods. The crystallographic 
statistics are summarized in Table 9.  
 
Figure 61: Crystallization drop of human APT1 L58A. Crystals grew within 21 days in condition B11 of Core3 
available from Qiagen containing 0.2 M sodium formate and 20% PEG 3350. Photograph taken by Formulatrix 
Rock Imager.  
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Table 9: Crystallographic statistics of human APT1 L58A. Values for the highest shell are given in parentheses. 
Values for Ramachandran plot are given for favoured, allowed and outlier 
 
human APT1 
L58A   
 
Data collection  Refinement  
Space group C2 Resolution (Å) 127.58-2.62 (2.69-2.62) 
Cell dimensions  Number of Reflexes 364026 (21382) 
    a, b, c (Å) 
181.52, 79.73, 
154.94 Rwork 
19.8 (50.1) 
    α, β, γ (°) 
90.00, 
124.5710, 
90.00 
Rfree 
26.5 (52.4) 
Resolution (Å) 50.0-2.62 
(2.69-2.62) Number of Atoms 
 
Monomers / au 8     Protein 13336 
Wave length (Å) 0.99989     Ligand/Ions 37 
CC 1/2 99.2 (37.2)     Water 215 
I / σ(I) 7.67 (1.24) B-factor (Å2)  
Completeness (%) 98.1 (83.7)     Protein 67.1 ± 19.0 
Redundancy 3.45 (3.22)     Ligands 78.6 ± 7.0 
 
    Solvent 62.6 ± 15.4 
RMSD  
    Bond length (Å) 0.0117 
    Bond angle (°) 1.55 
Ramachandran (%) 95.17, 4.60, 0.23 
Clashscore 4.72 
Rotamer outlier (%) 6.63 
Molprobity score 2.20 
 
Similar to the L171 mutants, the L58A mutation does not change of the conformation of the lid-loop 
or the overall conformation, and the monomers have an rmsd in the range of 0.54 to 0.62 Å2 over 
219 amino acids to human APT1 wild type. The asymmetric unit contains four dimers comparable 
to the dimer of human APT1 wild type[69]. The second monomer of the dimers is rotated between 
5.6 and 7.9˚ compared to the wild type structure. An analysis of the crystal packing reveals that the 
lid-loop is stabilized by a neighbor via a salt bridge between the guanidine head of R144 and the 
carboxylic acid of D76 in monomers B, D, F, and H, while the tip of the lid-loop does not form 
crystal contacts in monomers A, C, E, and G. Thus, one molecule of each dimer has a lid-loop 
involved in crystal contacts, and the other has a free lid-loop. This is also reflected in the B-factors 
of the lid-loops, which are in the range between 48.8 and 71.1 Å2, but systematically lower for 
monomer B, D, F, and H (54.2 Å compared to 66.1 Å) which form a salt bridge via D76 of the lid-
loop. The overall B-factor is 59.5 Å2.  
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Figure 62: Comparison between human APT1 wild type (blue) and L58A mutant (green), containing eight 
monomers per asymmetric unit that form four dimers. The monomers are highly similar to the wild type with an 
rmsd of 0.54 to 0.62 Å over 219 amino acids, and no conformational change of the lid-loop is observed. The 
dimers are rotated by 5.6 to 7.9˚ compared to the wild type.  
Interestingly, the monomers A, C, E, and G (with the free lid-loop) show a linear electron density 
inside the tunnel, while the other monomers contain only water molecules. Here, the side chain of 
F176 is rotated into the tunnel, a conformation only possible in absence of a tunnel-binding ligand. 
The linear density is not well defined at both ends, but a palmitate molecule fits into the density 
without causing negative difference electron density to appear. Thus the density could be a co-
purified fatty acid. A PEG molecule is unlikely, as despite the presence of PEG is most 
crystallization conditions of human APT1, no PEG molecule was observed to bind inside the tunnel. 
Each palmitate-bound monomer forms a dimer with an empty monomer. The lid-loop of the 
palmitate - containing monomers is slightly opened by about 1 Å to accommodate the ligand inside 
the tunnel. This has also been observed for the wild type in complex with 2BP (compare Figure 48), 
and was discussed in Chapter 5.1.5 for the structure of human APT1 in complex with 2BP. 
However, the L58A mutation allows the small “foot-rest” loop containing L58 to move away from the 
lid-loop (Figure 63), the Cα of L58A is dislocated by 1.0 to 1.5 Å compared to the wild type. The 
conformation of this loop also differs in both apo form structures of human APT1 wild type([69], and 
PDB ID 1fj2), which differ in space group, dimer formation and crystal packing, and it lokks as if this 
“foot-rest” loop is flexible enough to adapt (in a certain extend) to its environment.  
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Figure 63: Comparison between the palmitate-bound (A) and empty (B) tunnel of human APT1 L58A (shown in 
green). In all monomers, the loop containing L58 is moved upwards compared to the wild type (shown in blue). 
(A): Palmitate bound inside the tunnel corresponds to an opening of the lid-loop by about 1 Å. F176 is shifted out 
of the lumen of the tunnel. (B): Movement of F176 into the binding tunnel.  
Summarized, L58 is not a crucial residue for the conformation of the lid-loop, but instead causes 
the neighboring “foot-rest’ loop to move away from the lid-loop. Interestingly, the mutant L58A 
seems to facilitate binding of a ligand inside the tunnel, perhaps allowing an easier opening of the 
lid-loop due to reduced fixation of the lid-loop by the “foot-rest” loop. Also, crystal packing seems to 
influence ligand binding, since one monomer of the dimers is empty.  
 
5.2.4 Crystal structure and biochemical activity of human APT1 L73A mutant  
The previous chapters showed that mutations of either L58 or L171, the suspected interaction 
partner of L73, did not alter activity of the biochemical protein or the shape of the binding tunnel. In 
this chapter, the role of leucine L73, located in the lid-loop and forming the tunnel entrance (Figure 
56), is investigated on its biochemical activity using the PPTS activity assay (Chapter 7.5.1), and 
structurally via x-ray crystallography. In contrast to the L58A and L171A mutants, human APT1 
L73A showed a significantly decreased activity compared to the wild type in the PPTS activity 
assay. Vmax was decreased to about 30% of the wild type with a kcat of 0.95 ± 0.32 s-1, while KM is 
also reduced to 0.94 ± 0.28 µM.  
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Figure 64: Human APT1 L73A activity on PPTS compared to human APT1 wt, L171A and L171V. The L73A 
mutation decreases kcat to about 30% compared to human APT1 wild type. The apparent KM observed in the 
assay is also decreased, indicating a stronger binding of PPTS to the mutant. Data averaging and error 
calculation was done using Microsoft Excel, data was plotted and fitted using Origin Pro.  
Table 10: Kinetic parameters of human APT1 wild type and L73A mutant on PPTS used as test substrate. 
 Vmax [µmol s-1] kcat [s-1 x104] KM [µM] kcat / KM [µM-1 s-1 x104] 
L171V 195 ± 16 3.90 ± 0.32 3.79 ± 1.09 1.03 
wild type 170.5 ± 11 3.41 ± 0.22 3.38 ± 0.77 1.01 
L171A 135 ± 10 2.70 ± 0.20 2.84 ± 0.77 0.95 
L73A 47.5 ± 3 0.95 ± 0.06 0.94 ± 0.28 1.01 
 
Human APT1 L73A was subjected to screening for suitable crystallization conditions as described 
in Material and Methods. Crystals of satisfying quality (Figure 65) were isolated directly from 
screening condition and diffraction data was collected at X10SA at SLS, Villigen, (CH). The data 
was processed and the structure solved via Molecular Replacement using the wild type as template 
as described in Material and Methods. The crystal belongs to space group P21 and contains one 
monomer per asymmetric unit. The final model was refined to a resolution of 1.6 Å with an Rwork of 
19.8% and Rfree 24.6%. The crystallographic statistics are presented in the following Table 11. 
 
Figure 65: Crystallization drop of human APT1 L73A. Well-diffracting crystals were obtained from screening 
condition Core1 A2 of Qiagen, containing 0.1 M Bicine, pH 8.5 and 20% PEG 6000. Photograph taken by 
Formulatrix Rock Imager.  
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Table 11: Crystallographic statistics of human APT1 L73A. Values for the highest shell are given in parentheses. 
A molecule of bicine is bound to the protein. Values for Ramachandran plot are given for favoured, allowed and 
outlier.  
 
human APT1 
L73A  
 
Data collection  Refinement  
Space group  P21 Resolution (Å)  47.36 - 1.6 (1.64 - 1.6) 
Cell dimensions   Number of Reflexes  166881 (12618) 
    a, b, c (Å) 
 35.65 57.41 
47.92 Rwork 
 19.8 (28.5) 
    α, β, γ (°)  90.00 98.76 
90.00 Rfree 
 24.6 (38.3) 
Resolution (Å)  47.36 - 1.60 
(1.64 - 1.6) Number of Atoms 
  
Monomers / au  1     Protein  1681 
Wave length (Å)  0.91639     Ligand/Ions  11 
CC 1/2  99.8 (71.7)     Water  212 
I / σ(I)  10.77 (1.81) B-factor (Å2)  
Completeness (%)  99.7 (99.5)     Protein  23.7 ± 7.4  
Redundancy  3.37 (3.44)     Ligands  56.7 ± 1.0 
 
    Solvent  38.6 ± 8.4 
RMSD  
    Bond length (Å)  0.0067 
    Bond angle (°)  1.32 
Ramachandran (%)  98.22, 1.78, 0.0  
Clashscore  6.74 
Rotamer outlier (%)  2.70 
Molprobity score  1.7 
 
The L73A mutant does not form a dimer under the conditions and belonged to the best-diffracting 
APT crystals investigated to date. A comparison of the structure of human APT1 wild type and the 
L73A mutant shows that the overall structure is unchanged with an rmsd of 0.53 Å2 covering 217 
Cα. However, the conformation of the lid-loop is significantly changed compared to the wild type 
and folded into the tunnel (see Figure 67). As the crystal contacts also differ from the wild type 
(Figure 66A), it raises the question if the packing influences the lid-loop conformation, or the lid-
loop conformation is also altered in solution, and thus enables the altered crystal interface. The tip 
of the lid-loop forms two salt bridges via the backbone amide of S74 and the side chain of D76 to 
the side chains of Q207 and Q208 of the neighbor molecule (see Figure 66B), thus the lid-loop 
conformation could be influenced by the neighbor molecule and be a crystalization artifact. 
Furthermore, a lid-loop in the wild type conformation would not fit in the L73A crystal and would 
clash with a neighbor molecule. However, keeping in mind that a comparable conformation of the 
lid-loop has not been observed in a crystal structure of the wild type of human APT1 before, it is 
more likely that the L73A mutation causes the lid-loop to fold into the tunnel also in solution, and 
the changed conformation of the lid-loop allows the altered crystal packing via this new interface 
(Figure 66A). An analysis of this interface using PISA[97] predicts no complex formation of human 
APT1 L73A via this interface in solution. The electron density of the lid-loop is well defined, while 
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some side chains of the preceding “foot-rest” loop containing L58 are less well defined. The 
average B-factor of the Cα atoms of the lid-loop is higher than the average over all Cα atoms, with 
31.6 and 23.2 Å2, respectively. The slightly increased B-factor of the lid-loop shows that it is 
probably flexible and not locked in the crystal interface.  
 
Figure 66: Panel A: Overview of the crystal contacts of human APT1 L73A shown in green. The symmetry mates 
are presented in grey. The protein dies not form the typical dimer, and the lid-loop is not involved in crystal 
contacts. Panel B: Detailed view on the two H-bonds formed between the backbone amide of S74 and the 
carboxyl side chain of D76 of the lid-loop (red) and the side chains of Q207 and Q208 of the crystal neighbor 
(grey).  
The structure shows a significant conformational change of the lid-loop compared to the wild type 
which has not been observed in any structure of human APT1 so far. P75 of the lid-loop is moved 
into the hydrophobic tunnel and blocks it, as shown in the superimposition with human APT1 wild 
type in Figure 67.  
 
Figure 67: Comparison of human APT1 wt (blue) and human APT1 L73A (lime green). Human APT1 wt is shown 
as surface representation with the lid-loop colored in red to highlight the wild type shape of the binding tunnel. 
The mutation causes L73A to rotate and exposes the side chain to the solvent; this enables P75 to move into the 
tunnel towards the inner wall and obstruct it. The catalytic triad can be seen through the transparent surface.  
A comparison of human APT1 wild type and L73A mutant in ribbon representation (Figure 68) 
highlights the significantly different conformation of the whole lid-loop. The Cα of L73A is moved by 
2.5 Å, but the rotation by 45˚ of the side chain from an inward pointing L73 to outward facing Cβ of 
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the alanine L73 enables the strong movement of the following amino acids of the lid-loop. The non-
polar side chain of P75 is moved in front of W140 inside the hydrophobic tunnel, over a distance of 
5.5 Å comparing the Cα of P75 in the L73A mutant and human APT1 wild type. The less well-
defined electron density of the turn containing L58, indicating a destabilization of the “foot-rest” lid-
loop; it looks like it might have two conformations. This could be caused either by the missing L73 
side chain (also the Cα of L58 is less moved than the rest of the “foot-rest” loop), or by the changed 
conformation of the preceding residues, e.g. the carbonyl of I71 is flipped and thus does not form 
the H-bond to the backbone amide of L58. The conformation of the “foot-rest” loop differs between 
L73A mutant and wild type of up to 1 Å distance, observed at the Cα of M60. The amide head 
group of N61 forms a H-bond to the backbone amide of P6 of the neighbor molecule, due to the 
crystal packing, and L5 of the symmetry related molecule would come very close to N61, which is 
rotated away a bit in the structure of the L73A mutant. Thus, the packing of the N-terminus to the 
“foot-rest” loop would also be a potential reason for the destabilization of this loop, and is likely to 
be the cause.  
 
Figure 68: Comparison of human APT1 wild type (blue) and L73A (green). The large movement of P75 in the lid-
loop closing the tunnel involves a movement of the whole lid-loop. The Cα of P75 of L73A moves by 5.5 Å 
compared to the wild type. The L58 containing loop is less well defined, and reliable measurements of the 
movement are not possible.  
Interestingly, one molecule of bicine is bound at the groove close to W32, coordinated by D27, 
S205, and two water molecules as shown in the following figure, stressing the potential of this 
groove as a potential secondary binding site, e.g. for the peptide moiety of the natural substrate 
(palmitoylated proteins).  
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Figure 69: Bicine (grey) from the crystallization buffer binds at the groove on top of W32 next to the active site. 
Bicine is coordinated by H-bonds to the side chain hydroxyl and backbone amide of S205, the side chain of D27 
and two water molecules. Electron density of bicine is contoured to 1 σ.  
The collapsed tunnel of human APT1 L73A raised the question if the tunnel can be reformed upon 
substrate binding or if the tunnel is closed permanently. The reduced but existent biochemical 
activity (Figure 64) indicates that substrates can bind at least next to the active site, but it was 
unclear if the tunnel could still accommodate an acyl chain. Therefore, human APT1 L73A was co-
crystallized in complex with 2BP and the structure is described in Chapter 5.2.5.  
5.2.5  Crystal structure of human APT1 L73A in complex with 2BP 
The complex of human APT1 L73A and 2BP was prepared similar to the wild type complex 
described in Chapter 5.1.5. Briefly, the protein was mixed with a 3-fold molar excess of 2BP and 
heated to 50 ˚C for 5 to 10 min, and then subjected to co-crystallization and yielded crystals in a 
few conditions. Interestingly, the best-diffracting crystals grew in a condition that does not contain 
PEG, unlike most crystallisation conditions of human APT1. Diffraction data was collected at 
X10SA at SLS at 0.92 Å x-ray wavelength, the adsorption edge of bromide, to obtain an anomalous 
signal to support fitting of 2BP into the electron density. The structure belongs to space group 
P21 21 21 and was solved via Molecular Replacement using human APT1 wild type as template and 
refined to 1.85 Å as described in Material and Methods. The crystallographic statistics are 
summarized in Table 12.  
 
Figure 70: Crystallization condition of human APT1 L73A in complex with 2BP. The best-diffracting crystals grew 
in condition Core4 G5, containing 0.1 M MES pH 5.0 (final pH 6.0) and 1.6 M (NH4)2SO4. withing 2 days. Human 
APT1 L73A was preincubated with 2BP (5 mM) for 5 to 10 min at 50 ˚C, as described in Chapter 5.1.5. Photograph 
taken by Formulatrix Rock Imager.  
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Table 12: Crystallographic statistics of human APT1 L73A in complex with 2BP. Values for the highest shell are 
given in parentheses. Besides the four molecules of 2BP bound inside the tunnel, two sulfates ions are observed 
within the asymmetric unit. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
L73A + 2BP   
Data collection  Refinement  
Space group  P212121 Resolution (Å) 
49.09 – 1.85 (1.90 
- 1.85) 
Cell dimensions   Number of Reflexes 1011337 (76477) 
    a, b, c (Å) 
73.97, 109.70, 
109.79 Rwork 27.45 (37.7) 
    α, β, γ (°) 90.0, 90.0, 
90.0 Rfree 32.65 (44.7) 
Resolution (Å) 
49.09 – 1.85 
(1.90 - 1.85) Number of Atoms  
Monomers / au 4     Protein 6729 
Wave length (Å) 0.92018     Ligand/Ions 86 
CC 1/2 99.7 (69.0)     Water 481 
I / σ(I) 10.89 (2.20) B-factor (Å2)  
Completeness 
(%) 
100 (100)     Protein 33.9 ± 10.9 
Redundancy 6.86 (6.98)     Ligands 58.1 ± 18.9 
 
    Solvent 36.0 ± 8.4 
RMSD  
    Bond length (Å) 0.0130 
    Bond angle (°) 1.66 
Ramachandran (%) 97.20, 2.46, 0.34 
Clashscore 12.39 
Rotamer outlier 4.37 
Molprobity score 2.24 
 
The human APT1 L73A - 2BP complex crystallizes in a different space group and unit cell than the 
L73A apo protein. The asymmetric unit of the complex contains four monomers that do not form the 
typical dimer of human APT1 wild type[69], but a dimer rotated by 113˚, but similar (1.8˚ rotated) to 
the dimer observed in the published structure (PDB ID 1fj2, [58]). The lid-loop is located next to a 
solvent channel, but is partially stabilized by crystal contacts, forming a H-bond between D76 of the 
lid-loop, and R40 of symmetry mates (see Figure 71). The average B-factor of the Cα in the four lid-
loops is 41.7 Å and in the range of the average B-factor of 34.4 Å2 of all Cαs atom in the protein. 
This indicates a stabilization of the lid-loop both by 2BP and/or crystal contacts.  
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Figure 71: Crystal contacts of human APT1 L73A in complex with 2BP.The dimer molecules (as observed in PDB 
ID 1fj2, [58]) are presented in green. The lid-loop (red) is not part of the dimer interface, but stabilized via a salt 
bridge formed by D76 to R40 of a symmetry mate (grey). 2BP (cyan) bound inside the hydrophobic tunnel.  
The electron density shows an well-defined elongated electron density inside the binding tunnel. 
However, it lacks the typical bifurcated head group of 2BP next to the active site. Electron density 
continues into the tunnel in varying intensity in all four monomers. The linear density could fit to 
long-chained PEG, but PEG has not been observed bound inside the tunnel in any structure of 
human APT1 so far, nor is it present in the screening condition, assuming no contamination. More 
liekly is a co-purified fatty acid, as observed in X. tropicalis APT1 [69].  
In order to support positioning of 2BP in the structure, an anomalous map corresponding to . 
However, no significant anomalous signal of bromide could be detected in the whole asymmetric 
unit, either indicating a disordered binding of 2BP in human APT1 L73A, or the presence of a co-
purified molecule, e.g. a fatty acid. The elongated density in the tunnel could also indicate a sliding 
motion of 2BP with the head group not exclusively bound directly next to the active site. This would 
also explain the absence of an anomalous signal for bromide. Interestingly, the complex was 
crystallized at pH 5.0; the pH being lower than for complexes of human APT1 wild type with 2BP, 
which was observed to crystallize in complex with 2BP at pH 6.5 to 8.5 (see Chapter 5.1.5). For 
comparison, 2BP was fitted in a orientation related to the major conformation of wild type complex 
(see Figure 49).  
  Results 
 69 
 
Figure 72: Electron density of the unknown ligand in the hydrophobic binding tunnel. The 2Fo-Fc density is long 
and linear, but lacks a clear furcation at the head group of 2BP. Moreover, no anomalous signal of bromide could 
be detected. 2BP (cyan) was fitted for refinement, but the head group does not fit into the density. This might be 
caused by undefined binding with multiple conformations, e.g. sliding motions of 2BP within the tunnel.  
A comparison of hte human APT1 L73A + 2BP complex with the published apo form structure of 
human APT1 (PDB ID 1fj2, [58]), that both form similar dimers, again shows a different conformation 
of the “foot-rest” loop shifted towards L73A, and indicates that this is potentially caused by the 
shortened side chain. A comparison of the 2BP complexes of human APT1 L73A mutant and the 
wild type is shown in Figure 73, and reveals no significant difference of the backbone of the lid-
loop. In the 2BP complex of L73A mutant, the “foot-rest” loop containing L58 is again moved by 
~1 Å compared to the apo form of human APT1 wild type[69]. However, movements in this range are 
also observed for human APT1 wild type apo form and the 2BP complex, and argues against (as 
mentioned above) that L73A as main cause for the movement of the “foot-rest” loop. The 
movement of the “foot-rest” loop is more likely due to crystal contacts, but the shortened L73A side 
chain could facilitate this movement due to a reduced stabilization.  
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Figure 73: Comparison of the complexes of 2BP with human APT1 L73A and human APT1 wild type (Chapter 
5.1.5, Table 5). The conformation of the lid-loop is identical, but the L58 containing loop is moved by 1 Å towards 
L73A; the shortened side chain enables this movement. In human APT1 wild type, 2BP (cyan, transparent) is 
bound with the head at the active site. In the L73A mutant, 2BP (cyan, solid) most likely can slide within the 
binding tunnel leaving the head group without defined electron density.  
The altered side chain in the L73A mutant leaves a small gap between L171 and L58, as 
highlighted in the surface representation in Figure 74. This gap supports the movement of L58 
mentioned before, and is partially filled by its side chain. Comparing the position of 2BP in the 
human APT1 wild type and L73A complex reveals differences. Bound 2BP could either be pushed 
out of the active site by the movement of L58, but could also slide its head into the gap. The binding 
in multiple orientations can result in a less defined electron density and also explain the lack of a 
strong anomalous signal for bromine.  
 
Figure 74: Human APT1 L73A mutation (surface representation) causes a small gap (encircled in red) between 
L171 and L58. This gap is partially filled by the movement of L58 towards the lid-loop. The head group of 2BP 
could be moved away from the active site by the movement of L58, but could also remain in the gap between L58 
and L171, thus explaining the ambiguous electron density.  
Taken together, L73, located in the lid-loop with its side chain between L58 and L171, is an amino 
acid relevant for the formation of the tunnel. The lid-loop of the apo form of the L73A mutant folds 
back into the tunnel and thus collapses the hydrophobic tunnel in absence of ligands, indicating the 
importance of the L73 side chain as structural anchor of the lid-loop. The biochemical activity of 
human APT1 L73A is reduced to 30%. However, the structure of the complex with 2BP proves the 
lid-loops ability to bind substrates inside a re-formed binding tunnel. 
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5.2.6 Crystal structure and biochemical activity of human APT1 LP insertion mutant  
The homolog of APT in A. thaliana (characterized by Marco Bürger in his thesis [69]) has an 
extended lid-loop containing a leucin-prolin (LP) insertion between G72 and the above discussed 
L73, as seen from the sequence alignment shown in Figure 75.  
 
Figure 75: Sequence alignment of human APT1 and the APT1 homolog in A. thaliana SOBER1 (name highlighted 
in green). The lid-loop is within the red square, the LP insert present in SOBER1 is highlighted in red. Taken from 
[69] (Table 4.15, p.121) and modified using Gimp [4].  
The binding tunnel of the APT homolog in A. thaliana SOBER1 is closed by the side chains of the 
leucine of the insertion and a phenylalanine present in the lid-loop, and only very little biochemical 
activity on PNP-ester substrates longer than propionate was observed[69]. A human APT1 LP 
insertion mutant was assayed against PPTS as test substrate for hydrolytic activity on long-chained 
substrates in a detergent-free system. Strikingly, the extended lid-loop mutant show for PPTS as 
test substrate a kkat reduced to 20% of hAPT wild type, a level roughly comparable to the L73A 
mutant (see Chapter 5.2.4). Surprisingly, the apparent KM derived from the activity assay is reduced 
to 1.72 ± 0.35 µM, approximately 50% of the wild type.  
 
Figure 76: Activity of human APT1 +LP mutant on PPTS. As shown in the graph, its Vmax is reduced compared to 
human APT1 wild type and in the range of human APT1 L73A. KM is not slightly lower than the wild type. Data 
averaging and error calculation was done with Microsoft Excel, the plot was fitted with Origin.  
Table 13: Kinetic parameters of human APT1 wild type, L73A and +LP mutants on PPTS used as test substrate. 
 Vmax [µmol s-1] kcat [s-1 x104] KM [µM] kcat / KM [µM-1 s-1 x104] 
wild type 170.5 ± 11 3.41 ± 0.22 3.38 ± 0.77 1.01 
L73A 47.5 ± 3 0.95 ± 0.06 0.94 ± 0.28 1.01 
+LP 29.5 ± 1.5 0.59 ± 0.03 1.72 ± 0.35 0.34 
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Screening for crystallization conditions for the human APT1 +LP mutant was performed as 
described in Material and Methods (Chapter 7.3.2). Crystals were isolated directly from the 
screening plate. Diffraction data was collected at X10SA at SLS, and processed as described in 
Material and Methods. The crystal (Figure 77) belongs to space group P21 with one molecule per 
asymmetric unit and diffracted to a resolution of 2.0 Å. The structure was solved via Molecular 
Replacement using human APT1 wild type as template. The crystallographic statistics is presented 
in Table 14.  
 
Figure 77: Crystallization drop of human APT1 +LP mutant. Crystals grew within 21 days in condition Core1 C10 
containing 0.1M HEPES, pH 6.5 (final pH 7.0) and 20% PEG 6000. Photograph taken using Formulatrix Rock 
Imager.  
Table 14: Crystallographic statistics of human APT1 +LP. Values for the highest shell are given in parentheses. 
Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
+LP  
 
Data collection  Refinement  
Space group  P21 Resolution (Å)  37.71-2.00 (2.05-2.00) 
Cell dimensions   Number of Reflexes  46843 (3390) 
    a, b, c (Å) 
 36.37 59.44 
49.55 Rwork 
 18.1 (27.6) 
    α, β, γ (°)  90.0 100.03 
90.0 Rfree 
 21.1 (31.6) 
Resolution (Å)  37.7 - 2.0 
(2.05 - 2.00) Number of Atoms 
  
Monomers / au  1     Protein  1685 
Wave length (Å)  0.97962     Ligand/Ions  0 
CC 1/2  99.9 (78.8)     Water  78 
I / σ(I)  18.91 (1.97) B-factor (Å2)  
Completeness (%)  99.5 (99.2)     Protein  45.1 ± 13.1 
Redundancy  3.3 (3.3)     Ligands  - 
 
    Solvent  54.5 ± 11.4 
RMSD  
    Bond length (Å)  0.0071 
    Bond angle (°)  1.23 
Ramachandran (%)  98.20, 1.80, 0.0 
Clashscore  4.71 
Rotamer outlier (%)  1.09 
Molprobity score  1.27 
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Interestingly, the +LP mutation crystallizes in the same space group and roughly comparable 
crystal packing as the L73A mutation (see Figure 78). The protein does not form the human APT1 
wild type dimer, and wild type of human APT1 cannot form this crystal interface, as the lid-loop 
would clash with its neighbor. Residues P74 to D77 of the extended lid-loop of human APT1 +LP 
are at the interface to the symmetry molecule, the backbone amide of D78 (D76 in wild type) forms 
an H bond to the side chain of Q210 (Q208 in wild type) of the neighbor, and P77 (P75 in wild type) 
is largely buried in the interface. This raises the question if the crystal contact forces the lid-loop 
into the observed conformation and thus the observed lid-loop conformation is a crystallization 
artifact, or if the lid-loop pre-forms this conformation in solution and thus enables the altered crystal 
interfaces. An analysis of this interface using PISA[97] predicts no quaternary complex formation of 
human APT1 +LP in solution (see Chapter 5.4). The increased average B-factor of the Cα atoms of 
the lid-loop (67.9 Å2, compared to the average overall Cα atom B-factor of 43.7 Å2) indicates that 
the lid-loop is not fixed in the interface. Thus, it can be assumed that the lid-loop forms this 
conformation in solution.  
 
Figure 78: Comparison of the interfaces of human APT1 +LP (yellow) and L73A (green). Both mutants belong to 
the same space group and have comparable packing, probably as the lid-loop of both mutants is folded into the 
tunnel. Human APT1 +LP mutant crystallized with a different unit cell (approx. 2 Å difference on all axes, 
compare Table 11 and Table 14).  
In Figure 79, the structure of the human APT1 +LP mutant is compared to human APT1 wild type. 
The comparison revealed that the binding tunnel is blocked by the inserted L73 and L75 (L73 in 
wild type, see sequence alignment in Figure 75) in this crystal structure of the mutant. The wild type 
tunnel entrance is closed by with the side chain of L73, and L75 is located in front of W140, which 
marks the middle of the human APT1 wild type tunnel. Similar to the human APT1 L73A mutant, 
the human APT1 +LP mutant does not pre-form an accessible hydrophobic tunnel, and binding of 
long-chain substrates would require a rearrangement of the lid-loop. However, the remaining 
biochemical activity (at the level of only 20% of the wild type) observed in the PPTS activity assay 
indicates that a reformation of the tunnel is possible, similar to human APT1 L73A mutant (see 
Chapter 5.2.4 and 5.2.5). Thus, the LP insertion alone is not sufficient to abolish biochemical 
  Results 
 74 
activity and the further differences in the sequence of the lid-loop of SOBER1 (see Figure 75) might 
be responsible for the abolished biochemical activity of SOBER1 on long chain substrates.  
The side chain of L58 is rotated compared to the apo form of human APT1 wild type, as its wild 
type conformation would clash with the G72 of the extended lid-loop. The overall conformation of 
the “foot-rest” loop is not affected. 
 
Figure 79: Superimposition of human APT1 wild type (blue) and human APT1 +LP mutant (yellow). A: The view 
through the binding tunnel reveals its blockage by L73 and L75 of the extended lid-loop. L75 is located close to 
W140 in the middle of the tunnel, while the inserted L73 blocks the tunnel entrance directly at the active site 
serine. B: View rotated by 90˚ and cut through the surface, L73 and L75 are visible blocking the entrance next to 
S114 and middle part at W140 of the tunnel, respectively. Amino acids not forming the lid-loop are numbered 
according to the wild type; the wild type lid-loop is labeled in blue.  
Albeit the mutations are of different nature, the lid-loop is folded into the tunnel in both human APT1 
+LP and L73A mutants. This is probably caused by the missing stabilizing effect of the side chain of 
L73: in the extended lid-loop of the +LP mutant, the side chain is dislocated from its wild type 
position, while the side chain is lacking in the L73A mutant. In Figure 80, both structures are 
compared. While in the human APT1 +LP mutant, the side chains of the inserted L73 and L75 
block the complete tunnel beginning from the entrance, the tunnel of the human APT1 L73A mutant 
is blocked by P75 in front of W140, which marks the middle of the wild type tunnel.  
The different shape of the entrance to the blocked tunnel also influences the side chain of L58, 
which is rotated in the +LP mutant due to the extended lid-loop as the conformation of L73A would 
clash.  
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Figure 80: Comparison of the lid-loop of human APT1 +LP (yellow) and L73A (green). Both mutations remove the 
stabilizing effect via the side chain of L73, and thus the lid-loop is folded into the tunnel. In human APT1 +LP, the 
tunnel is blocked by the side chains of the inserted L73 at the entrance and L75 in the middle of the wild type 
tunnel, marked by W140. In human APT1 L73A, the stump of L73A is rotated outwards, thus enabling P75 to 
move into the middle of the tunnel.  
Attempts to co-crystallize the +LP mutant with 2BP resulted in a few conditions with small crystals, 
but no diffraction data of reasonable quality could be collected from these crystals, therefore no 
complex structure of this mutant with 2BP is available.  
In conclusion, the fact that both the human APT1 L73A and the +LP mutants show the lid-loop 
collapsed into the tunnel suggest that removal or shifting the L73 side chain eliminates the 
interactions that are most important for stabilization of the open tunnel.  
 
5.2.7 Biochemical activity of lid-loop truncation mutants ΔL73S74 and ΔS74P75 of 
human APT1  
The investigation of the influence of the length of the lid-loop on tunnel shape and activity of APT 
included deletion mutants of the lid-loop. Three versions of lid-loop mutants lacking two amino 
acids each were prepared, and two of these mutants with a shortened lid-loop, human APT1 
ΔL73+S74 or ΔS74+P75, could be crystallized (see the following Chapter 5.2.8 and 5.2.10) and 
subsequently were tested on their biochemical activity on PPTS. Both mutants behave similarly in 
the biochemical assay and have a reduced kcat on PPTS to about 20 to 25% compared to the wild 
type, which is in the range of the previously described human APT1 L73A and human APT1 +LP 
(see Chapter 5.2.6). The apparent KM of both mutants is again reduced compared to the wild type.  
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Figure 81: Lid-loop deletion mutants compared to human APT1 wild type activity on PPTS. Both human APT1 
ΔL73S74 and ΔS74P75 mutants show a kcat reduced to about 25% of the wild type. Data averaging and error 
calculation was done with Microsoft Excel, the plot was fitted with Origin.  
Table 15: Kinetic parameters of human APT1 wild type, ΔL73S74 and ΔS74P75 mutants on PPTS used as test 
substrate.  
 Vmax [µmol s-1] kcat [s-1 x104] KM [µM] kcat / KM [µM-1 s-1 x104] 
wild type 170.5 ± 11 3.41 ± 0.22 3.38 ± 0.77 1.01 
ΔL73S74 39 ± 3.5 0.78 ± 0.07 0.59 ± 0.25 1.32 
ΔS74P75 52.5 ± 2.5 1.05 ± 0.05 1.03 ± 0.20 1.02 
 
5.2.8 Crystal structure of human APT1 ΔL73S74  
Human APT1 ΔL73S74 was subjected to screening for crystallization conditions, and optimized 
conditions yielded crystals of high quality belonging to space group C2 (Figure 82). Diffraction data 
was collected at X10SA at SLS to a resolution of 2.55 Å. The structure was solved by Molecular 
Replacement using human APT1 wild type as template. The asymmetric unit contains eight 
monomers. The crystallographic statistics is summarized in Table 16.  
 
Figure 82: Crystallization drop of human APT1 ΔL73S74. The protein crystallized within 3 days in condition 
Core1 B12 of Qiagen. Larger and better diffracting crystals were obtained from optimization in a 24-well grid 
screen in a condition containing 0.1 M KF and 21% PEG 3350. Photograph taken using an Olympus DP21 camera 
attached to an Olympus CX-60 microscope with a polarization filter. 
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Table 16: Crystallographic statistics of human APT1 ΔL73S74. Values for the highest shell are given in 
parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
ΔL73S74  
 
Data collection  Refinement  
Space group C2 Resolution (Å) 49.09 - 2.55 (2.62 - 2.55) 
Cell dimensions  Number of Reflexes 174535 (13357) 
    a, b, c (Å) 
106.57, 105.23, 
143.74 Rwork 
25.3 (32.7) 
    α, β, γ (°) 90.0, 92.88, 
90.0 Rfree 
32.1 (38.3) 
Resolution (Å) 49.09 - 2.55 
(2.62 - 2.55) Number of Atoms 
 
Monomers / au 8     Protein 13360 
Wave length (Å) 0.97886     Ligand/Ions 0 
CC 1/2 98.2 (41.6)     Waters 79 
I / σ(I) 5.96 (2.00) B-factor (Å2)  
Completeness (%) 96.0 (97.5)     Protein 51.1 ± 20.3 
Redundancy 1.79 (1.81)     Ligand - 
 
    Waters 33.9 ± 8.4 
RMSD  
    Bond length (Å) 0.0125 
    Bond angle (°) 1.54 
Ramachandran (%)  95.29 / 3.63 / 1.08 
Clashscore  8.18 
Rotamer outlier (%)  3.15 
Molprobity score  2.19 
 
The asymmetric unit contains eight monomers that are arranged in four dimers, which are rotated 
about 9˚ - 11˚ compared to the typical human APT1 wild type dimer[69]. Despite the shortened lid-
loop, the mutation does not significantly alter the dimer type formed under this crystallization 
condition. The overall structure of human APT1 ΔL73S74 mutant is similar to the wild type, as 
indicated by the average rmsd of 0.65 Å over 217 Cα. The crystal structure reveals that the 
shortened lid-loop still pre-forms an accessible hydrophobic tunnel in all eight monomers (see 
Figure 83). This could be influenced by the dimer, which is predicted (using PISA[97]) to be stable in 
solution. The shape of the tunnel entrance at the active site is changed due to the shortened lid-
loop that leaves a gap between L58 and L171 due to the deletion of L73. A comparison of the 
surfaces of human APT1 wild type and ΔL73S74 is given in Figure 83.  
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Figure 83: Comparison of human APT1 wild type with human APT1 ΔL73S74. Both proteins form a comparable 
dimer in the crystal, despite the shortened lid-loop. The shortened lid-loop changes the tunnel entrance and 
length, leaving a gap (encircled) between L171 and L58.  
The shortened lid-loop pre-forms a binding shorter tunnel of a diameter comparable to the wild 
type. The high number of eight molecules in the asymmetric unit further allows a statistical analysis 
on the conformation of the lid-loop. Structure refinement omitting NCS restraints resulted in a better 
structure model as indicated by the lower Rfree, indicating that the conformation of the lid-loop 
slightly varies between the eight monomers. The differences within the monomers of human APT1 
ΔL73S74 could be due to varying contacts to neighboring molecules. The superimposition of all 
eight monomers of human APT1 ΔL73S74 (salmon) with the apo-form of human APT1 wild type 
(blue) is shown in Figure 84. The lid-loop is stabilized by crystal contacts, partially by van-der-
Waals interactions within the dimer (I71-M200, P73-P168) and by neighbor molecules via a salt 
bridge formed between D74 and either K45 of the neighbor, or by an H-bond network with the 
backbone of different amino acids of the N-terminus. However, the B-factors of the lid-loops varies 
strongly, with monomer A having a B-factor of 39.0 Å2 lower than the average B-factor of 48.5 Å2 of 
all Cα in the eight monomers, while monomer B, C, and D have B-factors of 50.0, 47.3, 45.8 Å2 that 
are in the range of the overall average B-factor. The lid-loops of the remaining four monomers have 
an increased B-factor of 62.2 to 72.1 Å2. No correlation between an increased B-factor and the 
interaction of the lid-loop by the described salt bridge or H-bonds to the N-terminus of neighbor 
molecules is observed.  
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Figure 84: Comparison of the lid-loop conformation of human APT1ΔL73S74 (salmon) and wild type (blue). The 
shortened lid-loop pre-forms a hydrophobic tunnel in all eight monomer.  
The structure of the lid-loop in the shortened mutant differs significantly from the wild type. In the 
wild type of human APT1, the side chain of L73 forms the tunnel entrance, and S74 and P75 the tip 
of the lid-loop. In the shortened lid-loop of the ΔL73S74 mutant, the deletion of L73 and S74 results 
in a shift of the Cα of P73 by 5.0 to 7.5 Å (varying between the individual monomers) towards the 
position of L73 in the apo-form of human APT1 wild type (see Figure 85). Thus, in the ΔL73S74 
mutant, P73 forms the tunnel entrance. 
 
Figure 85: Side view of the binding tunnel in human APT1 ΔL73S74 (salmon) with human APT1 wild type (blue) 
as reference. P73 moves to the position of L73 of human APT1 wild type. The detailed structure of the lid-loop 
varies between the different monomers of the ΔL73S74 mutant.  
The eight molecules in the asymmetric unit are sufficient for a statistical analysis of side chain 
conformation. R144 and F176 are located at the end of the binding tunnel. To enable binding of 
long-chained ligands reaching to the exit of the tunnel, both side chains have to be rotated outside 
of the tunnel, as it is the case in e.g. the complex of human APT1 wild type with 2BP (Figure 86B) 
or human APT1 L58A (Figure 63). In the absence of any ligand bound inside the tunnel, both amino 
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acids can move into the binding tunnel, but as observed in this crystal, not necessarily do so. 
Figure 86A illustrates the four possible combinations of either both side chains inside the tunnel, or 
one side chain inside and the other side chain rotated out of the tunnel, or both side chains rotated 
out of the binding tunnel and leaving it solvent occupied. The observation of these multiple 
conformations within one crystal shows that these conformations are energetically equivalent or 
determined by minor details of the crystal packing environment.  
 
Figure 86: Panel A: View on human APT1 ΔL73S74 with focus on R144 and F176, located at the end of the 
hydrophobic binding tunnel. A superimposition of the eight monomers present in the asymmetric unit reveals 
that all four possible combinations of side chain conformations are present within one crystal: both R142 and 
F174 together (grey, monomer H) are located inside the tunnel, either R144 (yellow, monomer B) or F176 (purple, 
monomer D) are separately rotated into the tunnel, or the tunnel is free (green, monomer A). Panel B: 
Comparison with human APT1 wild type in complex with 2BP (cyan), which illustrates the clash of 2BP with side 
chains rotated into the tunnel.  
The apo structure of human APT1 ΔL73S74 shows that the shortened lid-loop still pre-forms a 
hydrophobic tunnel. The tunnel entrance is significantly changed, which could be the reason for the 
reduced biochemical activity. Interestingly, the dimer formation in the crystal is not significantly 
affected as the dimer is rotated by about 10˚ compared to the apo form of human APT1 wild type. 
The effect of the shortened lid-loop on ligand binding was investigated by co-crystallization of a 
complex with 2BP described in Chapter 5.2.9.  
5.2.9 Crystal structure of human APT1 ΔL73S74 in complex with 2BP 
The complex of human APT1 ΔL73S74 and 2BP was prepared similar to the human APT1 wild type 
2BP complex described in Chapter 5.1.5 and subjected to screening for crystallization conditions as 
described in Material and Methods. In the case of the human APT1 ΔL73S74 2BP complex, a 
mixture containing 1.5 mM of protein and 5 mM of 2BP was incubated for 10 min at 45˚C before 
crystal setup. Crystals of satisfying size and quality (Figure 87) were isolated directly from the 
screening plate. Diffraction data was collected at X10SA at SLS using monochromatic x-rays of 
0.9188 Å wavelength to obtain an anomalous data for bromine present in the inhibitor 2BP. The 
crystal belonged to space group C2 and diffracted to 1.62 Å. Diffraction data was processed as 
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described in Material and Methods. The structure was solved via Molecular Replacement using the 
apo form of human APT1 ΔL73S74 as search model. The crystallographic statistics are presented 
in Table 17.  
 
Figure 87: Crystals of human APT1 ΔL73S74 in complex with 2BP grew in condition Classics F2 containing 1.6 M 
MgSO4, and 0.1 M MES pH 6.5 within 8 days. Photograph taken by Formulatrix Rock Imager and scale bar 
inserted using Gimp[4].  
Table 17: Crystallographic statistics of human APT1 ΔL73S74 in complex with 2BP. Values for the highest shell 
are given in parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
ΔL73S74 + 2BP   
 
Data collection  Refinement   
Space group  C2 Resolution (Å)   
Cell dimensions   Number of Reflexes  428980 (56755) 
    a, b, c (Å) 139.37, 57.71, 
64.33 Rwork 
 22.22 (35.5) 
    α, β, γ (°) 
90.0, 92.71, 
90.0 Rfree 
 25.74 (40.2) 
Resolution (Å) 
69.61-1.62 
(1.66-1.62) Number of Atoms 
  
Monomers / au  2     Protein  3393 
Wave length (Å)  0.91882     Ligand/Ions  74 
CC 1/2  99.2 (61.4)     Water  472 
I / σ(I)  6.97 (1.61) B-factor (Å2)   
Completeness (%)  97.5 (86.4)     Protein  19.5 ± 7.4 
Redundancy  3.4 (3.2)     Ligand  35.1 ± 11.0 
 
    Water  30.9 + 10.5 
RMSD   
    Bond length (Å)  0.0116 
    Bond angle (°)  1.63 
Ramachandran (%)  97.33, 2.45, 0.22 
Clashscore  10.69 
Rotamer outlier (%)  3.23 
Molprobity score  2.06 
 
The complex crystallizes in a different condition and space group than the apo form of the human 
APT1 ΔL73S74 mutant described in the previous chapter. Under this condition, the protein forms a 
dimer via the same interface as the typical dimer found in the apo form human APT1 wild type 
crystallized in P1[69]. The dimer of human APT1 ΔL73S74 in complex with 2BP is rotated by 5.4˚ 
compared to the dimers of the apo form of human APT1 ΔL73S74 (see 5.2.8) and rotated by 12.3˚ 
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compared to the apo form of human APT1 wild type. The two monomers of the human APT1 
ΔL73S74 – 2BP complex have different environments (see Figure 88). The lid-loop of monomer A 
is buried in the dimer interface and a symmetry molecule of itself that stabilizes the lid-loop by a salt 
bridge of 3.7 to 4.0 Å distance between D74 and R142 (R144 in the wild type) that is located at the 
exit of the binding tunnel. The lid-loop of monomer B does not form this interaction, as the crystal 
interface differs and the symmetry-related molecule is located farther away, leaving the tunnel exit 
exposed to a solvent channel. The B-factors of the Cα of the lid-loop are increased to 35.7 and 
30.5 Å2 in monomer A and B, respectively, compared to the average overall B-factor of 20.0 Å2, and 
the electron density of the lid-loop of monomer A is weaker than in monomer B, despite the crystal 
contact in monomer A. Strong electron density for 2BP can be seen inside the shortened tunnel. 
However, the shortened lid-loop is not significantly stabilized upon binding of 2BP, as indicated by 
the B-factor, which is also 1.7-fold increased compared to the protein overall B-factor. The following 
Figure 88 provides an overview of the lid-loop’s surface contacts. 
 
Figure 88: Comparison of the crystal contacts of monomer A (salmon) and monomer B (dark pink). The left side 
presents the close contact next to the lid-loop between monomer A and its symmetry mate (grey). On the right 
side, shown in the same orientation, a gap is found between monomer B and its symmetry mate (grey). The 
active sites are encircled in red.  
The conformation of the lid-loop of the complex of human APT1 ΔL73S74 with 2BP differs slightly 
from the apo form. The inhibitor bound inside the tunnel prevents the inward movement of P73 and 
the lid-loop into the binding tunnel, thus the Cα of P73 is located about 2 Å further out in the 2BP 
complex compared to the apo form of human APT1 ΔL73S74. The shortened lid-loop is unable to 
form the proper entrance of the hydrophobic tunnel, leaving a gap between the side chains of L58 
and L171 and forming the tunnel entrance in front of the side chain of W140, which marks the 
middle of the wild type tunnel. In addition, the shortened lid-loop leaves a wider exit of the tunnel. 
The anomalous signal of the α-bromide was used to verify the presence of 2BP and its binding 
mode, similar to the complex of human APT1 wild type - 2BP complex described in chapter 5.1.5. 
Interestingly, the binding mode of 2BP differs between the two monomers, in contrast to the 
complex of hAPT1 wild type with 2BP that contains an identical binding mode in all four monomers 
(see chapter 5.1.5). In monomer A of the human APT1 ΔL73S74 - 2BP complex, two peaks of the 
anomalous map are observed, one at the active site and a second inside the binding tunnel, 
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corresponding to the α-bromine of 2BP bound in two positions. The first is identical to the major 
conformation of 2BP in the human APT1 wild type complex, where the carboxylate of 2BP is bound 
in the oxyanion hole next to the active site serine (Figure 89, anomalous signal 1). No binding mode 
similar to the minor conformation of 2BP in the human APT1 wild type complex is observed.  
 
Figure 89: Detailed view on human APT1 ΔL73S74 in complex with 2BP(cyan). 2BP is presented in the binding 
mode supported by the stronger anomalous signal (yellow, right) for the α-bromide atom. Due to the shortened 
lid-loop, the lacking L73 leaves a gap between L58 and L171. The tunnel entrance of the ΔL73S74 mutant is 
formed in front of W140, next to the second anomalous signal (yellow, left).  
The conformation of 2BP bound to human APT1 ΔL73S74 shown in Figure 89 is comparable to 
2BP bound to human APT1 wild type (Figure 90). In both complexes of the human APT1 wild type 
and ΔL73S74 mutant, the carboxylic head group of 2BP is coordinated by the oxyanion hole formed 
by the backbone amides of L25 and Q115 next to the active site serine. The aliphatic tail is bound 
inside the hydrophobic tunnel formed by the lid-loop. The high flexibility of 2BP allows induced fit to 
the altered shape of the binding tunnel in the ΔL73S74 mutant, and thus differs in its conformation 
from 2BP bound to the wild type (Figure 90).  
 
Figure 90: Comparison of the conformation of 2BP bound to human APT1 ΔL73S74 (pink) and human APT1 wild 
type (blue). The head group of both 2BP molecules is coordinated via H-bonds to the oxyanion hole formed by 
L25 and Q115. The aliphatic chain is bound inside the tunnel formed by the lid-loop (red), and is adapted to its 
shape and thus differs between 2BP bound to the wild type (green) and 2Bp bound to human APT1 ΔL73S74 
(cyan).  
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The second peak of the anomalous density map in monomer A of the human APT1 ΔL73S74 - 2BP 
complex corresponds to the α-bromide of 2BP bound in an alternative conformation with the head 
group at the altered tunnel entrance of human APT1 ΔL73S74 (Figure 91). This supports the 
hypothesis that 2BP can slide into the binding tunnel until the charged head group of 2BP is next to 
the new tunnel entrance. 2BP is not completely covered by the shortened lid-loop. The electron 
density of the tip of 2BP protruding from the tunnel exit is weaker than for the part bound inside the 
tunnel. An adjustment of the occupancy of both molecules of 2BP resulted in a 60:40 distribution of 
2BP in favor for the binding mode with the carboxylic head group located at the oxyanion hole next 
to the active site. The conformation of 2BP bound with the head group at the new tunnel entrance 
inside the tunnel found in monomer A is shown superimposed with the human APT1 wild type (2BP 
complex, 2BP not shown) in Figure 91. The side chain of L73 is part of the wild type tunnel 
entrance, and the comparison shows that the head group is located at the middle of the wild type 
tunnel.  
 
Figure 91: Comparison of the 2BP complexes of human APT1 ΔL73S74 (pink, 2BP in cyan) and wild type (blue, 
2BP not shown). The shortened lid-loop of human APT1 ΔL73S74 monomer A (pink) enables the binding mode of 
2BP (cyan) with its head group located at the new tunnel entrance formed next to W140, which marks the middle 
of the wild type tunnel. The 2Fo-Fc electron density of 2BP is shown in blue and contoured to 1 I/σI, while the 
anomalous density is presented at a level of 3.5 I/σI in yellow.  
The protruding part of 2BP bound in the second conformation in monomer A is located in the 
interface between monomer A and its symmetry molecule (see Figure 88). This artificial cavity is 
lined with the hydrophobic side chains of M174, F176 and L179 from monomer A, and P173 and 
P73 of the symmetry mate of monomer A, which all form hydrophobic contacts to the tail of 2BP 
bound in the tunnel of monomer A, and vice versa.  
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Figure 92: Hydrophobic space between monomer A (salmon) and its symmetry mate (grey). The molecule 2BP 
(cyan) bound with the head at the new tunnel entrance of monomer A has the tunnel exit protruding tip located in 
the interface between monomer A and its symmetry mate. The side chains of amino acids in the distance of van-
der-Waals interactions with 2BP are shown as sticks. Side chains outside the lid-loop are numbered according to 
the wild type.  
Monomer B contains one strong anomalous peak for bromide plus two weak ones and the 
elongated electron density of 2BP resides inside the binding tunnel. Interestingly, the forked density 
of the head group of 2BP is found at the rear exit of the tunnel. The electron density of the reverse 
conformation is well defined and the carboxylic head group has a charged interaction with the 
guanidine moiety of the R144 side chain at the tunnel exit. A strong peak in the anomalous density 
map supports this conformation. There are two further weak peaks of the anomalous map at two 
‘bulks’ next to the linear density of 2BP, one close to the active site, potentially indicating weak 
binding of 2BP in the conformation observed in the human APT1 wild type complex, and one 
towards the dimer interface, between N59 and M64 of both monomers. However, these signals are 
very weak and nearly on the level of background noise (independent of the resolution cut-off of the 
anomalous map), and as one molecule of 2BP fitted according to the strongest anomalous density 
peak explains the electron density well, alternative conformations were not included in the model 
building process. The reverse binding mode found in monomer B is presented in Figure 93.  
 
Figure 93: Orientation of 2BP in the human APT1 ΔL73S74 complex bound to monomer B. The well-defined 
forked electron density (blue, contoured to 1 I/σI) and the anomalous signal of bromine (yellow) support the 
presented binding mode with the carboxylic acid forming a charged interaction with the guanidine moiety of the 
R144 side chain. The weaker anomalous signal closer to the active site lacks density for the forked head group, 
but could correspond to weakly bound 2BP in the major conformation as observed in monomer A and the wild 
type.  
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Summarized, the two monomers of the asymmetric unit contain 2BP bound in three conformations, 
of which two were not observed in the human APT1 wild type complex. Both new orientations of 
2BP bind with the carboxylic head group distant from the active site; either slid deeper into the 
tunnel due to the different shape of the tunnel entrance of the human APT1 ΔL73S74 mutant, or at 
its wider exit. A substrate bound in a similar manner would have the cleavable ester located outside 
of the active site, thus being bound in an unproductive binding mode. The relevance of this binding 
mode is further analyzed in chapter 5.2.13.  
5.2.10 Crystal structure of human APT1 ΔS74P75 
The second successfully crystallized mutant of human APT1 containing a shortened lid-loop lacked 
amino acids S74 and P75, shifting the double deletion by one amino acid further compared to the 
mutant described in the Chapter 5.2.8. Human APT1 ΔS74P75 was screened for crystallization 
conditions and suitable crystals (shown in Figure 94) were isolated directly from the screening 
plates. The selected crystal belonged to space group P21 and diffraction data to a resolution of 
1.85 Å was collected at X10SA at SLS, Villigen, as described in Material and Methods. The 
structure was solved by Molecular Replacement using the structure of human APT1 apo as 
template.  
Table 18: Crystallographic statistics of human APT1 ΔS74P75. Values for the highest shell are given in 
parentheses. A molecule of HEPES is bound to the protein. Values for Ramachandran plot are given for 
favoured, allowed and outlier.  
 
human APT1 
ΔS74P75  
 
Data collection  Refinement   
Space group  P21 Resolution (Å)  48.72-1.85 (1.90-1.85) 
Cell dimensions   Number of Reflexes  113133 (8495) 
    a, b, c (Å) 
 36.47, 58.46, 
49.63 Rwork 
 21.45 (40.9) 
    α, β, γ (°) 
 90.0, 100.96, 
90.0 Rfree 
 25.33 (40.0) 
Resolution (Å)  48.72-1.85 
(1.90-1.85) Number of Atoms 
  
Monomers / au  1     Protein  1646 
Wave length (Å)  0.91639     Ligand/Ions  15 
CC 1/2  99.8 (85.5)     Water  102 
I / σ(I)  10.33 (1.93) B-factor (Å2)   
Completeness (%)  99.7 (100)     Protein  37.3 ± 13.1 
Redundancy  3.30 (3.35)     Ligand  95.8 ± 8.5 
 
    Water  43.8 ± 8.9 
RMSD   
    Bond length (Å)  0.0112 
    Bond angle (°)  1.55 
Ramachandran (%)  94.47, 3.61, 0.92 
Clashscore  10.48 
Rotamer outlier (%)  1.14 
Molprobity score  1.96 
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Figure 94: Crystallization drop of human ΔS74P75. Crystals grew within 13 days in screening condition Core1 B5 
containing 0.1M HEPES pH7.5, 20% PEG 4000 and 10% 2-Propanol. Photograph taken using Formulatrix Rock 
Imager.  
The structure of human APT1 ΔS74P75 contains one monomer per asymmetric unit, which does 
not form a crystal contact via the typical dimer interface observed for the apo form of human APT1 
wild type[69]. Compared to the apo form of human APT1 wild type, the structure has an overall rmsd 
of 0.52 over 214 aa. The shortened lid-loop forms a tunnel and is not affected by salt bridges or H-
bonds, but the side chain of L73 is part of the interface to the neighbor. The protein is not predicted 
(using PISA[97]) to form stable assemblies via interfaces to the neighbors shown in Figure 95A. The 
average B-factor of all Cα atoms of the whole protein is 35.7 Å2, and the B-factor of the lid-loops Cα 
atoms is slightly increased with a value of 49.4 Å2. This is in a range comparable to the wild type 
structure that also has a 1.5-fold increased B-factor of the lid-loop compared to the overall B-factor. 
The crystal contacts of human APT1 ΔS74P75 are compared to the dimer of the apo form of 
human APT1 wild type in Figure 95A.  
 
Figure 95: Panel A: Crystal contacts of human APT1 ΔS74P75 (orange) and the symmetry molecules (grey) 
compared to the dimer formed by human APT1 wild type (blue ribbon). Panel B: Close-up on the symmetry mate 
next to the lid-loop. No salt bridges or H-bonds between the lid-loop and the symmetry mate (grey) could be 
detected.  
The lid-loop of human APT1 ΔS74P7 pre-forms a short tunnel with a wider tunnel entrance and 
exit. Despite the high resolution, the electron density of the lid-loop is weak at the tip of the lid-loop 
formed by L73 and D74 (D76 in the wild type). In human ΔS74P75, the side chain of L73 forms the 
tip of the lid-loop instead of forming the tunnel entrance, and the Cα of L73 is dislocated by 5.4 Å 
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compared to the apo form of human APT1 wild type. This results in a gap between L58 and L171 
as illustrated in Figure 96, similar to the gap observed in human APT1 ΔL73S74 (see Figure 83). 
Since the asymmetric unit contains only one monomer, a comparison between several monomers 
of the asymmetric unit, as in the previous case of human APT1 ΔL73S74, is not possible.  
 
Figure 96: Side view of human APT1 ΔS74P75 (orange) compared to the apo form of human APT1 wild type 
(blue) The shortened lid-loop significantly alters the tunnel shape, L73 is dislocated by 5.4 Å (measured at the 
Cα) and forms the tip of the lid with its side chain. The resulting gap between L58 and L171 creates the tunnel 
entrance in front of W140, comparable to human APT1 ΔL73S74. The tunnel exit is also wider than in the apo 
form of human APT1 wild type.  
The superimposition of the lid-loop of human APT1 ΔL73S74 and ΔS74P75 mutants (Figure 97) 
shows some differences. In human APT1 ΔS74P75, the new tunnel entrance formed by the side 
chain of L73 is slightly larger and shifted further compared to the ΔL73S74 mutant (see also Figure 
99). As the lid-loop of the ΔS74P75 mutant lacks the rigid P75, it is more flexible and forms a larger 
tunnel exit.  
 
Figure 97: Superimposition of the lid-loops of human APT1 ΔL73S74 (pink) and ΔS74P75 (orange). In human 
APT1 ΔS74P75, the tunnel entrance is formed by the side chain of L73 and is slightly larger compared to the 
tunnel entrance of human APT1 ΔL73S74 formed by P75 (wild type numbering).  
Taken together, the crystal structure of human APT1 ΔS74D75 shows a similar effect on the tunnel 
formed by the lid-loop as observed for the human APT1 ΔL73S74 mutant. The shortened lid-loop 
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pre-forms a tunnel, but leaves a gap between L58 and L171, resulting in a tunnel entrance formed 
in front of W140, which marks the middle of the tunnel of human APT1 wild type. The tunnel exit is 
also wider than in human APT1 wild type. The biochemical activity is reduced to ~20% of the wild 
type, comparable to the activity of human APT1 ΔL73S74 (Figure 81). A structure of a complex with 
2BP could not be obtained so far due to insufficient diffraction quality of the crystals.  
5.2.11 Human APT1 ΔI71-D76 lid-truncation mutant shows lowest activity  
Human APT1 ΔI71-D76 contains a complete truncation of the lid-loop by deleting six amino acids 
from I71 to D76 and shows the lowest biochemical activity of all mutants of this study. Figure 98 
shows the Michaelis-Menten kinetics using PPTS as substrate. The fitted curve is defined by few 
data points at low concentrations before reaching Vmax. While still being significantly active 
compared to the auto-hydrolysis control of PPTS, the mutant shows a kcat rate of 0.079 x104 s-1, 
that is 3% activity compared to the wild type of human APT1, indicating that the lid-loop is essential 
for catalysis. Another reason for the nearly abolished activity could be a not properly folded protein. 
From this residual activity, a very low apparent KM,app of 0.43 ± 0.16 was calculated from the fit, 
being 40-fold lower than the KM of human APT1 wild type. However, this value should be treated 
with caution.  
 
Figure 98: Comparison of the biochemical activity of human APT1 Δ71-76 to human APT1 wild type and the lid-
loop shortened ΔL73S74 and ΔS74P75 mutants of human APT1. While the shortened lid-loop reduced the activity 
to ~20%, the complete removal of the lid-loop nearly abolishes biochemical activity, reducing it to 3% compared 
to the wild type. Data averaging and error calculation was done with Microsoft Excel, the plot was fitted with 
Origin.  
Table 19: Kinetic parameters of human APT1 wild type, ΔL73S74, ΔS74P75 and ΔI71-D76 mutants on PPTS used 
as test substrate.  
 Vmax [µmol s
-1 
x104] kcat [s
-1 x104] KM [µM] kcat / KM [µM
-1 s-1 
x104] 
wild type 170.5 ± 11 3.41 ± 0.22 3.38 ± 0.77 1.01 
ΔL73S74 39 ± 3.5 0.78 ± 0.07 0.59 ± 0.25 1.32 
ΔS74P75 52.5 ± 2.5 1.05 ± 0.05 1.03 ± 0.20 1.02 
ΔI71-D76 3.95 ± 0.3 0.079 ± 0.006 0.43 ± 0.16 0.18 
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5.2.12 Crystallization of human APT1 ΔI71-D76 
So far, no structural data of the lid-less ΔI71-D76 mutant of human APT1 is available. Screening for 
crystallization conditions for human APT1 ΔI71-D76 failed to result in crystals of promising quality 
and size. Optimization of conditions resulting in initial hits in 24well plate format grid screens either 
failed to reproduce the crystals or could not improve the unsatisfactory x-ray diffraction quality of 
the initial hits. Two further deletion mutants, human APT1 ΔI71-S74 and ΔL73-D76, did not yield 
promising crystal hits either. The pure protein of human APT1 ΔI71-D76 cannot be concentrated as 
high as human APT1 wild type or the other mutants (maximum of 11 mg/ml of human APT1 ΔI71-
D76 compared to 30-40 mg/ml for human APT1 wild type), as the protein precipitates upon further 
concentration. As the activity assay data shows a low yet significant activity that also follows 
Michaelis-Menten kinetics, it is unlikely that the protein is completely denatured.  
5.2.13  Hypothetical non-productive binding mode of PPTS enabled by the non-wild 
type tunnel entrance  
Some lid-loop mutants of human APT1 investigated in this thesis show a reduced efficiency in the 
hydrolysis of the test substrate PPTS compared to the human APT1 wild type, and all except 
human APT1 +LP, where it is unknown, have an altered shape of the tunnel entrance. The 
hypothesis is that the linear palmitate moiety of the substrate slides into the hydrophobic tunnel 
until the larger (thio-)ester is stopped at the entrance. Thus, a different shape of the tunnel entrance 
caused by mutations of the lid-loop can result in unproductive binding of the substrate, with the 
ester dislocated from the active site serine and the oxyanion hole (see Figure 91). A comparison of 
the structures of human APT1 ΔL73S74 and ΔS74P75 mutants reveals a comparable change of 
the shape of the tunnel entrance. The shortened lid-loop causes a gap between L58 and L171 
(Figure 99, compare also Figure 83), and thus the tunnel entrance is formed further away from the 
active site. In the wild type of human APT1, this gap is filled by the side chain of L73, which forms a 
part of the tunnel entrance.  
 
Figure 99: Comparison of the surface of the human APT1 lid-loop mutants ΔL73S74 and ΔS74P75. Both 
mutations cause a gap between L58 and L171, thus the tunnel entrance is not formed next to the active site but 
farther away. Electrostatic surface potential is presented in a gradient of blue over white to red (from positive to 
negative). Electrostatic surface potential calculated and image created using CCP4mg[93].  
The gap between L58 and L171 is also present in the structure of human APT1 L73A (when co-
crystallized with 2BP binding inside the tunnel), although to a lesser extent (Chapter 5.2.5, see 
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Figure 74). It can be assumed that the changed tunnel entrance of the L73A mutant of human 
APT1 also enables unproductive binding of PPTS in a conformation comparable to the 
hypothesized binding of PPTS described in Figure 100. 
The extended lid-loop of the apo form of human APT1 +LP insertion mutant folds into the tunnel 
and blocks it (Figure 79). This mutant is active, so rearrangement of the lid-loop is necessary for 
ligand binding in a re-formed tunnel that is expected to enable efficient substrate turnover. The lack 
of structural data of a complex and thus the shape of the tunnel entrance of this mutant prevents 
description of a potential binding mode of the substrate.  
No structural data is available for the four (ΔI71-S74 and ΔL73-D76) and six (ΔI71-D76) amino acid 
lid-loop truncation mutants. The very short (respectively missing) lid-loop cannot form a tunnel, so 
these mutants are expected to be strongly impaired in substrate coordination, which is corroborated 
by the nearly abolished biochemical activity of the human APT1 ΔI71-D76 mutant.  
It can be assumed that the unproductive binding mode of 2BP observed in the complex with human 
APT1 ΔL73S74 could potentially also occur in the other mutants of human APT1 that show a 
comparably reduced biochemical activity (20 to 30% of the wild type) and shape of the tunnel 
entrance. The 2BP complex of human APT1 ΔL73S74 has a high resolution and well-defined 
electron density for the 2BP molecules bound in multiple conformations, resulting in an 
unproductive binding mode of 2BP (with the carboxylic head group at the mutant tunnel entrance, 
see Figure 91). Modeling was used to check if the substrate PPTS used for the biochemical assay 
could fit in this non-productive binding mode with the palmitate ester position as the carboxylic head 
group of 2BP. The model of the PPTS fluorophore head group (HPTS) was added next to the 
carboxylic acid head of 2BP, mimicking the proposed hypothetical non-productive binding mode of 
a PPTS molecule (illustrated in Figure 100). In this position, the hypothetical palmitate ester of 
PPTS is 7.2 Å away from the active site serine. By interesting coincidence, one sulfonate group of 
PPTS would bind inside the oxyanion hole close to the active site serine, and the aromatic pyranine 
ring system is located between the hydrophobic side chains of L58 and L171. Both interactions are 
likely to stabilize this hypothetical binding mode.  
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Figure 100: Hypothetical binding mode of PPTS, created by fitting HPTS next to 2BP in the unproductive binding 
mode observed in the human APT1 ΔL73S74 + 2BP complex. The hypothesis is that the gap between L58 and 
L171 (resulting from the shortened lid-loop) enables PPTS to slide deeper into the tunnel until reaching the new 
entrance, thus binding with the ester dislocated from the active site. This proposed unproductive binding mode 
would prevent hydrolysis, and stresses the important function of a correctly formed tunnel entrance in 
coordinating the substrate. 
Summarized, this hypothetical binding mode could explain the reduced activity of the lid-loop 
mutants of human APT1. The structure of human APT1 ΔL73S74 in complex with 2BP reveals the 
important function of the tunnel entrance formed by the lid-loop in positioning the substrate’s ester. 
The entrance of the binding tunnel limits the penetration depth of palmitate into the tunnel similar to 
a funnel. In the wild type it positions the ester close to the active site serine and the oxyanion hole, 
which is essential for efficient ester hydrolysis catalyzed by human APT1. Binding with the ester 
dislocated from the active site cannot result in APT-catalyzed hydrolysis, thus being a “non-
productive binding mode”, which can be observed in the 2BP complex of the human APT1 
ΔL73S74 mutant. The PPTS test substrate is bound with its aliphatic chain inside the tunnel and 
the aromatic pyranine ring system in the gap between the hydrophobic side chains of L58 and 
L171, and with one sulfonate group in the oxyanion hole. This unproductive binding mode could 
potentially be stronger than binding next to the catalytic serine and cause substrate inhibition, but 
no evidence for substrate inhibition (a peak of Vmax and a decline at further increasing substrate 
concentration) was observed in the biochemical data.  
5.2.14 Binding of 2BP is dependent on the lid-loop of human APT1  
Binding of 2BP to human APT1 wild type or the ΔI71-D76 lid-loop lacking mutant was measured via 
Stopped Flow as described in Material and Methods (Chapter 7.6.1) and in Chapter 5.1.7. A 
comparison of the association rate of 2BP to human APT1 wild type (Figure 101, green) and the 
human APT1 ΔI71-D76 mutant lacking the complete lid-loop (Figure 101, red) shows that the 
binding rate of the mutant is – unexpectedly – significantly decreased compared to the wild type. 
The data of human APT1 wild type and mutant both show more than one binding rate constant, and 
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thus require a multi-exponential fit. As mentioned in Chapter 5.1.7 describing 2BP binding to human 
APT1 wild type, multi-exponential functions can be unstable if the rate constants are too similar as 
in the case here, and thus the binding data is compared qualitatively.  
 
Figure 101: Stopped Flow measurements of binding of 2BP to human APT1 wild type (green) and the lid-lacking 
mutant Δ71-76 (red). 5 µM of human APT1 (wild type or mutant) were mixed with 50 µM of 2BP. The lid-loop 
lacking mutant shows a reduced binding rate compared to the wild type. Data averaged, normalized, and plotted 
by Ingrid Vetter using gnuplot[94]. Labels were added using Gimp[4].  
The facts that also the human APT1 ΔI71-D76 mutant contains more than one binding rate (like the 
wild type) corroborates that rearrangements of the lid-loop are not the only reason for the multiple 
binding rate constants. The significantly reduced binding rate of human APT1 ΔI71-D76 is an 
indicator that although W140 (forming the inner wall of the tunnel in the wild type) is quenched by 
2BP binding it might not be readily accessible from the solvent in the mutant. Hypothetically, the 
deletion mutant of human APT1 could form (unspecific) aggregates via the exposed inner wall of 
the hydrophobic tunnel (due to the lacking lid-loop) and thus reduce the accessibility of the 
remaining inner wall of the tunnel (and slow down the binding rate of 2BP, see Figure 101). 
Blocking of the active site by this mechanism cold also explain the strongly reduced biochemical 
activity of the mutant (see Figure 98). However, aggregation is contradicted by the observed high 
dissociation rate of 2BP from the human APT1 ΔI71-D76 2BP complex (see Figure 102, red curve). 
Therefore, unspecific binding, similar to the slow binding observed for 2BP at the groove (see 
Figure 53, green curve), could be an explanation for the reduced binding rate despite the direct 
accessibility (as the lid-loop und thus the tunnel is lacking). 2BP would then bind unspecifically at 
the new hydrophobic patch of the mutant without influencing the fluorescence signal of W140, and 
over time arranges itself next to the W140 side chain, i.e. 2BP could be sequestered at the 
additional binding sites, reducing the concentration of free 2BP. Thus, the complete ensemble 
would show an apparent slower binding rate of 2BP.  
5.2.15 Dissociation of human APT1 lid-loop – 2BP complexes  
Three lid-loop mutants of human APT1 were selected to compare the dissociation rate of their 
respective 2BP complex with human APT1 wild type. Human APT1 L73A contains only a point 
mutation, which probably increases the flexibility of the lid-loop (see Chapter 5.2.4); human APT1 
ΔS74P75 contains a shortened lid-loop forming a shorter tunnel with wider entrance and exit (see 
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Chapter 5.2.10); and human APT1 ΔI71-D76, whose biochemical activity is reduced to 3% 
compared to the wild type and probably cannot form a tunnel at all since the lid-loop is too short 
(see Chapter 5.2.11). The qualitative comparison of the dissociation rates of the respective 2BP 
complex measured via Stopped Flow (using L-FABP as competitor) is shown in Figure 102. The 
2BP complexes of human APT1 wild type (blue) and the L73A (green) and ΔS74P75 (magenta) 
mutants show two fast dissociation rates, while the human APT1 ΔI71-D76 mutant (red) can be 
described reasonably well using a single dissociation rate constant. The dissociation rate of the 
human APT1 ΔI71-D76 mutant is the fastest of the tested mutants, and corresponds to a 
dissociation of 2BP independent of the lid-loop (which is lacking in the ΔI71-D76 mutant). A 
comparably fast dissociation rate is also present in the 2BP complexes of the wild type and the 
L73A and ΔS74P75 mutants (Figure 102). Since this rate is present in 2BP complexes of the 
human APT1 wild type and lid-loop mutants, it is probably lid-loop independent and corresponds to 
2BP unspecifically bound at the groove close to W32. After the first fast dissociation rate, the 2BP 
complexes of both human APT1 L73A and ΔS74P75 mutants show a comparable second fast 
dissociation rate that is significantly increased compared to the second fast dissociation rate of the 
2BP complex of human APT1 wild type. Concluding from this, the second and slower rate (not 
present in the ΔI71-D76 mutant) could correspond to the influence of the lid-loop on the 
dissociation of 2BP bound inside the tunnel, which is faster in the mutant complexes due to the less 
stabilized 2BP by the (shorter) tunnel formed by the mutant lid-loop (see Chapters 5.2.5 and 5.2.9) 
compared to the wild type of human APT1. A potential third rate could be explained by the 
dissociation of dimers formed of the complex, which is likely to influence the release of 2BP from 
the tunnel, but dimerization plays probably a minor role at this protein concentration (protein 
concentration of 5 µM, dimer KD of 2.8 µM[69]).  
 
Figure 102: Comparison of the dissociation of 2BP (20 µM) complexes of human APT1 wild type and selected 
human APT1 lid-loop mutants (all APTs 5 µM). L-FABP (45 µM) is used as competitor to bind 2BP. The first fast 
dissociation rate of 2BP is roughly comparable for the four measurements and probably corresponds to 
unspecifically/weakly bound 2BP close to W32 at the groove. This rate is expected to be independent of the lid-
loop and the lid-loop lacking mutant ΔI71-D76 (red) can indeed be described using only this rate. The second 
dissociation rate is slower in the wild type (blue) than in the L73A (green) and ΔS74P75 (magenta) mutants, and 
would be expected to be sensitive to the influence of the lid-loop (which is less stable in the mutants) on the 
dissociation. The influence of dimer dissociation on the release of 2BP from the complex is unknown and could 
add a further rate constant to the equation. Data averaged, normalized, and plotted by Ingrid Vetter using 
gnuplot[94]. Labels added using Gimp[4].  
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As described in Chapter 5.1.8, the dissociation constant KD (a measurement for affinity) is defined 
as KD = koff/kon and could be determined from the binding rate constant and dissociation rate 
constant. However, since no reliable rate constants can be determined from complex formation and 
dissociation, the affinity of 2BP towards the human APT1 wild type and ΔI71-D76 mutant was 
compared qualitatively. The faster complex formation (kon) and a slower dissociation (koff) results in 
a lower KD of human APT1 wild type for 2BP (and thus a higher affinity) compared to the human 
APT1 ΔI71-D76 lid-loop lacking mutant. This appears to be a contradiction to the previously (in the 
activity assay) determined apparent KM (see Chapter 5.2.11), which is significantly lower for the 
human APT1 ΔI71-D76 mutant than for the wild type (see Figure 98). However, only under 
conditions where the turnover number kcat is insignificantly small compared to koff, KM is a 
reasonable approximation of KD. As these conditions are not fulfilled, KM cannot be compared to KD.  
Taken together, human APT1 wild type containing the properly folded lid-loop is faster in the 
formation of the complex with 2BP and slower in its dissociation, compared to the lid-loop lacking 
mutant ΔI71-D76. This corresponds to an (expected) higher affinity of human APT1 wild type for 
2BP compared to the lid-loop lacking mutant. The single fast dissociation rate of 2BP form the lid-
loop lacking mutant ΔI71-D76 probably corresponds to dissociation of unspecifically bound 2BP. A 
second fast dissociation rate is only present in lid-loop containing and therefore tunnel forming 
mutants, and thus are likely to be lid-loop dependent. It is observed that this dissociation rate is 
faster in the L73A and ΔS74P75 mutant than in the human APT1 wild type, which indicates that 
2BP is probably less tightly bound due to the more flexible lid-loop and wider tunnel entrance that is 
found in the corresponding crystal structures (see Chapter 5.2.5 and 5.2.9).  
5.2.16 Summary of the lid-loop mutants of human APT1  
Summarized, the study of various mutants addressing the flexibility and shape of the lid-loop 
revealed that a properly formed tunnel entrance is essential for efficient biochemical activity. Table 
20 provides an overview of the results of the human APT1 lid-loop mutants.  
Human APT1 L58A and L171A mutants show that both residues are not crucial for the stabilization 
of the lid-loop and formation of the wild type shaped tunnel. However, shortening the L73 side chain 
to alanine significantly decreases the stabilization of the lid-loop and thus increases the flexibility of 
the lid-loop significantly to enable the lid-loop to fold into the tunnel (see x-ray structure of human 
APT1 L73A, Figure 67). In addition, the shorter side chain of the L73A mutant alters the shape of 
the tunnel entrance, which then becomes less efficient in coordinating a ligand bound inside the 
tunnel (see Chapter 5.2.5), thus reducing the biochemical activity to about 30%. The crystal 
structure of human APT1 +LP insertion mutant showed that two leucine side chains of the extended 
lid-loop are located inside the tunnel and thus block it (see Figure 79). Here, rearrangement of the 
lid-loop would be necessary to allow ligand binding inside the tunnel. Due to the lack of a structure 
of a complex, no information on the shape of the tunnel and its entrance with a ligand bound inside 
is available, but it can be speculated that the altered lid-loop, even when “opened” to allow 
substrate binding, is unable to position the substrate in an optimal way. It is not a purely competitive 
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effect of the blocked tunnel since the KM value is not significantly altered (reduced to 50%). 
Biochemical activity of the human APT1 +LP mutant is reduced to about 30% of the wild type, the 
same level as human APT1 L73A.  
Shortening the lid-loop results in a reduction of the biochemical activity to about 20% compared to 
human APT1 wild type: both structures of human APT1 ΔL73S74 and ΔS74P75 have a shorter 
tunnel that is pre-formed in the absence of a ligand, has a wider exit and the entrance forms at the 
middle of the wild type tunnel (see Figure 83 and Figure 99). This relocated entrance enables 
binding of the substrate in an unproductive orientation, as concluded from the complex structure of 
human APT1 ΔL73S74 and 2BP (see Figure 91 and Figure 100). The complete truncation of the 
lid-loop nearly abolished biochemical activity, most likely due to the inefficient substrate positioning 
during catalysis caused by the lacking tunnel.  
Dimer formation (see Table 20 and Figure 115) is influenced by the shape of the hydrophobic patch 
and tunnel entrance but is not exclusively dependent on it, as the wild type dimer is also observed 
for the apo form of human APT1 ΔL73S74.  
Table 20: Overview of the lid-loop mutants described in this thesis. The biochemical activity is given in percent 
compared to human APT1 wild type. Except the human APT1 ΔI71-D76 lid-loop truncation mutant, mutants 
without structural data were not characterized biochemically.  
Mutant of 
human APT1 
Crystal 
structure 
wild type 
tunnel 
Dimer formation in crystal 
(˚ rotated compared to wt) 
Biochemical activity 
(% of wild type) 
L171A yes yes yes (6.3-7.1˚) 100%  
L171V yes yes yes (1˚) 100%  
L58A yes yes yes (5.6-7.9˚) - 
L73A 
yes (apo 
and +2BP) 
loop in 
tunnel  no dimer  30% 
L73A+L171A no - - - 
+LP yes 
loop in 
tunnel no dimer  30%  
ΔG72L73 no - - - 
ΔL73S74 
yes (apo 
and +2BP) 
wider 
entrance 
+ exit yes (9-11˚) 20% 
ΔS74P75 yes 
wider 
entrance 
+ exit no dimer  20% 
ΔI71-S74 no - - - 
ΔL73-D76 no - - - 
ΔI71-D76 no - - 3% 
 
5.3  Shallow groove as potential secondary binding site  
The exact binding mode of a palmitoylated protein to APT is unknown since no crystal structure of a 
complex is available so far, but the hydrophobic tunnel has been identified as the primary binding 
site of the palmitoyl moiety (see co-purified fatty acids[69] and product-mimicking 2BP, Chapter 
5.1.5) and seems to be required to position the cleavable ester at the active site (see Chapter 5.2).  
This shallow groove leads to the active site and binding tunnel, as shown in Figure 103 and could 
be a secondary binding site for e.g. the peptide chain of a palmitoylated protein or a second lipid 
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anchor. The surface of this groove is conserved to large extent in shape and surface charge in 
APTs of different organisms and other α,β-hydrolases, as for instance in the carboxyl esterase of 
P. aeruginosa (PDB ID 3cn9, [57]), which crystallized with a PEG bound into this groove (see Figure 
6). Other molecules besides PEG have been observed to weakly bind at this groove, for instance 
the hydrophobic 2BP (communication by Stefan Baumeister, also shown via Stopped Flow, Figure 
53), or the polar buffer bicine in the crystal structure of human APT1 L73A (Figure 69), revealing 
the ambiguous binding potential of the groove. Therefore, this groove is investigated by 
biochemical and structural methods using 2BP and a hexadecylated peptide mimicking the 
palmitoylated N-terminus of human APT1 (see Chapter 3.4.1) as test ligand for human APT1 as 
described in the following.  
 
Figure 103: Overview of the surface topology of human APT1. The lid-loop is shown in red, the catalytic triad in 
orange, and the shallow groove in yellow. A PEG molecule of the superimposed structure of a bacterial carboxyl 
esterase (PDB ID 3cn9, [57]) reveals the surface groove as potential secondary binding site.  
5.3.1 Obstacles for crystallographic investigation of the shallow groove as 
secondary binding site 
Binding assays based on the intrinsic tryptophan fluorescence of W32 (see Figure 103) have 
shown that 2BP binds with a weak affinity in the range of 100 µM in the groove next to the active 
site [communications by Stefan Baumeister]. This binding mode has not been observed 
unambiguously so far in any crystal structure of human APT1 with 2BP, although the groove often 
shows weak density that could be correspond to a partially disordered 2BP molecule (Stefan 
Baumeister, private communications). To further address the question whether the groove might 
bind palmitoylated peptide of substrate proteins with higher affinity than 2BP, human APT1 wild 
type was subjected to co-crystallization with a hexadecylated peptide corresponding to the N-
terminus of human APT1 (residues 1-10, see Figure 113). It was shown that APT1 is palmitoylated 
N-terminally and able to de-palmitoylate itself[98,99], thus, an un-cleavable hexadecylated thioether 
was attached to the N-terminal cysteine in position 2 of the peptide. However, no peptide was 
visible in the crystal. One possible reason for the failure to obtain a complex with a peptide could be 
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the fact that the wild type of human APT1 forms a dimer with a KD of 2.8 µM as described [69]. In the 
most common form of the dimer, the side chain of M60 (located in the loop next to the lid-loop) 
blocks the groove of the dimer partner as shown in Figure 104 and competes with the binding of 
ligands at this site.  
 
Figure 104: The side chain of M60 of the dimer partner blocks the shallow groove (yellow), which potentially 
hosts the substrate protein. The groove is located next to the active site (cyan), and the entrance of the binding 
tunnel formed by the lid-loop (red). The structure of the P. aeruginosa carboxyl esterase (PDB ID 3cn9, [57]) 
contains a molecule of PEG bound at the groove, which is superposed here (yellow sticks) to highlight the 
potential binding site.  
To enable ligand binding, the groove needs to be made accessible by either removing the side 
chain of M60 and/or rearranging the dimer. The effect of a shortened side chain or removal of M60 
was investigated by X-ray crystallography using M60S and ΔM60 mutants of human APT1, 
respectively. M60 is not part of the lid-loop or tunnel, or involved in an expected binding motif on 
the monomeric protein, therefore a mutation or deletion of M60 was not expected to alter the 
proteins binding characteristics. The structures presented in the following part were obtained and 
refined by B. Darius Bothe during his master thesis[100] under my supervision.  
5.3.2 Crystal structure of human APT1 M60S apo and in complex with 2BP 
Human APT1 M60S, both as apo form and in complex with 2BP, was subjected to screening for 
suitable crystallization conditions. Co-crystallization with 2BP was carried out as described before 
in Chapter 5.1.5. Briefly, 1.3 mM protein was mixed with 5 mM 2BP and heated to 50 ˚C for 5 to 10 
min while being mixed gently with the fingers. Crystals were isolated directly from the screening 
plate (Figure 105) as described in Material and Methods. The apo form and the 2BP complex of 
human APT1 M60S diffracted to 1.95 Å and 1.85 Å, respectively, at X10SA at SLS. The diffraction 
data was processed and the structure solved via Molecular Replacement using human APT1 wild 
type as template as described in Material and Methods. The crystals of the apo form and the 2BP 
complex belonged to space group P21 2121 and P21, respectively[100]. The crystallographic statistics 
are summarized in Table 21. Both data sets were collected at the bromine edge to potentially allow 
precise localization supported by the anomalous signal of 2BP in the complex form.  
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Figure 105: Left: Crystallization condition for the apo form of human APT1 M60S: Condition PEG screen, C7 
containing 0.1 M MES at pH 6.5, and 25% PEG 3000 resulted in crystals within 5 days. Right: Crystals of the 
human APT1 M60S – 2BP complex appeared within 12 hours and were grown for five days in condition PEG 
screen, C11 containing 0.1 M MES at pH 6.5 and 20% PEG 10,000. Photographs taken using Formulatrix Rock 
Imager.  
Table 21: Crystallographic statistics of the structures of human APT1 M60S as apo form and in complex with 
2BP. Values for the highest shell are given in parentheses. Values for Ramachandran plot are given for favoured, 
allowed and outlier.  
 
human APT1 
M60S apo 
human APT1 
M60S +2BP  
human APT1 
M60S apo 
human APT1 
M60S +2BP 
Data collection   Refinement   
Space group P212121  P21 Resolution (Å) 
42.32 - 1.95 
(2.00 - 1.95) 
46.43 - 1.85 
(1.90 - 1.85) 
Cell 
dimensions 
  Number of 
Reflexes 
 561706 
(42019) 
    a, b, c (Å) 
70.850   
77.830  
143.550 
72.17, 61.63, 
114.08 Rwork 
18.40 (24.0) 16.27 (21.4) 
    α, β, γ (°) 
90.0, 90.0, 
90.0  
90.0, 101.98, 
90.0  Rfree 
23.57 (27.7) 20.72 (27.7) 
Resolution (Å) 42.32 - 1.95 
(2.00 - 1.95) 
46.43 - 1.85 
(1.90 - 1.85) 
Number of 
Atoms 
  
Monomers / au 4 4     Protein 6748 6892 
Wave length 
(Å) 
0.91939 0.91939     
Ligand/Ions 
0 158 
CC 1/2 99.9 (73.5) 99.8 (77.6)     Water 342 943 
I / σ(I) 13.25 (2.19) 11.50 (2.21) B-factor (Å2) 
  
Completeness 
(%) 
100 (100) 99.6 (99.7) 
    Protein 
36.0 ± 8.9 28.8 ± 8.2 
Redundancy 6.93 (6.86) 13.37 (13.45)     Ligand - 57.3 ± 19.4 
 
    Water 41.4 ± 8.8 43.2 ± 11.4 
RMSD   
    Bond 
length (Å) 
0.0163 0.0199 
    Bond 
angle (°) 
1.31 1.93 
Ramachan-
dran (%) 
96.89 / 3.11 / 
0.0 
97.26 / 2.52 / 
0.22 
Clashscore 16.61 16.73 
Rotamer 
outlier (%) 
3.12 2.11 
Molprobity 
score 
2.28 2.11 
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Both the apo form of human APT1 M60S mutant and the complex with 2BP crystallized well in 
conditions containing different polyethylene glycols (PEG). The overall structure of the protein is 
similar to the wild type of human APT1, having an average rmsd of 0.52 Å and 0.55 Å for the apo 
form and the 2BP complex of human APT1 M60S, respectively. The formation of the typical 
dimer[69] is observed in both crystal structures. In the apo form of human APT1 M60S, the second 
monomers of the two dimers of the asymmetric unit are rotated by 2.3˚ and 3.2˚, respectively 
compared to the apo form of human APT1 wild type. The 2BP complex of human APT1 M60S 
forms a similar dimer, on average rotated by 5.4˚ (4.9˚ and 5.8˚) compared to the apo form of 
human APT1 wild type. Comparing the apo form and the 2BP complex of human APT1 M60S to 
each other, both structures contain two dimers per asymmetric unit, but these dimers are not 
arranged similarly as the space group and unit cell differs between both crystals. Between the apo 
form and the 2BP complex of human APT1 M60S, the second monomer of the dimers are rotated 
by 3.9˚, and no significant overall change of the protein structure is caused by binding of 2BP, as 
both structures have an average rmsd of 0.47 Å over 221 amino acids.  
 
Figure 106: Comparison of the human APT1 wild type (blue) dimer with the dimers formed by the human APT1 
M60S mutant as apo form and 2BP complex (yellow).  
As the wild type dimer is still formed, the groove is still not completely accessible as it is blocked by 
the side chain of M60S, although to a lesser extent due to the shorter side chain (Figure 107). In 
the structure of human APT1 M60S in complex with 2BP, 2BP binding can be observed in the 
hydrophobic tunnel identical to the wild type structure (see 5.1.5). At the partially blocked groove, a 
short linear density can be observed. This density could correspond to a molecule of 2BP that was 
co-crystallized, or a molecule of PEG of the crystallization condition. This density lacks a forked 
head group, and no peak corresponding to the bromide atom was found in the anomalous map, 
thus a short PEG molecule that originates from the crystallization condition is most likely and was 
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fitted into the density. Interestingly, the structure of human APT1 M60S in the apo form did not 
contain a density in the groove, indicating that a (partially disordered) 2BP molecule is still a 
possibility. On the other hand, the observed difference could be due to the different size of PEG in 
the condition, as the apo form and complex crystallized in PEG 3000 and PEG 10,000, 
respectively.  
 
Figure 107: Human APT1 M60S (gold) in complex with 2BP(green, bound inside the tunnel) still forms the wild 
type dimer (dimer partner shown in grey) and contains a (partially) blocked groove (highlighted in yellow) next to 
the active site (cyan). The electron density (2Fo-Fc, blue, scaled to 1σ) of a short linear ligand is observed at the 
groove, and was fitted to a PEG molecule (green), but it could also correspond to a partially disordered 2BP 
molecule since no density was observed in the apo form.  
Taken together, the M60S mutation in human APT1 does not change the dimer formed, and thus 
still partially blocks the groove with the – albeit shortened – serine side chain. A short, linear 
electron density was observed at the groove, lacking a forked head group and peak at the 
anomalous map, and was thus fitted to a molecule of PEG. As a further attempt to disrupt the 
dimer, a deletion of M60 was structurally investigated as described in the next chapter.  
5.3.3  Crystal structure of human APT1 ΔM60 apo form and in complex with 2BP 
The 2BP complex of human APT1 ΔM60 was prepared similarly to the wild type 2BP complex and 
the procedure is described there (see 5.1.5). Briefly, 1.3 mM protein was mixed with 5 mM 2BP and 
heated to 50 ˚C for 5 to 10 min, mixing the solution by gently tapping the tube with the finger. 
Screening for crystallization conditions for human APT1 ΔM60 as apo form and in complex with 
2BP resulted in crystals under conditions containing short-chained PEGs shown in Figure 108. 
Crystals of the apo form also grow in the condition of the 2BP complex (and vice versa). Diffraction 
data was collected from crystals grown in the conditions shown in Figure 108 at X10SA at SLS, 
Villigen, and the apo form and complex diffracted to a resolution of 1.34 Å and 1.56 Å, respectively. 
Both crystals belonged to the space group P1 with a similar unit cell. The structures were solved via 
Molecular Replacement using human APT1 wild type as template. The structure of human APT1 
ΔM60 apo form was refined to an Rfree and Rwork of 18.22% and 15.56%, respectively, and the 2BP 
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complex was refined to an Rfree and Rwork of 19.98% and 16.72%, respectively. The crystallographic 
statistics are shown in Table 22.  
 
Figure 108: Crystallization condition of human APT1 ΔM60 containing 0.1 M Tris at pH 8.5, and 30% PEG 400 
(PEG B9, apo, left) or 30% PEG 300 (PEG B8, 2BP complex, right), respectively. The complex was prepared as 
described in Chapter 5.1.5. No additional cryo protectant was added as the conditions are cryogenic. Photograph 
taken using Formulatrix Rock Imager.  
Table 22: Crystallographic statistics of human APT1 ΔM60 in absence and presence of 2BP. Values for the 
highest shell are given in parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
ΔM60 apo 
human APT1 
ΔM60 +2 BP  
human APT1 
ΔM60 apo 
human APT1 
ΔM60 +2 BP 
Data collection   Refinement   
Space group P1 P1 Resolution (Å) 
35.63 - 1.34 35.71 - 1.56 
Cell 
dimensions 
  Number of 
Reflexes 
157075 97589 
    a, b, c (Å) 
39.66, 39.67, 
69.70 
39.71, 39.76, 
69.87 Rwork 
16.99 (18.6) 17.12 (16.8) 
    α, β, γ (°) 
86.95, 88.91, 
63.95  
89.07, 87.10, 
63.92 Rfree 
19.68 (23.1) 20.46 (21.5) 
Resolution (Å) 50 - 1.34 50 - 1.43 Number of Atoms 
  
Monomers / au 2 2     Protein 3293 3413 
Wave length 
(Å) 
0.91939 0.91939     
Ligand/Ions 
0 67 
CC 1/2 99.7 (93.0) 99.7 (97.7)     Water 577 293 
I / σ(I) 12.18 (4.03) 15.88 (6.5) B-factor (Å2) 
  
Completeness 
(%) 
91.7 (86.5) 78.8 (36.0) 
    Protein 
13.6 ± 4.8 14.1 ± 5.0 
Redundancy 2.48 (1.84) 1.79 (1.68)     Ligand -  29.4 ± 10.4 
 
    Water 30.5 ± 10.7 23.6 ± 6.7 
RMSD   
    Bond 
length (Å) 
0.0216 0.0204 
    Bond 
angle (°) 
1.88 1.70 
Ramachan-
dran (%) 
98.21 / 1.79 / 
0.0 
97.14 / 2.86 / 
0.0 
Clashscore 12.36 11.85 
Rotamer 
outlier (%) 
0.86 2.15 
Molprobity 
score 
1.60 2.00 
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Both the apo form and the complex of human APT1 ΔM60 contain two monomers per asymmetric 
unit, and in contrast to human APT1 M60S, the dimer arrangement differs from the human APT1 
wild type dimer[69] by a rotation of 136˚ of the second monomer. Since the crystallization conditions 
do not differ significantly in pH, salt or precipitant from other conditions that contain the wild type 
dimer, the rotation of the second monomer is likely to be caused by the ΔM60 mutation, In the wild 
type, the M60 side chain is located at the groove of the neighbor molecule in the “standard” dimer. 
The comparison to the human APT1 wild type dimer and the new interface is shown in Figure 109.  
 
Figure 109: Comparison of the human APT1 wild type (blue) dimer with the largest non-crystallographic interface 
in the crystal of human APT1 ΔM60 mutant (yellow). Monomer B of the ΔM60 mutant is rotated by 136˚ compared 
to the wild type dimer.  
The rotation of the second monomer of human APT1 ΔM60 moves the (in the wild type) M60 
containing “foot-rest” loop away from the shallow groove, which is now occupied the side chain of 
M202. In the new dimer, M202 does not block the groove to the same extent as M60 of the wild 
type as it binds closer to the active site, still, it reduces the space available at the groove and the 
passage to the active site and binding tunnel is not free, as shown in Figure 110. The dimer is 
symmetric, so both binding sites are buried equally. Both in the apo form and the 2BP complex, a 
linear density can be observed close to the indole side chain of W32, comparable to the M60S 
mutant (compare Figure 107). A bifurcated density or an anomalous signal of bromide could not be 
detected at the binding groove. As this electron density is present in both the apo form and the 2BP 
complex, it probably corresponds to a molecule of PEG from the crystallization condition.  
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Figure 110: Human APT1 ΔM60 (gold) crystallized in complex with 2BP. Due to the new dimer orientation, M202 
of the dimer partner (grey) is located at the groove (yellow), narrowing the connection between the groove and 
active site (cyan). 2BP (green) binds inside the binding tunnel, but the electron density at the groove (2Fo-Fc 
scaled to 1σ shown) is present in both the apo form and the 2BP complex, and thus was fitted with a short PEG 
molecule. 
Darius Bothe also tried soaking and co-crystallization with various alkylated peptides that he 
synthetized during his thesis, but no peptide complex structure of any human APT1, neither wild 
type nor ΔM60S mutant, could be obtained [100].  
A human APT1 ΔM60 structure co-crystallized with a peptide and solved from a crystal grown in a 
PEG-free condition containing 0.1 M imidazole at pH 6.5 and 1.0 M sodium acetate as precipitant 
(Qiagen screen Core3 E10) showed the presence of water molecules in the groove, but no electron 
density of a peptide (data not shown). This supports the conclusion that in the structures obtained 
from PEG-containing crystallization conditions presented here, PEG and not 2BP is binding at the 
groove, most likely not due to a higher affinity but rather due to the higher concentration. 
Since M202, which is blocking the groove of the human APT1 ΔM60 mutant, is located next to 
H203 of the catalytic triad, a M202 deletion mutant seemed to be likely to alter the proteins 
structure and function too much, therefore, the less drastic M202A mutation was chosen. The 
human APT1 ΔM60 + M202A double mutation was cloned, purified and screened for crystallization 
conditions as described in Chapter 5.3.4.  
5.3.4 Crystal structure of human APT1 ΔM60+M202A 
The double mutant was subjected to screening for conditions suitable for crystallization as apo form 
and in complex with a hexadecylated N-terminal APT1 peptide (see Figure 113). Two well 
diffracting crystals of human APT1 ΔM60+M202A grew in Core2 G8 containing 0.16 M (NH4)2SO4, 
0.08 M NaAc pH 4.6, 20% PEG 4000, and 20% glycerol (Crystal form 1) and Core3 D1 containing 
1 M K Na tartrate, 0.2 M NaCl, and 0.1 M imidazole at pH 8.0 (Crystal form 2). Crystal form 1 was 
isolated in a thin liquid film of reservoir without an additional cryo protectant. Crystal form 2 was 
cryo-protected using perfluorated polyether of 2900 Da average molecular weight as cryo oil. 
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Diffraction data of both crystals was collected on a Nonius microstar rotating copper anode and 
detected on a mar345 dtb image plate detector in-house at MPI Dortmund. Data processing was 
carried out as described in Material and Methods; the structures were solved via Molecular 
Replacement using human APT1 wild type as template, and roughly refined to a resolution of 2.2 Å. 
The preliminary crystallographic statistics are shown in the following Table 23.  
Table 23: Crystallographic statistics of both human APT1 ΔM60+M202A. Values for the highest shell are given in 
parentheses. Values for Ramachandran plot are given for favoured, allowed and outlier.  
 
human APT1 
ΔM60+M202A 
(Crystal 1) 
human APT1 
ΔM60+M202A 
(Crystal 2)  
human APT1 
ΔM60+M202A 
(Crystal 1) 
human APT1 
ΔM60+M202A 
(Crystal 2) 
Data collection   Refinement   
Space group P1 C2 Resolution (Å) 
36.44 - 2.22 
(2.28 - 2.22) 
35.86 – 2.22 
(2.35 - 2.22) 
Cell 
dimensions 
  Number of 
Reflexes 
33429 (5033) 9627 (1403) 
    a, b, c (Å) 41.64, 68.18, 
76.23 
68.00, 41.46, 
71.96 Rwork 
22.91 (26.1) 33.87 (40.8) 
    α, β, γ (°) 
112.15 104.31  
89.91 
90.00, 94.68, 
90.00 Rfree 
31.05 (38.9) 37.74 (42.5) 
Resolution (Å) 
36.44 - 2.22 
(2.36 - 2.22) 
35.86 - 2.22 
(2.28 - 2.22) 
Number of 
Atoms 
  
Monomers / au 4 1     Protein 6761 1632 
Wave length 
(Å) 
1.5418 1.5418     
Ligand/Ions 
76 0 
CC ½ 99.7 (97.1) 99.0 (88.0)     Water 203 0 
I / σ(I) 11.45 (6.05) 7.25 (3.21) B-factor (Å2) 
  
Completeness 
(%) 
90.4 (84.6) 95.5 (87.7) 
    Protein 
18.9 ± 8.7 33.6 ± 13.6 
Redundancy 2.14 (2.05) 4.23 (3.78)     Ligand 43.0 ± 11.5 - 
 
    Water 25.1 ± 11.6 - 
RMSD   
    Bond 
length (Å) 
0.013 0.011 
    Bond 
angle (°) 
1.670 1.518 
Ramachan-
dran (%) 
94.98 / 4.24 / 
0.78 
92.66 / 5.05 / 
2.29 
Clashscore 21.27 16.48 
Rotamer 
outlier (%) 
8.13 5.29 
Molprobity 
score 
2.86 2.73 
 
The crystal structure of human APT1 ΔM60+M202A crystallized in P1 (crystal form 1) contains four 
monomers per asymmetric unit. The largest interface formed in this crystal is rotated and tilted by 
138˚ compared to the wild type of human APT1 (Figure 111A). A comparison of the interface of 
human APT1 ΔΜ60 (see Chapter 5.3.3) and human APT1 ΔM60+M202A shows that these 
interfaces are not identical, but the second monomer is rotated further by about 10˚ (see Figure 
111C). The overall structure of human APT1 ΔM60+M202A mutant is not altered from the wild type, 
having an rmsd of 0.56 Å over 218 amino acids.  
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In crystal form 2, which belongs to space group C2, the monomer of the asymmetric unit forms a 
dimer with a crystallographic symmetry mate, and is again rotated by 138˚ compared to the wild 
type of human APT1. Despite the different space group, the interfaces formed in both crystal forms 
of the ΔΜ60+M202A mutant are identical and differ only by 1.4˚ rotation, which is in the range 
observed for multiple dimers within the asymmetric unit of one crystal.  
 
Figure 111: Panel A: Comparison of the human APT1 wild type dimer (blue) and human APT1 ΔM60+M202A 
(yellow/grey). The second molecule of the dimer is tilted by 138˚ compared to the wild type. Panel B: Comparison 
of the dimer of both crystal structures obtained for human APT1 ΔM60+M202A. The second monomer of the 
dimer is rotated by 1.4˚ between both structures. Panel C: Comparison between human APT1 ΔM60+M202A and 
ΔM60 (second monomer shown in green), the second monomer is rotated by 10˚ between the different mutants. 
The active sites are encircled in red.  
The connection between the groove and the active site is not completely blocked due to the shorter 
side chain of the M202A mutation, but in the crystal, it forms a restricted entrance with a diameter 
of less than 5 Å. In addition, P170 of the dimer partner narrows the gap between the two molecules 
deeper buried in the interface and closer to the active site. In crystal form 1, a weak elongated 
electron density is observed at the binding tunnel, but not at the groove. The density inside the 
tunnel could fit the hexadecyl chain or palmitate, but electron density for the rest of the peptide is 
lacking. PEG has not been observed to bind inside the tunnel, and the condition of crystal form 2 is 
PEG-free. It is possible that the density could be caused by a co-purified fatty acid as it has been 
found in X. tropicalis APT1 and some human APT1 crystal forms (private communications Marco 
Bürger).  
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Figure 112: View on the tunnel entrance of human APT1 ΔM60+M202A (gold) that is restricted in size by the 
second monomer as observed in two crystal structures. The space between the groove (yellow) and the catalytic 
triad (cyan) is narrowed but not completely blocked by M202A of the dimer partner (shown in grey). 
Summarized, although some conditions of the protein - peptide mixture resulted in crystals, no 
structures contained clear evidence that the peptide was bound. 
Even the double mutant ΔM60+M202A cannot provide enough space to accommodate a 
hexadecylated peptide in the binding groove (with the aliphatic tail inside the hydrophobic binding 
tunnel). The amino acids of the second molecule of the dimer narrowing the connection between 
groove and active site are M202A and P170. Both amino acids are flanking positions of the catalytic 
triad (S114, H203 and D169), so a deletion mutation is not feasible due to the high probability of 
causing serious effects on the protein’s structure. Since the hexadecylated cysteine of the peptide 
is not at the very terminus of the peptide, even more space would be required in the crystals to 
accommodate residues. The crystallization project was stopped at this point due to the limited 
chances of success. Therefore, binding of a hexadecylated peptide was investigated via the 
fluorescence based activity assay as described below.  
5.3.5 Inhibition of human APT1 by a hexadecylated peptide 
A hexadecylated decapeptide with the N-terminal sequence of human APT1 (MpalmCGNNMSTPL, 
shown in Figure 113) was synthesized by Philipp Cromm as described in Material and Methods 
(see Chapter 7.6.4). For reasons of stability, a hexadecyl thioether was chosen instead of the 
natural palmitoyl thioester at the side chain of Cys2. In vivo, the human APT1 N-terminus can be 
palmitoylated and is probably hydrolysable by the protein, thus it cannot be used for crystallization. 
The first 10 N-terminal amino acids of human APT1 were chosen since it was proposed that human 
APT1 can de-palmitoylate itself and human APT2[98,99]. Darius Bothe worked in parallel on the co-
crystallization with different Ras-peptides in his master thesis[100].  
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Figure 113: Structure of the hexadecylated N-terminal human APT1 peptide, which covers the first 10 amino 
acids. The C-terminus is amidated to increase solubility in aqueous buffer. For stability reasons, Cys2 was 
modified as a hexadecyl thioether instead of the natural palmitoyl thioester. Figure created using ChemBioDraw 
13.  
The peptide was tested on its inhibitory potency on human APT1 ΔM60 using OPTS (commercially 
available from Sigma Aldrich) as a substrate. The activity assays was performed as described in 
Material and Method (Chapter 7.5.2). The ΔM60 mutation of human APT1 was chosen for this 
assay due to the expected reduced stability of the protein dimer (see Chapter 5.3.3) and thus 
increased accessibility of the groove. The ΔM60+M202A mutant was not available at the time the 
assay was performed. The result of the measurement is shown in Figure 114. Biochemical activity 
of human APT1 is inhibited by the hexadecylated peptide in a concentration-dependent 
mechanism. The IC50 of the peptide to human APT1 ΔM60 can be estimated from the three 
replicates of the measurements to be in the range between 20 to 80 nM. These results are 
preliminary and the assay should be optimized and repeated to validate and further refine the IC50 
value. The very strong inhibitory effect of the hexadecylated peptide indicates a binding mode 
blocking the active site. The aliphatic tail is expected to bind inside the tunnel, and if the high affinity 
proves to be true, the peptide moiety confers additional  
 
Figure 114: Inhibition of human APT1 ΔM60 catalyzed OPTS hydrolysis by the hexadecylated peptide. The three 
independent measurements give differing high-affinity IC50 values in the range between 20 to 80 nM and confirm 
the inhibitory effect of the hexadecylated peptide. Data evaluated using Microsoft Excel and plotted using Origin 
Pro.  
In the future, peptide binding at the groove could be verified via intrinsic tryptophan fluorescence 
measurements using the human APT1 W140F mutant (see Chapter 5.1.7). An unmodified peptide 
could be used as control.  
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Summarized, all attempts to co-crystallize or soak a peptide into human APT1, either wild type or a 
mutant have failed to obtain a crystal structure with unambiguous electron density proving the 
complex formation so far. One reason might be that the binding sites in the crystal are obstructed 
by dimer formation. High-affinity binding of a hexadecylated peptide near the active site could be 
shown via its concentration dependent inhibition of human APT1 ΔM60.  
 
5.4 Analysis of the dimer interface of lid-loop mutants and point mutations 
In crystals of human APT1 wild type, the active site is buried in the interface of a dimer (see Figure 
11) formed in all structures solved to date including the published structure of human APT1 wild 
type ([58], PDB ID: 1fj2). The relative position of the second molecule of the dimer mostly differs by a 
few degrees in various crystals obtained under different, mostly PEG containing conditions, but the 
analysis of structures containing multiple dimers in the asymmetric unit shows that these usually 
also vary by a few degree (see human APT1 L58A, Chapter 5.2.3). In contrast, the wild type 
structure of human APT1 published in 2000 (PDB ID 1fj2, [58]) shows a rotation of 112˚ compared to 
the “standard” dimer found in this work as well as in earlier work [69]; the N-terminal cloning artifact 
of the construct of the published structure was proposed to cause this rotation.  
To further investigate the properties of this dimer interface, the binding energy of the interfaces of 
human APT1 wild type and mutants were calculated using PISA[97] of the CCP4i program 
package[101]. The ΔG value given by PISA for each interaction surface is a prediction of the free 
energy generated upon complex formation via this interface. The ΔG value depends on the size of 
the hydrophobic interaction surface, but the stabilizing effect of hydrogen bonds and salt bridges 
(though both are reported) are not considered in the prediction. The free solvation energy ΔG can 
be used as rough estimate of the binding strength. Based on this calculation, PISA offers a 
prediction if the quaternary complex could potentially be stable in solution.  
All lid-loop mutations described in Chapter 5.2 were investigated with respect to the interfaces 
formed in the crystal (Table 24). The rotations compared to the typical dimer of human APT1 wild 
type are listed in the last column. The interfaces of the wild type structures of human APT1 and 
APT2 solved by Marco Bürger[69] are used as reference.  
In human APT1, mutations L58A, L171A, and L171V have no strong effect on the conformation and 
flexibility of the lid-loop or the overall structure of the protein, and do not significantly change the 
dimer formed in crystals. In contrast, the human APT1 L73A mutant crystallizes as a monomer in 
the asymmetric unit. The side chain of L73 is crucial for stabilization of the lid-loop in the wild type 
conformation, and apparently the lid-loop is essential for the formation of the canonical dimer as its 
disturbance destroys the dimer (see Figure 66). The human APT1 L73A - 2BP complex shows that 
the hydrophobic tunnel can be reformed upon ligand binding and contains a larger crystal contact, 
but this interface is rotated by 113˚ compared to the typical dimer of the wild type apo form of 
human APT1, and is similar orientation as PDB ID 1fj2 [58]. The same effect on the crystal interfaces 
has been observed for the LP insertion mutant that crystallizes as monomer in the same space 
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group with similar interfaces as human APT1 L73A apo form (see Figure 78), although the 
conformation of the lid-loop differs between both mutants. Interestingly, human APT1 ΔL73S74 that 
contains the shortened lid-loop still forms the “standard” dimer comparable to the wild type (see 
Chapter 5.2.8), while the ΔS74P75 mutation that has a similarly shortened lid-loop crystallizes via 
different crystal interfaces (see Chapter 5.2.10).  
 The results show that the human APT1 wild type dimer and similar dimer formed by various 
mutants are comparably stable, as derived from the calculated ΔG of about -16 kcal/mol. The 
mutants forming other crystal contacts close to the hydrophobic patch show that these crystal 
contacts are smaller and thus less strong than the wild type dimer. This is also illustrated in Figure 
115.  
Table 24: Calculated free solvation energy of the dimer interface of the human APT1 wild type forming the 
canonical dimer and lid-loop mutants as well as mutations designed to alter dimer formation. The proteins 
written in italics do not form a single large interface similar to the wild type, but two smaller interfaces. If the 
asymmetric unit contains more than one dimer, the range of the interface size and free solvation energy is given. 
Values calculated using PISA[97] of the CCP4I suite[101].  
dimer interface Area [Å2] ΔG [kcal/mol] H-bonds Salt bridges  Rotation [˚] 
hAPT1 wt (crystal form 
P1, standard dimer, [69]) 
810 -16.2 2 0 - 
hAPT1L171V 777 -15.4 2 0 1 
hAPT1 L171A 809 -15.3 2 0 6.3 – 7.1 
hAPT1 L58A 810 - 844 -16.7 / -18.1 2 0 5.6 – 7.9 
hAPT1 ΔL73S74 790 - 856 -16.2 / -17.6 4 / 6 0 9 – 11 
hAPT1 M60S 737 -13.2 5 / 3 0 / 0 2.7 – 5.3 
rotated dimer interface      
1fj2 1170 -27.6 4 0 136 
hAPT1 L73A + 2BP 996 - 1056 -23.4 / -25.3 2 / 4 0 138 (as 1fj2) 
hAPT1 ΔM60 601 -10.1 2 0 136 
hAPT1 ΔM60+M202A 754 -12.0 5 0 138 
human APT2 wt 1045 -27.2 2 0 167 
Monomers 
Crystallographic 
interfaces area [Å2] 
    
hAPT1 L73A 478 - 540 -4.4 / -8.0 3 / 4 1 / 2 - 
hAPT1 +LP 417 - 578 -4.3 / -9.4 3 / 4 0 / 1 - 
hAPT1 ΔS74P75 410 - 470 -4.8 / -8.3 1 / 3 0 / 2  
  
As described in Chapter 5.3, the groove of human APT1 wild type is blocked by the second 
monomer of the dimer. To enable crystallographic investigations of the groove as potential binding 
site for peptides, mutants of human APT1 were designed to interrupt the dimers and increase the 
space to enable peptide binding. The truncation of M60 side chain to serine did not change the 
dimer, but reduces the buried interface area and thus the calculated free solvation energy of this 
interface (see Table 24). The deletion of M60 further weakens the interaction and causes the 
protein to crystallize with a different dimer interface that is rotated by 136˚, as shown in Chapter 
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5.3.3. In this new dimer, the groove now hosts the side chain of M202 instead of M60. Shortening 
the side chain of M202 to alanine in addition to ΔM60 causes the new dimer to slightly rotate further 
by 10˚ compared to the human APT1 ΔM60 mutant, but the groove is still partially blocked. The free 
solvation energy is increased due to the larger interface (which in addition also contains more salt 
bridges, see Table 24). The dimer with the smallest buried interface is formed by human APT1 
M60S with a ΔG of 13.2 kcal/mol, indicating that the side chain of M60 has a strong contribution to 
the formation of the wild type dimer (ΔG of -16.2). Deletion of M60 also shortens the loop next to 
the lid-loop, and reduces the buried area of the dimer interface. The additional truncation of the 
M202 side chain to alanine in the ΔM60+M202A mutant increases the size of the buried interface 
slightly and stabilizes the rotated dimer.  
The structure of human APT2 was solved by Marco Bürger in his thesis[69]. The crystallographic 
dimer interface of human APT2 is larger, and a higher ΔG of -27.2 kcal/mol has been predicted by 
PISA. PISA predicts the dimer of human APT2 to be stable in solution. However, AUC experiments 
determined human APT2 as monomeric in solution[69], revealing the limitation of the quaternary 
complex prediction by PISA.  
A superimposition of the dimers comparable to the wild type of human APT1 (blue) is presented in 
Figure 115A, and contains human APT1 L58A, L171A, L171V, ΔL73S74, and M60S mutants. The 
alternative dimer-like contacts are shown in Figure 115B, superimposed with the wild type are 
human APT1 ΔM60, L73A+2BP and human APT2. Their individual rotation compared to the wild 
type is given in Table 24.  
 
Figure 115: Superimposition of the typical human APT1 wild type dimer and mutants. Panel A shows the human 
APT1 wild type dimer (blue, from [69]), superimposed with L58A(light green), L171A(green), L171V(purple), 
ΔL73S74(salmon), and M60S(gold) mutants. Panel B shows the wild type dimer in blue, superposed with ΔM60 
(gold), and L73A+2BP (neon green) mutants and human APT2 (maroon). Human APT1 L73A + 2BP forms the 
same dimer as the published structure of human APT1 (PDB ID 1fj2, not shown).  
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5.4.1 Analysis of the interface formed between the lid-loop and the core of APT in 
human APT1 wild type and lid-loop mutants  
PISA[97] was used to analyze the influence of the mutations on the binding strength of the lid-loop of 
human APT1. The calculations were performed using modified structure files, as described in detail 
in Material and Methods Chapter 7.7. Briefly, the lid-loop was given a different Chain ID to be 
treated as a different molecule not covalently attached to the core protein (by deleting D69 and D80 
of the hinge regions). For comparison and to account for conformational changes of the lid-loop 
caused by the leucine to alanine mutations, the respective mutations were also done in silico by 
side chain truncation without further energy optimization on the apo structure of human APT1 wild 
type structure and used as theoretical value.  
The data shown in Table 25 contains two parts of the lid-loop analysis. The first part investigates 
the importance of the three leucines L58, L73 and L171 on the interaction strength between the lid-
loop and protein. The second part describes the more drastic mutations affecting the length of the 
lid-loop. In general, the interaction between the lid-loop and the core protein is reduced if one of the 
three leucines 58, 73 or 171 is mutated. The mutation of L58 and L171 to alanine only slightly 
decreases interaction area. The free solvation energy calculated from the actual crystal structure is 
always lower than the theoretical value, calculated from in silico mutations of human APT1 wild 
type. This is most likely caused by slight movements of the loops caused by the mutations.  
In the second group, the lid-loop shows larger conformational changes. The side chain of L73 is 
located in the middle of the three leucines and stabilizes the lid-loop in the wild type conformation. 
Shortening the side chain of L73 results in the lid-loop folding into the hydrophobic tunnel as shown 
in Chapter 5.2.4, thus stabilizes the interaction with the protein due to the increased contact 
surface, which is confirmed by the significantly decreased ΔG value. Interestingly, in the structure 
of human APT1 L73A in complex with 2BP, the lid-loop is in a conformation comparable to the wild 
type (Figure 72), enabling a comparison of the lid-loops binding energy with other structures.  
The ΔG of the L73A mutant (in complex with 2BP, to keep the lid-loop in the tunnel-forming 
conformation, see Chapter 5.2.5) has the weakest interaction (-3.8 kcal/mol vs. 6.9 kcal/mol of the 
wild type), although the confirmation of the lid-loops of human APT1 wild type and L73A mutant in 
complex with 2BP are in a comparable conformation (see Figure 73). This significant difference is 
not seen in the theoretical value obtained from the in silico L73A mutant.  
The extended lid-loop of the +LP mutation occupies the hydrophobic tunnel with the side chain of 
the inserted L73 and L75 (wild type L73), thus increasing the interaction surface with the protein 
core. This stabilization of the lid-loop is also reflected in the decreased ΔG, which is the lowest of 
all mutants (-9.4 kcal/mol).  
Shortening the lid-loop reduces the interaction surface and thereby also the binding strength. No 
significant difference in the ΔG is observed between both ΔL73S74 and ΔS74P75 lid-loop mutants, 
both are similarly increased compared to the wild type.  
While the lid-loops of human APT1 wild type and all mutants except the shortened ΔL73S74 and 
ΔS74P75 are predicted to form stable complexes with the core protein in solution, the interaction of 
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the L73A mutant and the shortened lid-loops are weaker and a theoretical complex formation is not 
predicted. This suggests an increased flexibility as the result of the smaller interaction surface and 
less optimal substrate binding and catalysis, as shown in Chapter 5.2.13.  
Table 25: Free energy of the lid-loop of human APT1 wild type and lid-loop mutants. The lid-loop was treated as 
separate molecule by changing the Chain ID and removing D69 and D80 of the hinge regions. The binding energy 
between the lid-loop and protein was calculated using PISA[97] available in the CCP4I program suite[101]. The 
influence of the three leucines L58, L73 and L171 on the binding energy of the lid-loop was additionally 
calculated from in silico mutants of the human APT1 wild type structure as theoretical values.  
Group 1: wild 
type tunnel 
Interface 
Area [Å2] 
Stable 
complex 
predicted? 
ΔG 
[kcal/mol] 
Theoretical ΔG 
[kcal/mol] 
Number of 
H-bonds 
Number of 
Salt bridges  
hAPT1 wt 448 yes -6.9 -6.9 3 1 
hAPT1 L58A 452 yes -4.5 -5.9 7 0 
hAPT1 L171A 517 yes -5.8 -6.6 5 1 
hAPT1 L171A +  
in silico L58A  484 yes -4.8 -5.5 5 1 
hAPT1 L58A +  
in silico L171A  
444 yes -4.3 -5.5 7 0 
hAPT1 L73A 
+2BP (2BP 
bound inside wild 
type-like tunnel)  
452 yes -3.8 -5.9 5 0 
Group 2: lid-loop 
significantly 
changed  
      
hAPT1 L73A apo 
(lid-loop folded 
into the tunnel) 
501 yes -6.1 / 5 2 
hAPT1 +LP  545 yes -9.4 / 5 0 
hAPT1 ΔL73S74 378 uncertain -4.5 / 4 0 
hAPT1 ΔS74P75 315 uncertain -4.4 / 4 0 
 
5.4.2 Comparing the lid-loop of human APT and lipases  
Lipases contain large lids that cover the complete hydrophobic patch around the active site and 
exclude it from the solvent in their inactive state. Contact to (bio-) membranes triggers the opening 
of the lid and its attachment or insertion into the membrane to enable catalytic activity. It is tempting 
to assume that the lid-loop if APTs might have a similar role as the lid in lipases as regulatory 
element by e.g. inserting into the membrane or even opening up upon membrane association. 
Indeed the opm database (orientation of protein in membranes, [102]) predicts a partial insertion of 
APT into membranes. Therefore, in the following the properties of the lids of lipases and APT are 
compared. The ΔGtransfer values upon membrane insertion predicted from crystal structures 
available in the PDB database is taken from the opm database, and compared to the predicted 
dissociation energy of the lid-loop of APT and lipases using PISA as described in Chapter 7.7 of 
Material and Methods. In addition to APT, Table 26 shows the values of Bacillus and C. rugosa 
lipase in open and closed form, of cutinase, and of the (to human APT1) most similar esterase of P. 
aeruginosa. The Bacillus lipase is the structurally most similar mono-acylglycerol lipase to human 
APT1 (PDB structure similarity search), having an rmsd of 2.14 Å over 162 amino acids and 15.4% 
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sequence identity. The lipase of C. rugosa was chosen because of the availability of both open and 
closed state, and the reasonable similarity, having an rmsd of 2.5 Å over 172 amino acids and 11% 
sequence identity. The cutinase of A. oryzae was chosen due to the high similarity to APT and high 
resolution of the structure. The carboxyl esterase of P. aeruginosa is the protein with the most 
similar structure (rmsd of 1.31 over 206 amino acids and 34% sequence identity) found in the 
literature to human APT1, besides human APT2 and APTs of other organisms.  
Table 26: Comparison of the free solvation energy ΔG of human APT1 dimer, the estimated free solvation energy 
of the lid-loop and the lid-loops of related lipases shown together with their theoretical membrane insertion 
energies as calculated for the opm database[102].  
 
Buried dimer 
area [Å2] 
Dimer ΔG 
[kcal/mol] 
Buried lid-
loop area 
[Å2] 
Lid-loop ΔG 
[kcal/mol] 
ΔG [kcal/mol] 
opm database 
Depth [Å] 
opm database  
hAPT1 [69]  810 -16.2 448 -6.9 -4.7 9.6 ± 2.0 Å 
Bacillus sp.  
monoglycerid 
lipase (PDB ID 
4lhe, [56]) 
952 -12.5 952 -12.5 n.d. n.d. 
C. rugosa open 
(PDB ID 1lpp, 
[103]) 
monomer monomer lid opened lid opened -28.0 10.0 ± 0.4  
C. rugosa 
closed  
(PDB ID 1trh, 
[104]) 
monomer monomer 1132 -21.3 -7.4 4.0 ± 1.3  
A. oryzae 
cutinase (PDB 
ID 3gbs, [105]) 
monomer monomer no lid no lid -12.6  11.2 ± 0.5  
P. aeruginosa 
esterase (PDB 
ID 3cn9, [57]) 
monomer monomer no lid no lid -4.1  3.5 ± 2.1 
 
The lid of the Candida rugosa lipase 1 (PDB ID 1trh, [104]) releases a ΔG of -21.3 kcal/mol upon 
binding to the core protein. The opm database[102] predicts a ΔGtransfer of -28.0 kcal/mol for the open 
form of C. rugosa lipase 1 (PDB ID 1lpp, [103]) upon binding to a biomembrane, while the closed 
form of the lipase (PDB ID 1trh, [104]) gains a ΔGtransfer of -7.4 kcal/mol. The opened lid and three 
other loops are predicted to be partially inserted up to 10 Å into the outer membrane, allowing the 
active site being placed directly at the membrane, while the penetration depth of the closed lid 
structure is significantly reduced and the active site residues moved away and shielded from the 
membrane. This emphasizes the energetic preference of the lid of lipases to open up upon 
membrane insertion and enables substrates to access the active site.  
A comparison revealed that the interface between the large lid and the core protein of lipases, e.g. 
Bacillus sp. monoglycerol lipase (PDB ID 4lhe, [56]) is roughly comparable in size and free solvation 
energy to the dimer of human APT1 (ΔG of -12.5 kcal/mol and -16.2 kcal/mol, respectively). The 
Aspergillus oryzae cutinase 1 (PDB ID 3gbs, [105]) is used as example for an α,β-hydrolase active on 
long chained fatty acid esters, but lacking a lid that shields the active side from the solvent in the 
inactive state. Similar to APTs, this cutinase is predicted to be inserted into the membrane by 
11.2 Å with the active site serine located at the membrane surface resulting in a ΔGtransfer 
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of -12.6 kcal/mol. Other cutinases (PDB ID 1oxm, 3dcn, 4oyy and 5ajh) are also predicted to be 
partially inserted into membranes in a comparable depth with a comparable ΔGtransfer. Inspections of 
wild type structures of cutinase published in the PDB database revealed that they contain one 
monomer per asymmetric unit. A detailed investigation [Jelsch1998] revealed that under certain 
conditions cutinases can form a head-to-head dimer with crystallographic neighbors, e.g. triggered 
by mutations or ligand binding[106]. However, the apo form of the wild type crystallizes as monomer, 
thus indicates a monomeric state and membrane association instead of a soluble dimer with a 
shielded active site (as a contrast to human APT1, which weak dimer has a KD of 2.8 µM[69]).  
Carboxyl esterase of P. aeruginosa (PDB ID 3cn9, [57]) (see Chapter 3.4) also lacks a lid and 
contains an open, solvent-accessible active site. The predicted ΔGtransfer of -4.1 kcal/mol upon 
membrane “insertion” of 3.5 Å could indicate a weak membrane attachment rather than a real 
insertion, but as esterases are inactive on long-chained fatty acid esters it is unlikely that this 
predicted interaction has a biological relevance at all.  
 
The role of the lid-loop of human APT differs from the lid of lipases. In human APT, the lid-loop pre-
forms a stable hydrophobic tunnel that coordinates the substrate close to the active site serine (see 
Chapter 5.2). The opm database predicts a ΔGtransfer of -4.7 kcal/mol upon 9.6 Å deep membrane 
insertion of human APT1. However, the prediction does not account for the potential flexibility of the 
lid-loop, which hypothetically could open up when inserted in a membrane (triggered by an 
unknown mechanism) comparable to lipases, and also resulting in a stronger interaction with the 
membrane, (see ΔGtransfer of C. rugosa lipase in open and closed form, Table 26). The ΔGtransfer 
upon membrane insertion of one protein can differ significantly depending on the state of the lid as 
seen from the C. rugosa lipase 1 (ΔGtransfer = -28.0 and -7.4 kcal/mol of open and closed lid, 
respectively). This potentially is also the case for APTs, as lid-loop opening was observed in one 
crystal structure of Oryza punctata APT[69], and could be a hypothetical secondary function of the lid 
in substrate extraction from membranes. This is pure speculation as no structure of human APT1 
with an opened lid-loop is available in the literature and it is not possible to calculate the ΔGtransfer of 
own structures (e.g. O. punctata APT containing the opened lid-loop[69]). Furthermore, human APT 
has been reported to be palmitoylated at the N-terminus[98,99], which would increase the membrane 
affinity significantly. 
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6 Discussion 
6.1 S. cerevisiae APT serves a model for structural investigation of inhibitor 
complexes 
In this thesis, the putative Ras-regulator acyl protein thioesterases (APT) were investigated 
structurally and biochemically and co-crystallized with various inhibitors. APTs feature a pre-formed 
solvent-accessible hydrophobic binding tunnel that is a rare (and possibly unique) structural motif 
only found in APTs of different organisms. The tunnel is located next to the active site and was 
shown to be essential for the catalysis of long-chained fatty acid substrates, as the APT homolog of 
A. thaliana, SOBER1, which has a blocked tunnel is limited in its activity to shorter substrates[69]. 
Thus, it is assumed that the aliphatic moiety is bound inside the tunnel during catalytic hydrolysis. 
However, to my knowledge only one complex structure was known, the structure of X. tropicalis 
APT1 in complex with a co-purified palmitic acid / stearic acid mixture showing that the aliphatic 
product of the de-palmitoylation reaction indeed binds inside the hydrophobic tunnel[69].  
Attempts to co-crystallize or soak covalent and non-covalent ligands or inhibitors into human APT1 
or APT2 were not successful prior to this thesis as the active site is usually occluded in a dimer 
interface (see Figure 11). APTs of other organisms were structurally investigated before[69], and 
APT of Saccharomyces cerevisiae was found to crystallize in four different space groups, all with 
an accessible active site. The high sequence identity of 36% between yeast APT and human APT1 
and the conservation around the active site (see Figure 23) justifies the use of yeast APT as a 
model for structural investigation of inhibitor binding.  
Inhibitors of the palmostatin class were designed on basis of orlistat (see Figure 13) to covalently 
address human APT1 and APT2 without isoform specificity using a β-lactone core as nucleophilic 
trap for the active site serine and an aliphatic tail as substrate mimic. The complex of yeast APT 
with palmostatin B solved in this thesis provided evidence that the aliphatic tail of the covalent 
inhibitor is indeed located inside the hydrophobic tunnel (see Figure 30). As designed, the ester is 
formed upon opening the β-lactone core by the nucleophilic serine and can be regarded as a mimic 
of the covalent reaction intermediate, the palmitoylated serine (see Figure 7). Palmostatin B 
contains a bulky aromatic head group that structurally differs from the suspected natural substrates, 
a palmitoylated peptide or lysophosphocholine. Indeed, the aromatic head of palmostatin B has 
limited contribution to the binding affinity due to its rigidity and limitation in forming H-bonds (see 
Figure 30, Chapter 3.4.3). The high-resolution structure of the covalent yeast APT – palmostatin B 
complex provides an explanation why the enzyme regenerating hydrolysis reaction is drastically 
slower (half life of minutes, private communications with Christian Hedberg) than the turnover of a 
substrate (in the range of ~20 µsec, or 3.41 x 104 s-1, see Table 7). As seen from the reaction 
mechanism schematically presented in Figure 7, the covalent reaction intermediate of APT is 
regenerated by a nucleophilic attack on the palmitoyl ester by a water molecule that is activated by 
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the histidine side chain of the catalytic triad. The position of this water molecule is occupied by the 
hydroxyl group of the β-lactone (see Figure 32), and thus probably slows down the off-rate of 
inhibitors of the palmostatin class that have the same chirality as palmostatin B. The β-lactone core 
and aliphatic tail is identical between palmostatin B and palmostatin M, which is reflected in a 
similar binding mode of this part of both inhibitors (compare Figure 33 and Figure 36) and a similar 
slow off-rate (communication with Stefan Baumeister). The head group of palmostatin was 
designed to mimic the charge and H-bond network expected to be formed by lysophosphocholine 
or a peptide backbone and is connected via a longer and more flexible linker than the head group 
of palmostatin B (see Figure 13). The interaction of the palmostatin M head group is influenced by 
crystal contacts in two of four monomers (see Figure 37), but confirms an interaction with the 
backbone amide of L23 of S. cerevisiae APT (see Figure 36) in the “free” monomer. The amino 
acids involved in the interaction with palmostatin M in the “free” monomer are conserved from yeast 
to human APT1 (Figure 23). Thus, the interaction with L23 of yeast APT is also possible in human 
APT1. The tunnel entrance is not conserved between human APT1 and yeast APT (see Figure 20), 
therefore the orientation of the tertiary amide head next to the aromatic W77, probably caused 
when the space in front of L23 is blocked by crystal contacts, has to be different in human APT.  
Judging from the yeast crystal structure, inhibitors containing an extended head group that targets 
the conserved residues of the groove close to the active site might result in more potent inhibitors. 
The monomers of the palmostatin M complex are rearranged compared to the apo structure of 
yeast APT and orientated in such way that the active site is completely accessible through a large 
solvent channel (Figure 35).  
The complex structures of yeast APT with palmostatin B and palmostatin M provide detailed insight 
on the inhibitor’s binding mode on atomic level. Optimized inhibitors derived from the structures 
presented in this thesis should include a specific and strong-binding head group in a pre-formed 
active conformation that could be iteratively optimized via structure based rational design. The 
reduction of rotational freedom of the very flexible head group of palmostatin M either by 
introducing a macro-cycle could further increase the affinity below the current low nanomolar 
range[77]. However, the general problem of the inhibitor’s inactivation after binding and release due 
to the hydrolysis of the opened β-lactone needs to be circumvented by introducing a reversibly 
binding and hydrolytically stable trap for the nucleophilic serine to extend the half-life of the inhibitor 
and thus its effect inside the body.  
6.1.1 Cerulenin binding to human APT1 provides insight into epoxides as 
nucleophilic trap 
Cerulenin is a commercially available natural product functioning as specific inhibitor of fatty acid 
synthases (see Chapter 3.4.4) and potent bacterial antibiotic, that has been investigated for its 
potential in treatment of cancer[107] and obesity[108]. The epoxide function of Cerulenin could act as a 
nucleophilic trap, similar to the β-lactone of palmostatin inhibitors, and its binding to human APT1 
was verified via ESI-MS (see Figure 41). Since APT is not the biological target of Cerulenin, the 
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inhibitor is not adapted to the active site of APT.The crystal structure confirmed a covalent adduct 
at the active site, but also two unspecific adducts at surface exposed cysteine side chains (see 
Figure 45). Despite the reasonable resolution of 2.5 Å, the electron density of the Cerulenin 
adducts is not sufficiently clear to unambiguously define the binding mode of Cerulenin. Most likely 
a mixture of adducts at C2 and C3 carbon (see Figure 44) formed at the active site serine are 
observed in the crystal. Thus, the structure of the most probable complex was build according to 
slightly diffuse electron density and chemical knowledge, both supporting an opening of the epoxide 
by forming the ether bond to the active site serine at C3, leaving the hydroxyl group on C2 
(compare Figure 45). This structure is different from a recently published covalent complex of 
Cerulenin with FabF published by Trajtenberg[85].  This FabF-Cerulenin complex is well described 
by the strong electron density and the high resolution (2.1 Å), and describes the covalent complex 
to form a hemiketal (PDB ID 4ls8, [85]). A hemiketal is expected to be unstable and its formation 
requires some intermediate rearrangements. Hemiketals are the result of an alcohol reacting with a 
ketone, not with an epoxide. The publication by Trajtenberg[85] lacks, as stated therein, a satisfying 
explanation for the formation of the O,S-hemiketal observed in the covalent FabF – Cerulenin 
complex, but it is suggested by the authors that Cerulenin might undergo some further 
rearrangements after initial binding, catalyzed by the FabF. The unambiguous electron density of 
the complex (PDB ID 4ls8) does not tolerate a different binding mode, but it is unlikely that APT can 
catalyze a similar rearrangement of unspecifically bound Cerulenin.  
Despite the unspecific attack of the catalytic serine of APT on the epoxide of Cerulenin, the 
complex structure shows the potential of an epoxide as trap for the active site serine. In addition, 
Cerulenin is also bound by surface exposed cysteines. The reactivity of the epoxide of Cerulenin is 
increased by the flanking electron-drawing carboxyl and amide, and could potentially be modulated 
to create a more specific and less reactive inhibitor of APT by removing one of the carboxyl groups. 
On the other hand, high reactivity and a stable covalent adduct have a high potential to be 
cytotoxic, and thus limits a clinical application.  
6.1.2 2-Bromopalmitate serves as a product mimic to investigate the binding to APT 
Crystallographic investigations of the binding mode of the natural product palmitate to human APT1 
were not available prior to this thesis. Surprisingly, a fatty acid was observed in a crystal structure 
only once in form of a co-purified in X. tropicalis APT1[69] where it was co-purified from E. coli. Mass 
spectrometry revealed that it was a 50:50 mixture of palmitic / stearic acid. Neither co-crystallization 
nor soaking approaches could obtain a complex of human APT with a fatty acid bound inside the 
pre-formed tunnel. At least one of the reasons probably is that long-chain fatty acids exhibit a low 
solubility in aqueous solutions. 2BP is a product mimic with high similarity to palmitate and 
increased aqueous solubility compared to unmodified fatty acids, despite the fact that its structure 
only differs by the additional bromine in α-position to the carboxylic acid. Indeed, mixing of 2BP with 
human APT1 wild type and mutants resulted in non-covalent complexes with near-complete 
occupancy of the ligand. 2BP is bound to APT1 with the aliphatic chain inside the tunnel while the 
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polar head is located at the active site at the entrance of the tunnel. The carboxylic acid forms H-
bonds with the oxyanion hole (see Figure 50). The positioning of the inhibitor inside APT leads to a 
model where the entrance acts as a funnel for substrates and inhibitors and sterically restricts the 
fatty acid moiety to slide deeper into the tunnel. This hypothesis was investigated in detail in 
Chapter 5.2 and is discussed in Chapter 6.2 below.  
A further advantage of 2BP in crystallographic studies is the anomalous signal of the α-bromide. 
This anomalous signal enabled us to discover two distinct binding modes of 2BP in the human 
APT1 wild type protein (see Figure 49) with either the carboxylic acid or alternatively the α-bromide 
coordinated by the oxyanion hole (which obviously cannot be observed for palmitate as it lacks a 
substituent at the α-position to the carboxylic acid). This structure confirms binding of the carboxylic 
head group inside the oxyanion hole, which usually stabilizes the tetrahedral intermediate of the 
opened ester during hydrolysis (see Figure 7). Heating the protein - 2BP mixture up to 50 ˚C before 
crystallization resulted in crystals of better quality and higher 2BP occupancy. The higher 
temperature increases the solubility of 2BP and the exchange dynamics of 2BP micelles potentially 
formed in aqueous suspensions. This interesting finding also raised the question if opening of the 
lid-loop can be thermodynamically triggered to facilitate binding of ligands inside the tunnel, 
inspiring the mutations targeting the flexibility of the lid-loop.  
 
6.2 Analysis of the lid-loop 
A lid-loop that pre-forms a solvent-accessible hydrophobic binding tunnel is a very rare (if not even 
unique) structural motif found only in acyl protein thioesterases. The exact function of the lid-loop 
and the substrate-binding tunnel has not been thoroughly investigated to date. So far, the lid-loop 
pre-formed the wall of the hydrophobic tunnel in all structures of APTs. Interestingly, in the crystal 
structure of an APT from O. punctata two of four monomers of the symmetric unit are found in a 
conformation with an opened lid-loop. This could be due to unusual crystal packing and/or the 
harsh crystallization condition at pH of 10.5 [69], or it might indicate a potential flexibility of the lid-
loop that might even have a physiological relevance, e.g. an opening of the lid-loop upon 
membrane binding. It is unknown if the lid-loop is interfacially activated and facilitates substrate 
extraction from a hydrophobic environment like a cellular membrane in case of APTs natural 
substrates, or from a vesicle or micelle in a biochemical assay. In the first structural 
characterization of an APT (PDB ID 1fj2, [58]), the lid-loop is suggested to play a role in the 
dimerization of the protein. However, the dimer formed in crystals is changed when the cloning 
artifact is shortened[69], so the lid-loop is not the only factor that determines the dimer.,An 
accessible binding tunnel has been proven to be essential for catalysis by long-chained fatty acid 
substrates[69], the closing or shortening of the tunnel shifted the protein’s specificity towards short-
chained substrates, but its potential function in substrate coordination has not been investigated so 
far. Another role of the lid-loop could be the ejection of palmitate from the tunnel at the active site to 
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prevent product inhibition. This is in accordance with the fact that only one fatty acid complex 
structure of an APT (X. tropicalis in complex with co-purified palmitic acid / stearic acid) is known[69]. 
These potential functional properties of the lid-loop were investigated by introducing mutations into 
the lid-loop designed to affect its flexibility and length, thereby changing the shape of the binding 
tunnel formed by the lid-loop. The mutations on the lid-loop can be grouped according their type as 
described in Chapter 5.2: The first group contains single point mutations of one of the three 
leucines 58, 73 and 171 to test for their role in stabilizing the lid-loop of human APT1 in its wild type 
conformation. The second group contains mutants with extended or shortened lid-loop that cause a 
decrease of biochemical activity, by either blocking the tunnel with side chains or relocating the 
tunnel entrance. A complete truncation of the lid-loop in the third group leads to a drastically 
decreased biochemical activity of the protein and failed to crystallize so far. The three groups are 
described in more detail in the following.  
6.2.1 The side chain of L73 is essential for a pre-formed tunnel  
Human APT1 L58A or L171A mutants have no significant effect on the conformation of the lid-loop 
and the tunnel formed by the lid-loop (see Figure 63 and Figure 60, respectively). Biochemical 
activity is not significantly affected by shortening the L171 side chain, as the kcat is 2.70 ± 0.20 s-1 
x104 for the L171A mutant compared to 3.41 ± 0.22 s-1 x104 of the wild type in the PPTS assay (see 
Figure 57). However, the mutation of L73 located at the tip of the lid-loop enabled a previously not 
observed conformation of the lid-loop: in the crystal, the lid-loop of the L73A mutant has the Cβ of 
L73A pointing towards the solvent and P75 relocated into the tunnel (see Figure 67). This 
conformation change is enabled by the decreased stabilitzation of the lid-loop caused by the 
shortened L73 side chain, showing its crucial role in the formation of the wild type tunnel shape. 
The electron density for the lid-loop in the L73A crystal is well defined, and although the lid-loop is 
involved in two H-bonds with the crystal neighbor, it is unlikely that this conformation is a 
crystallization artifact. Human APT1 L73A forms different crystal contacts than the typical wild type 
dimer (see Figure 66), and an analysis of the crystal interfaces using PISA[97] predicts no complex 
formation via this interface in solution. The crystallization conditions are comparable to other 
conditions which resulted in well-diffracting crystals of human APT, containing short to mid-sized 
PEGs, low salt concentration and a pH between 6.0-8.5, so the changed crystal packing is not the 
result of a harsh crystallization condition, as potentially in the case of O. punctata APT[69]. This 
corroborates that the different shape of the lid-loop is caused by the lack of the L73 side chain. 
Apparently, the aliphatic side chain of L73 keeps the tip of the lid-loop in its position and rigid 
enough to prevent folding into the tunnel. L73 interacts with both L58 and L171, but a deletion of 
one of the latter is not sufficient to destabilize the lid-loop enough to bind inside the tunnel (see 
Figure 60 and Figure 63). A double mutation of L58A+L171A which might be in a similar 
conformation of the lid-loop of L73A would argue in favor of this hypothesis (not tested). The side 
chain of L73 also forms a part of the tunnel entrance (see Figure 56A). The shortened side chain of 
the L73A mutation results in a gap between L58 and L171 (see Figure 74). This gap widens the 
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entrance of the tunnel and enables the substrate to slide deeper into the tunnel, moving the 
thioester away from the active site into a most likely unproductive binding mode. Thus, the position 
of the ligand’s head group differs between both complexes (Figure 73). The complex of human 
APT1 L73A with 2BP also has a weaker electron density than the 2BP complex of human APT1 
wild type and lacks a strong anomalous signal, indicating a less defined binding of the ligand 
compared to the wild type complex. The importance of the defined conformation of the lid-loop is 
reflected by the lower biochemical activity. The activity of the L73A mutant is decreased to about 
30% in case of the L73A mutant to a kcat of 0.95 ± 0.06 s-1 x104 compared to a kcat of 3.41 ± 0.22 s-1 
x104 for the wild type in the PPTS assay (see Table 10). The biochemical data shows a reduced KM 
of 0.94± 0.28 µM compared to 3.37 ± 0.77 µM of the wild type. KM is defined as KM = (koff + kcat) / 
kon. Thus, the 4-fold reduced KM is most likely the result of the significantly reduced activity (Vmax 
25% of the wild type) in combination with an only slightly increased dissociation rate (not quantified, 
see Figure 102).  
6.2.2 The extended lid-loop blocks the binding tunnel 
The extended lid-loop containing a +LP insertion between G72 and L73 was designed in analogy to 
the APT1 homolog of A. thaliana, SOBER1, that is impaired in catalysis of long-chained substrates 
due to its obstructed tunnel[69]. The crystal structure of the human APT1 +LP mutant showed that 
this insertion leads to a steric blocking of the tunnel by the side chains of L73 and L75 (Figure 79), 
comparable to A. thaliana SOBER1[69]. The opening and formation of the hydrophobic tunnel by 
rearranging the whole lid to enable binding of a long-chained fatty acid substrate poses an 
energetic barrier. However, while A. thaliana APT1 is fully inactive on substrates containing an 
ester longer than propionate [69], the extension of the lid-loop in human APT did not abolish activity 
on the long-chained substrate PPTS, but reduced it to ~25% of the wild type (see Figure 76). This 
residual activity indicates that the extended lid-loop is most likely still able to form a tunnel upon 
binding of a long, aliphatic substrate. A structure of the 2BP complex of the extended lid-loop 
mutant could not be solved so far, thus the binding mode of 2BP (or the test substrate PPTS) to the 
+LP insertion mutant remains unclear. Like the other mutants that have a reduced biochemical 
activity (L73A, ΔL73S74 and ΔS74P75), the extended lid-loop mutant of human APT1 shows a 
lower apparent KM (see Table 13).  
 The reduced biochemical activity seen in reduced Vmax (and kcat, see Table 13) is most likely 
caused by the lower efficiency in productive binding of substrate molecules and stabilization of the 
transition state compared to the wild type. The 2-fold reduced apparent KM (compared to the wild 
type) could result from the lower activity (Vmax, see Figure 76), while the binding and dissociation 
rates are not significantly altered (not tested).  
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6.2.3 Shortened lid-loops still pre-form a short hydrophobic tunnel but fail to 
efficiently coordinate the substrate 
The crystal structures of human APT1 ΔL73S74 and ΔS74P75 mutations were solved in the course 
of this thesis (see Chapter 5.2.8 and 5.2.10). In contrast, no suitable crystallizing condition could be 
identified for human APT1 ΔP75D76. Possible reasons for this are discussed further below in this 
chapter. Both available structures show that the shortened lid-loop pre-forms a tunnel in the 
absence of a ligand. The tunnel has a wider entrance and exit, as the shortened lid leaves a large 
gap between L58 and L171. This gap reduces the efficiency to coordinate the substrate next to the 
active site, shown by the structure of human APT1 ΔS74P75 in complex with 2BP, where 2BP is 
bound in multiple orientations (Chapter 5.2.8). The complex structure contains two monomers per 
asymmetric unit revealing three binding modes for 2BP (see Figure 89, Figure 91 and Figure 93). In 
monomer A, 2BP is bound in two partially occupied orientations that are occupied with a ratio of 60 
to 40. The favored orientation is identical to the major conformation observed in human APT1 wild 
type with the carboxylic acid group of 2BP located in the oxyanion hole (see Figure 90). The 
second binding mode observed with the lower occupancy binds deeper inside the binding tunnel, 
with the head group located at the new entrance formed by the shortened lid-loop in front of W140 
(Figure 91), the bromide of 2BP inside the hydrophobic tunnel, and the carboxylic acid of 2BP 
facing the solvent. Both binding modes show a strong electron density and anomalous signals for 
bromide at both positions. Monomer B contains electron density for one binding mode of 2BP, 
where the head group of 2BP is located at the enlarged tunnel exit instead of at the entrance close 
to the active site (see Figure 93). In this inverse binding mode, the carboxylate of 2BP is 
coordinated by the guanidine group of the R144 side chain located at the tunnel exit. The peak of 
the anomalous map for bromine is weaker in monomer B, which indicates that this binding mode is 
less occupied and might be in equilibrium with further less defined binding modes, most likely 
including a conformation of 2BP similar to the wild type complex. The fact that the shortened lid-
loop enables multiple binding modes of 2BP that have the carboxylate dislocated from the active 
site strongly supports the hypothesis that the wild type tunnel shape formed by the lid-loop is 
essential for efficient substrate coordination.  
The structure of human APT1 ΔL73S74 in complex with 2BP also shows that the new tunnel 
entrance allows 2BP to slide deeper into the tunnel. The human APT1 ΔS74P75 mutant is similar 
shape of the tunnel entrance despite the different deleted residues of the lid-loop (see Figure 97 
and Figure 99). Thus, it is likely that the binding mode of ligands is similar in both mutants. A 
binding mode comparable to the one observed for 2BP is also plausible for the substrate PPTS. It 
is possible to place a hypothetical pyrene ring system on top of the deeper bound 2BP to simulate 
the ‘PPTS’ ester bound in an unproductive binding mode with the ester dislocated from the active 
site and thus unavailable for enzyme-catalyzed hydrolysis (Figure 100). In this hypothetical 
orientation, the aromatic pyrene ring system fits nicely into the gap between the aliphatic side 
chains of L58 and L171, and by interesting coincidence, one oxygen atom of a sulfonate group 
precisely fits inside the oxyanion hole next to the active site. This binding mode might be stabilized 
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by interactions between the aromatic pyrene ring and the hydrophobic side chains of L58 and L171. 
A second unproductive binding mode with the aliphatic chain sticking reversely in the binding tunnel 
with the pyrene rings of the substrate located at the exit of the tunnel is also thinkable, but less 
clear where the pyrene rings would be coordinated.  
Both ΔL73S74 and ΔS74P75 mutants show a reduced Vmax (and kcat) in the activity assay (see 
Table 15) that can be explained by the reduced efficiency to coordinate a ligand or substrate 
molecule, as shown by the complex structure (see Figure 91). The ΔL73S74 and ΔS74P75 mutants 
show a 3- and 5-fold reduced apparent KM, respectively (see Table 15). KM is correlated to the 
affinity (KD) under certain conditions (koff >>kcat), but these are not fulfilled (see Chapter 5.1.8). The 
reduced KM could result from the strong reduction of activity (Vmax or kcat), while the dissociation 
(koff) rate is less affected by the mutation (not quantified, compare Figure 102), since the PPTS 
substrate is stabilized in the gap between L58 and L171 (see Figure 100).  
Extensive shortening or complete truncation of the lid-loop of human APT1, as tested with the ΔI71-
S74, ΔL73-D76, and ΔI71-D76 lid-loop truncation mutants, results a reduced solubility, and these 
mutants could not be concentrated as high as the wild type or the shorter lid-loop mutants of human 
APT1. This indicates some tendency to aggregate during concentration of the protein, potentially 
due to formation of an even larger solvent-exposed hydrophobic patch due to the removed lid-loop 
that needs to be covered by intermolecular contacts. Moreover, no crystal structure could be 
obtained for any of the proteins, which argues for an unstable protein and/or unspecific 
aggregation. Without a lid-loop, the formation of a proper hydrophobic tunnel is impossible, 
probably leading to unspecific and unproductive binding of the substrate on the remaining surface 
the forms the inner wall of the wild type binding tunnel. This hypothesized unspecific interaction 
with the substrate is reflected in a strong decrease of vmax. The human APT1 Δ71-76 truncation 
mutant shows a residual activity of only 3% compared to the wild type using PPTS as test substrate 
(see Table 19). Protein aggregation via the hydrophobic surface could block the active site and 
further reduce the activity.  
6.2.4 The wild type lid-loop stabilizes ligand binding  
Stopped Flow measurements using the intrinsic tryptophan fluorescence of human APT1 reveal a 
slower binding rate (kon) of 2BP by human APT1 Δ71-76 mutant than for the wild type (see Figure 
101). The 2BP binding rate of the lid-loop lacking mutant is faster by orders of magnitudes than 
binding detected at the groove using the human APT1 W140F mutant (compare Figure 54 and 
Figure 101), thus the signal corresponds to the new and open hydrophobic patch. This is counter-
intuitive, as the open hydrophobic patch of the lid-loop lacking ΔI71-D76 mutant is expected to be 
more accessible than the narrow tunnel, and thus show a faster binding rate. However, the new 
hydrophobic patch most likely enables unspecific binding distant to W140, thus causing no 
decrease of the fluorescence signal. Over time, the unspecifically bound ligand rearranges itself 
closer to the side chain of W140, and thus the ensemble causes a slow binding signal. The 
reduction of the binding rate could be also caused by aggregation of the Δ71-76 mutant via the new 
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hydrophobic patch, thus being dependent on the dissociation of these aggregates. This could be 
investigated by analytical ultracentrifugation.  
The tested lid-loop mutants also exhibit a faster dissociation of 2BP from the complex than the wild 
type of human APT1 (see Figure 102). All proteins, including the lid-loop lacking human APT1 
ΔI71-D76 mutant contain a first, similar fast dissociation rate. This rate most likely corresponds to 
the dissociation of 2BP from the groove, which is weakly (and potentially unspecifically) bound (KD 
of ~100 µM, communications with Stefan Baumeister). The signal of the ΔI71-D76 mutant can be 
fitted using a single rate, thus, 2BP bound at the new hydrophobic patch has a comparable 
dissociation rate as 2BP bound at the groove. The wild type of human APT1 and the mutants 
containing a lid-loop show a second fast binding rate, which is faster for the L73A and ΔL73S74 
mutant than for the wild type of human APT1. It is most likely that this dissociation rate corresponds 
to 2BP bound inside the tunnel, since it is missing in the ΔI71-D76 mutant that lacks the lid-loop. 
The less stable lid-loop of the mutants enables the faster dissociation rate compared to the wild 
type (see Figure 102 and Chapter 5.2.15).  
The faster lid-loop dependent dissociation rate (koff) of the mutants corroborates the expected 
reduced affinity (KD) towards 2BP. Since the binding rate (kon) was not measured, KD cannot be 
determined and it is not clear if the affinity is truly lower, but the weaker electron density of 2BP 
observed in the complexes with human APT1 L73A and ΔL73S74 (see Chapters 5.2.5 and 5.2.9, 
respectively) indicates a less stable binding of 2BP.  
6.2.5 Calculation of the binding strength of the lid-loop to the core protein 
PISA[97] as used to test if the observed effect on the stability of the lid-loop in the mutants is also 
corroborated by the theoretical calculation (see Table 25). First, the single point mutants used to 
investigate the effect of the leucine side chains of residue 58, 73 and 171 were analyzed. The 
calculated binding strength of the lid-loop of human APT1 wild type and the L58A and L171A 
mutants is comparable and not significantly reduced by the mutation (see Table 25). However, the 
binding strength of the lid-loop to the core protein of human APT1 L73A in complex with 2BP (to 
prevent folding of the lid-loop into the tunnel, see Chapter 5.2.4 and 5.2.5, 2BP is not considered in 
the calculation) is significantly reduced to  -3.8 kcal/mol (compared to -6.9 kcal/mol of the wild 
type). This indicates that the L73A mutation causes further minor structural changes that eventually 
lead to the significant destabilization of the lid-loop. This was also tested using theoretical in silico 
mutants based on the apo structure of human APT1 wild type. The lid-loop binding strength of the 
in silico L58A, L73A and L171A mutants is within the same range as the wild type and does not 
corroborate the increased flexibility in case of the L73A mutant observed the crystal structure, most 
likely due to the lack of minor conformational change that are present in the real crystal structures.  
The extended lid-loop of human APT1 +LP is present in such a conformation that two leucine side 
chains (one is part of the Pro-Leu insertion) are bound inside the tunnel, and thereby increases the 
interaction surface (545Å2 vs. 448Å2 for the wild type) and strength significantly (-9.4 kcal/mol 
vs. -6.9 kcal/mol for the wild type). The shortened lid-loops have a smaller interaction surface with 
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the core protein and thus a reduced binding strength. but surprisingly, the free dissociation energy 
is lower than of the human APT1 L73A + 2BP complex predicting a stronger binding to the core 
protein.  
Except the shortened ΔL73S74 and ΔS74P75 lid-loop mutants, all lid-loop – core protein 
“complexes” are predicted to be stable in solution (see Table 25). The predictions of the stability in 
solution for the shortened lid-loops are within an area of uncertainty of the prediction. However, 
these predictions have to be treated with caution, as e.g. the dimer of human APT2 is predicted to 
be stable, but AUC experiments could not detect any dimerization[69].  
6.2.6 Peptide binding to human APT1  
APT-catalyzed de-palmitoylation of palmitoylated proteins has been proven by biochemical 
assays[109] and in vivo studies[98,99], but structural data of a complex of APT with a modified peptide 
is missing to date. The shallow groove (see Figure 10) next to the active site could potentially be a 
binding site for either a second lipid modification (found e.g. in N-Ras[33]) or the protein chain next to 
the palmitoylated cysteine(s). A PEG molecule from the crystallization condition was found to bind 
at this groove in a related esterase structure (PDB ID 3cn9, [57]), and weak binding of 2BP at this 
groove was observed by Stefan Baumeister (private communications). Indications for a second 
binding site for 2BP could be verified in Stopped Flow measurements (see Figure 53). However, 
more detailed structural information could not be gathered, as the 2BP complex of human APT1 
wild type contains no anomalous signal at the groove (see Chapter 5.1.5).  
All trials to obtain a complex by soaking or co-crystallization of a peptide modified with an acyl 
chain failed so far since in all available crystal forms of human APT1, the passage between the 
putative binding site and the active site is blocked by the side chain of M60 of the second molecule 
of the crystallographic dimer (see Figure 104). In an effort to circumvent this obstacle, M60 was 
shortened to serine or deleted from human APT1. The dimer interface changes indeed, but, 
unfortunately, its position is then replaced in the new interface by M202 (see Figure 110), the 
neighbor position of H203 of the catalytic triad so that the available space is still too small for a 
larger ligand. A human APT1 ΔM60+M202A double mutant contains a slightly larger cavity (see 
Figure 112) between the groove and active site, but yet co-crystallization with hexadecylated 
peptides (see Chapter 5.3 and [100]) still failed to reveal the binding mode of the peptide to date, 
indicating that the cavity is still too small. 
Activity of human APT1 ΔM60 on OPTS could be inhibited using a hexadecylated peptide (see 
Figure 114), corresponding to the N-terminal sequence of human APT1 with the cysteine stably 
modified via a hexadecyl thioether that is resistant to hydrolysis by APT (see Figure 113). The 
ΔM60 mutant of human APT1 was used due to the expected reduced dimer KD compared to the 
wild type (2.8 µM). The inhibition of APT activity confirmed the binding of the hexadecylated peptide 
in a mode that blocks the active site, but cannot answer the question if the peptide is bound at the 
groove as well. Initial IC50 values of 20 to 80 nM estimated from the activity assay indicate a high 
affinity, but these results need to be verified.  
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In the future, groove binding by peptides could be verified via Stopped Flow using the tryptophan 
mutants (see Figure 53). Such an experiment should show fast binding of a hexadecylated peptide 
at the groove (using human APT1 W140F mutant) driven by the fast binding of the aliphatic tail 
inside the tunnel. An unmodified peptide of the same sequence could be used as a control and is 
expected to show slow binding (similar to 2BP binding at the groove, see Figure 53) and to dissect 
the contribution of the hexadecyl chain on peptide binding.  
 
6.3 Comparison of lipases, esterases and APT 
APT, along with lipases, esterases, the human depalmitoylases PPT1 and PPT2, and cutinases 
belong to the class of α,β-hydrolases, a family that has developed different mechanisms during 
evolution to cover the hydrophobic patch at the active site. (see Chapter 3.4) Lipases contain a 
large lid that folds back onto the patch, shielding the whole hydrophobic surface and the active site 
from the solvent. Lid opening of lipases is often (not always) interfacially activated upon membrane 
binding, and thus enables access to the active site when the parts of the lipase are inserted into the 
membrane (compare PDB IDs 1lpp and 1trh,[102,104]). Cutinases and esterases have a solvent-
accessible active site and completely lack a lid to cover the hydrophobic patch[110] since their 
substrates are often hydrophilic. PPT1 and PPT2 are responsible for lysosomal protein de-
palmitoylation[72,111], but lack the structural motif of a pre-formed binding tunnel. Cutinases are 
secreted enzymes produced in phytotoxic bacteria that degrade the protective cuticle (consisting of 
polyester of fatty acids) of plants[106,110,112]. Human APT1 could be structurally considered in 
between these classes of lipases that contain a lid and cutinases/PPT1/PPT2 without a lid, that are 
all able to hydrolyze long-chain substrates. It possesses a shorter lid-loop that creates a pre-formed 
solvent-accessible hydrophobic tunnel next to the active site. Human APT1 and APT2 have been 
shown to be palmitoylated themself[98,99], indicating their (temporal) membrane association. 
Therefore, a mechanism of association of APT to the membrane and lid-loop opening (comparable 
to lipases), potentially to facilitate substrate extraction from the membrane, could be hypothesized. 
Comparison of the size of the interface of the lid of lipases and the lid-loop of APT to the core 
protein, and the dimerization interface of APT shows that both the lipase lids and the dimer of APT 
are in a comparable range of free solvation energy around ΔG of about -20kcal/mol (see Table 26). 
Stability predictions calculated by PISA have to be treated with caution, as e.g. the crystallographic 
dimer interface of human APT2 is larger than human APT1, but in contradiction to this, AUC 
experiments indicate no dimer formation of human APT2, whereas human APT1 forms a 
moderately stable dimer with a KD of 2.8 µM[69]. The calculated ΔGtransfer of the membrane insertion 
of proteins deposited at the opm database[102] lists a value of -4.7 kcal/mol for human APT1 (PDB 
ID 1fj2, [58], see Table 26). The ΔGtransfer gained from the membrane insertion of human APT1 is 
lower than its homo dimerization (-16.2 kcal/mol) or even the binding strength of the lid-loop of 
human APT1 (-6.9 kcal/mol). The closed form of C. rugosa lipase (PDB ID 1trh, [104]) has a ΔGtransfer 
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in the same range of human APT1, which however is four-fold increased if the lid-loop is present in 
its open conformation (PDB ID 1llp, [103]).  
The insertion depth of the open form of C. rugosa lipase and human APT1 wild type is comparable 
(see Table 25). It could be hypothesized that the lid-loop of APT could also open upon membrane 
insertion of the protein, potentially triggered by membrane attachment mediated by N-terminal 
palmitoylation of APT [98,99], and thus the membrane insertion is strengthened (similar to C rugosa 
lipase open and closed form, see Table 25). The opened lid-loop could be involved in extraction of 
the substrates membrane anchors, as besides the propyl isomerase FKBP12 [113] no other co-factor 
has been identified so far (see Chapter 3.3.1). The Stopped Flow measurements (see Figure 53) 
show that human APT1 wild type binds 2BP at comparable rates from a solution of free 2BP and 
2BP incorporated in multi-lamellar DOPC vesicles (resulting in a reduced 2BP concentration on the 
surface of the vesicles, see 5.1.7.1), indicating a possible surface activation of human APT.  
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7 Material and Methods 
7.1 Chemicals 
Chemicals were purchased from Amersham-Pharmacia (Freiburg), Fluka (Neu-Ulm), GE 
(Freiburg), Merck (Darmstadt), Qiagen (Hilden), Roche (Mannheim), Roth (Karlsruhe), Serva 
(Heidelberg) and Sigma-Aldrich (Deisenhofen) at the highest purity grades available. Crystallization 
screens were obtained from Qiagen (Hilden) as 15 ml tubes and aliquoted by Georg Holtermann 
using a Lissy liquid handling robot (Zinsser Analytics, Frankfurt).  
Palmostatin B and palmostatin M were a kind gift from Christian Hedberg, former group leader at 
the Department of Chemical Biology at MPI Dortmund, now Professor at Univesity of Umeå, 
Sweden. 
Cerulenin (CAS Number 17397-89-6, ≥98% purity) was purchased from Sigma-Aldrich 
(Deisenhofen).  
2-Bromopalmitic acid (CAS Number 18263-25-7, ≥97% purity) was purchased from Sigma-Aldrich 
(Deisenhofen) as a racemic mixture.  
 
7.1.1 Kits  
QIAprep Spin Miniprep Kit    Qiagen (Hilden)  
QIAquick Gel Extraction Kit    Qiagen (Hilden)  
QIAquick PCR Purification Kit   Qiagen (Hilden)  
Dye-Deoxy-Terminator mix    Perkin Elmer (Überlingen)  
7.1.2 Enzymes  
Alkaline phosphatase    Calbiochem (Merck, Darmstadt)  
BSA       Sigma (Deisenhofen)  
Dnase I      Roche (Mannheim)  
PreScission protease     GE Healthcare  
Restriction enzymes     New England Biolabs (Schwalbach)  
T4 DNA ligase     New England Biolabs (Schwalbach)  
7.1.3 Protein and nucleic acid standards  
Wide Range, SDS7 protein marker   Sigma (Deisenhofen)  
Lambda phage DNA     Invitrogen (Karlsruhe)  
7.1.4 Buffers  
6x DNA loading buffer  30% (v/v) Glycerin  
0.25% (w/v) bromphenol blue  
0.25% (w/v) xylencyanole  
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solved in TAE buffer  
TAE buffer    40 mM Tris, pH 8.0  
40 mM acetic acid  
1 mM EDTA  
SDS buffer    25 mM Tris  
192 mM Glycine  
2% (v/v) SDS  
7.1.5 Bacterial strains  
DH5α F- ϕ80dlacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 λ- hsdR12(rK-, mK+) supE44, thi-1 
gyrA, relA1  
 
BL21 (DE3) codon+ RIL E. coli B F– dcm ompT hsdS(rB– mB–) gal λ(DE3)  
7.1.6 Media and antibiotics  
Luria Bertani (LB)   10 g/L Bacto tryptone  
10 g/L NaCl  
5 g/L Yeast extract  
 
SOC medium   2% (w/v) Bacto tryptone 
    0.5% (w/v) Yeast extract 
    10 mM NaCl 
    2.5 mM KCl 
    10 mM MgCl2 
    20 mM Glucose  
 
Antibiotics were used from GERBU (Gaiberg) and added to the media after sterilization in following 
final concentrations:  
Ampicillin 100 mg/L  
Kanamycin 50 mg/L  
Chloramphenicol 25 mg/L  
7.1.7 Machines  
FPLC (Gradifrac systems)    Pharmacia (Stockholm, SE)  
pH meter      Knick (Berlin)  
Centrifuges      Beckman (München)  
Tabletop centrifuges    Eppendorf (Hamburg) 
Sonifier 450      Branson (Dietzenbach)  
Balances      Satorius (Göttingen)  
Magnetic stirrer RCT basic    Eppendorf (Hamburg)  
VortexGenie     Scientific Industries (Bohemia, NY, USA) 
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Pipettes      Eppendorf (Hamburg)  
BioPhotometer     Eppendorf (Hamburg)  
PAGE chambers     BioRad (München)  
DNA electrophoresis chambers   BioRad (München)  
Microplate photometer Infinite M200  Tecan Group (Männedorf, CH) 
Microplate shaker     Variomag (USA) 
Liquidator96     Steinbrenner (Wiesenbach) 
Mosquito crystal    TTPLabtech (Melbourn, UK) 
Rock Imager 1000    Formulatrix (Bedford, MA, USA) 
MAR345 Image Plate Detector   X-Ray Research (Norderstedt)  
MicroMax-007HF Rotating anode   Rigaku (Ettlingen)  
MicroStar Rotating Anode    Bruker (Billerica, MA, USA) 
Stopped Flow     Applied Photophysics (Leatherhead, UK) 
7.2 Cloning, Protein Expression and Purification 
I gratefully acknowledge Patricia Stege for molecular engineering and cloning of all plasmid 
constructs, heterologous expression using E.coli, and purification of all protein constructs I worked 
with in the course of this PhD thesis.  
Molecular biology protocols for cloning and mutation as well as the protocols for protein expression 
and purification are well established by Patricia Stege and were carried out by her as described 
before[62,69].  
7.2.1 Preparation of chemically competent E. coli  
Preparation of chemically competent E. coli followed a standard protocol[114]. E. coli cells without 
antibiotic resistance were cultured on an agar plate at 37 °C overnight. 10 large colonies were used 
to inoculate 250 ml SOC medium and grown at 19°C, vigorously shaking to OD600 = 0.5. The cells 
were chilled on ice for 10 min and pelleted by spinning at 4000 rpm for 10 min at 4°C. For washing, 
cells were gently resuspended in 80 ml ice-cold TB buffer and stored on ice for 10 min. After 
spinning again at 4000 rpm (10 min, 4°C), cell pellets were gently resuspended in 20 ml ice-cold TB 
buffer and 1.4 ml DMSO. The homogeneous suspension of chemically competent cell was then 
aliquoted to 100 µl, flash-frozen in a dry ice-ethanol bath, and stored at -80°C.  
7.2.2 Transformation of chemically competent E. coli  
Chemically competent cells were transformed using the heat shock protocol. After thawing on ice, 
cells were incubated on ice with plasmid DNA for 30 to 60 min, followed by a heat shock at 42 ˚C 
for 30 s. Cells were shortly chilled on ice. 800 µl of SOC medium (without antibiotics) was added to 
the cells, which were incubated for 60 min at 37 ˚C on a shaker to allow expression of the antibiotic 
resistance genes. Cells were plated on LB agar plates containing the respective antibiotic.  
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7.2.3 Isolation of plasmid DNA  
Cell lysis, isolation and purification of plasmid DNA, and DNA extraction from agaraose gels were 
carried out as described in and using the QIAquick PCR Purification Kit, the QIAprep Spin Miniprep 
Kit and the QIAquick Gel Extraction Kit.  
7.2.4 Separation of DNA using agarose gel electrophoresis  
DNA fragments are separated in agarose gels according to their electrophoretic mobility, which is 
reciprocally proportional to their number of base pairs[115]. Agarose gel electrophoresis was carried 
out in horizontal chambers according to a standard procedure using agarose concentrations of 0.8-
2% (w/v) for the separation of DNA fragments. Gels were prepared by boiling agarose in TBE 
buffer, which also serves as running buffer. DNA samples were mixed with 6x loading buffer and 
separated by a constant voltage of 90-160 V. Gels were stained with 1% ethidium bromide or 
SYBR red (1:10,000 dilution) and excited with UV-light on a standard transluminator. BstEII-
digested lambda DNA was used as DNA standard.  
7.2.5 Polymerase chain reaction  
The polymerase chain reaction (PCR) is the biotechnological method for specific amplification of 
DNA sequences. Performing a conventional PCR, a DNA template sequence, a pair of specific 
primers, which hybridizes with the flanking sites, all four deoxyribonucleotide triphosphates 
(dNTPs), and a thermostable DNA polymerase are necessary[116,117]. For subcloning into the pGEX 
expression vectors the gene fragments of interest were amplified by a standard PCR protocol as 
follows: Initial dsDNA denaturation at 98 °C for 1 min, then 35 cycles consisting of denaturation at 
98 °C for 1 min, primer annealing at 57 °C for 30 s, elongation at 72 °C. Finally a last elongation 
step at 72 °C for 10 min was carried out.  
7.2.6 DNA sequencing  
DNA sequencing was carried out according to a standard protocol. The plasmid DNA was first 
amplified by PCR as follows: A 20 µl sample containing 4 µl of terminator reaction mixture, 100-
300 ng of plasmid template DNA, and 5 pmol of sequencing primer was subjected to the following 
PCR: 96°C for 10s, 50°C for 5s, 60°C for 2 min. These steps were repeated 30 times and at the 
end the reaction was cooled down to 4°C. The PCR product was then precipitated using 2 µl of 3 M 
Sodium acetate and 50 µl of 100% ethanol. After vortexing the sample and incubating it for 15 min 
at room temperature, it was centrifuged for 10 min at 10,000 g at 4°C. The supernatant was then 
discarded; the pellet washed using 400 µl of 70% ethanol, centrifuged again for 10 min at 10,000 g 
at 4°C. The supernatant was discarded again and the pellet dried. Analysis of the DNA fragments 
was carried out in in-house facilities. 
7.2.7 Molecular cloning of genes and gene fragments  
The DNA template was used as a template for PCR amplification. The resulting PCR product was 
gateway cloned into a pGEX 4T1 expression vector (GE Healthcare), the primer was modified to 
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encode a PreScission protease cleavage site immediately upstream to the start codon, that leaves 
after protease cleavage of the purified protein a cloning artifact of the amino acids GP at the N-
terminus.  
7.2.8 Expression and purification of proteins  
E. coli BL21 Codon +RIL cells were transformed using the appropriate cloned construct. Cells were 
grown at 25 °C in 800 ml cultures in Erlenmeyer flasks to an OD600=0.8, or in a LEX reactor up to 
an OD600=2.0, and protein expression was induced overnight at 20 °C using 0.1 mM IPTG. Cells 
were harvested, lysed using a high pressure cell disruptor, cell debris was removed by 
centrifugation at 100,000 g, and the supernatant was loaded on a GSH affinity column. The column 
was washed with 20 column volumes of buffer. PreScission protease (GE Healthcare) was then 
loaded on the column and slowly circulated over the column overnight. Afterwards, all cleaved 
protein was washed from the column. The entire GSH affinity chromatography[118] was carried out 
under the following buffer conditions for acyl protein thioesterases and related proteins: 20 mM 
Tris-HCl pH 8.5, 150 mM NaCl, 5% Glycerol, 5 mM DTE. The protein was subjected to subsequent 
gel filtration, using the following buffer: 20 mM Tris-HCl pH 8.0, 30 mM NaCl, 1 mM TCEP-HCl. 
Finally, the protein was concentrated using appropriate kDa MWCO spin filters, and flash-frozen.  
7.2.9 SDS PAGE  
Protein samples were analyzed using the denaturing SDS polyacrylamide electrophoresis method 
(SDS-PAGE), either following the Laemmli[119] or the Schägger/Jagow[120] protocol. SDS is an 
anionic detergent that denatures the proteins and shields their charges, making their mobility in the 
gel (driven by the electric field) dependent on their mass only. Protein samples were mixed with 4x 
loading buffer containing 10% SDS, 500 mM Tris/HCl, pH 6.8, 59% glycerol, 10 mM β-
mercaptoethanol, 0.01% bromphenol blue, and 0.01% xylencyanol. To aid denaturation, this 
mixture was heated to 95˚C for 10 min. Gels used in this study consisted of two gels. The upper 
collection gel consists of 5% (w/v) acrylamide/bisacrylamide solution in 125 mM Tris/HCl, pH 6.8 
buffer, polymerized by adding 0.1% (w/v) APS (ammonium perooxodisulfate) and 0.04% (w/v) 
TEMED (N,N,N,N-tetramethylethylendiamine). The lower sample separation gel consists of 8-18% 
(w/v) acrylamide/bisacrylamide solution and 125 mM Tris/HCl, pH 8.8, and was polymerized again 
by adding 0.1% (w/v) APS and 0.04% (w/v) TEMED. Electrophoresis was run at constant 
amperage of 50 mA per gel.  
7.2.10 Coomassie staining of protein gels  
Following SDS-PAGE, gels were stained in hot coomassie brilliant blue solution (40% (v/v) ethanol, 
10% (v/v) acetic acid, 0.2% (w/v) coomassie brilliant blue G250) for 10 min. To reduce the 
background staining, gels were destained in boiling water.  
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7.2.11 Size exclusion chromatography  
Size exclusion chromatography allows separation of proteins according to their hydrodynamic 
radius. Proteins with a smaller hydrodynamic radius have more interaction with the porous 
stationary phase (the column material) and thus to a longer retention time[3,121]. To achieve optimal 
protein separation the correct pore size of the stationary phase is required. For analytical purposes, 
a Superdex200 or Superdex75 10/30 column was used at a flow of 0.5 ml/min, for purification, a 
Superdex200 or Superdex75 16/60 or 26/60 column was used at a flow of 1.5-3 ml/min. The 
columns were run on a Gradifrac system (Pharmacia).  
7.2.12 Determination of protein concentrations  
Protein concentrations were measured by absorption at 280 nm caused by their amino acids 
tryptophan and tyrosine. The protein concentration is hereby derived from the absorption using the 
Lambert-Beer law[122] as described before[123,124]. A Nanodrop 1000 Photometer (PeqLab) was used 
to determine the absorbance.  
7.2.13 Mass spectrometry  
The precise mass of pure proteins, a mixture of few proteins, or covalent protein-inhibitor adducts 
can be detected via Electron-Spray Ionization mass spectrometry coupled to liquid chromatography 
(LC-MS). The sample was diluted in pure water to a concentration of 80 µM, and 10 µl of the 
dilution were added to 10 µl of pure acetonitrile and 2.2 µl of 1% TFA (0.1% final concentration). 
The sample was mixed and centrifuged at 16,000 rpm for 5 min. The clear supernatant was 
transferred to a HPLC vial. The protocol for the LC-MS using a LCQ (ThermoFisher) was as 
following: 10 µl containing 400 pmol protein were injected into a standard C4 column that was run 
with an linear acetonitrile gradient from 0% to 80% within 5 min, coupled to ESI-MS. Alternatively, 
10 µl sample (400 pmol) can be directly injected into the ESI-MS system without sample separation 
via LC.  
 
7.3 Protein Crystallogenesis 
7.3.1 Summarized theory of crystallogenesis 
Crystal growth is based on pushing the concentration of a molecule, proteins in this case, beyond 
the solubility level to form a solid, crystalline precipitant[125]. The transition is required to be slow 
enough to allow the proteins to arrange in a three-dimensional order to form crystals; if the solution 
is supersaturated too fast, the proteins precipitate in an amorphous state. Controlled concentration 
of the protein solution is achieved in a sealed environment, containing a hydroscopic reservoir that 
draws water the protein containing solution, thus slowly concentrating the protein. The protein 
solution is mixed with the reservoir to slow down the concentration process and prevent the drop 
containing the protein to completely dry out. Hydroscopic molecules like polyethylene glycols 
(PEGs), volatile alcohols, and high concentration of salts are used as precipitants. Additionally, 
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buffers controlling the pH and salts regulating the ionic strength are added to the solution that can 
be further modified using organic or biological compounds, termed additives, to improve crystal 
quality. The composition of the solution resulting in crystals is not predictable, thus the empirical 
methods requires a high parallel number of trial and error experiments to screen for conditions 
suitable to grow crystals. These conditions can be further refined, if necessary, by fine-tuning the 
concentration of both protein or precipitant, the temperature or volume of the crystallization drop to 
regulate the velocity of supersaturating the protein [125].  
7.3.2 Crystallization screening 
Screening for crystallization conditions were performed at 293 K in Corning 3553 / 3550, Greiner 
Low Profile CrystalQuick or TTP IQintelli 96-well plates. A Steinbrenner Liquidator96 was used to 
transfer the mother liquor from the master block to the screening plate. The crystallization drops 
consisted of 100 nl protein and mother liquor solution each, the reservoir had a volume of 70 µl. In 
general, proteins were kept on ice until being transferred to a Greiner V-shape 96-well plate used 
for setup of crystallization plate by TTP labtech Mosquito robot. The 2BP complexes were prepared 
as following: 47.5 µl of 1.3 to 1.5 µM protein stock solution was mixed with 2.5 µl of 2BP stock 
solution (100 mM in DMSO) to a final concentration of 5 mM and heated up to 50 ˚C for 5-10 
minutes and mixed gently several times during incubation by flicking the tube with the finger.  
7.3.3  Crystallization refinement in hanging drops 
Crystallization conditions were refined in hanging drop experiments using 24-well tissue culture 
plates from Linbro or Crychem and glass cover slides. Plates that are not pre-greased were sealed 
using Baysilon silicon oil that was applied to the edge of the well using a syringe with an attached 
200 µl tip. 1 µl of protein solution was mixed with the reservoir on glass slides in a ratio of 1:1 to a 
total volume of 2 µl, and the glass cover slip was turned upside down to seal the well. Crystals of S. 
cerevisiae APT in complex with palmostatin B and palmostatin M were obtained by drying 0.5 µl of 
100 mM DMSO stock of the respective inhibitor on glass slides over night to minimize the DMSO 
concentration in the crystallization drop while maintaining high amounts of inhibitor. 1 µl of protein 
solution was added onto the dried inhibitor, and mixed with 1 µl of reservoir solution.  
7.3.4 Crystal preparation for x-ray diffraction experiments 
Crystals were isolated using pre-mounted CryoLoops (Hampton). Isolated crystals were soaked for 
a few seconds in cryogenic solutions which composition is based on the reservoir solution. Different 
cryo-protectants like glycerol, small PEGs or sugars were used. If the usage of cryo-protectants 
resulted in visible damage of the crystal, or low-quality diffraction with either low resolution or 
smeared or streaky spots, crystals were isolated without cryo-protectant directly from the 
crystallization drop and tested at room temperature for diffraction of the crystal. In case of cryogenic 
crystallization conditions, crystals were directly isolated from the crystallization drop in a thin liquid 
film without additional cryo-protectant and flash frozen in liquid nitrogen.  
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7.4 X-ray crystallography 
7.4.1 Summarized theoretical background 
According to the Law of Ernst Abbe (Eq. 1)[126], the maximum resolution is determined by the 
wavelength of the light used for the observation. The resolution is the smallest distance in which 
two details or objects are still resolved as two individuals[127].  
 𝑑 = !!  !"        (Eq. 1) 
  d: resolution  
  λ: wavelength used for the observation  
  NA: Numerical Aperture  
Visible light in the range of 400 to 800 nm, as used in optical microscopes, is suitable for direct 
observation by eye. The Numerical Aperture of modern optical microscopes using immersion oils is 
increased to ~1.5[128], and thus restricts the resolution limit to 200 nm. This is suitable to study (sub-
)cellular processes, but insufficient to describe molecules. The average distance of carbon bonds in 
organic compounds as proteins are in the range of 150 pm or 1.5 Å[129]. To observe the position of 
single atoms, x-rays of a wavelength of around 1 Å are required[127]. X-rays are not directly 
observable by the naked human eyes[130], and their interaction with the atom electron shell is rather 
weak[125,127]. Multiple simultaneous measurements are performed within a crystal to enhance the 
signal strength, which is then measured on a detector[125,127]. This leads to systematic additions of 
the signal, when the criteria of Bragg’s law (Eq. 2) is fulfilled:  
 𝑛  𝜆 =   2  𝑑  𝑠𝑖𝑛𝜃        (Eq. 2) 
  n: natural number 
  λ: wavelength 
  d: distance between lattice planes 
  θ: angle between the incident x-ray beam and lattice plane 
The resulting distinctive diffraction pattern needs to be converted to an interpretable map. The 
intensities of the reflections are indexed and integrated, reducing the diffraction data from a set of 
images to one list of intensities[127]. The Structure Factor (correlating to the measured intensity) of 
each recorded reflection can be described in polar form as shown in (Eq. 3)[125] below: 
  𝐹!!" =   𝐹!!" exp 𝑖𝛼!!"        (Eq. 3) 
  Fhkl : amplitudes of the diffracted x-ray  
  αhkl: phases of the diffracted x-ray  
The transformation to an electron density function given in a cartesian coordinate system is 
calculated via Fourier-transformation as shown in (Eq. 4)[127].  
  𝜌 𝑥𝑦𝑧 = !!    ∙    |𝐹!!"  !!" |    ∙ exp −2𝜋𝑖 ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧 + 𝑖𝛼!!"    (Eq.4)  
This Fourier transformation requires both amplitude and phase of each observed x-ray. The 
amplitude is proportional to the intensity measured by the detector, but the phase information 
cannot be measured and is lost during the experiment. This is the so-called ‘phase-problem’ of x-
ray crystallography.  
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Phasing via Molecular Replacement requires the known structure of a homologues protein. 
Amplitudes and phases can be back-calculated from the known structure, and these phases can 
serve as starting phases to solve the structure[125,127]. The template structure is likely to be 
differently oriented in a crystal of different space group and unit cell, and must be aligned to the 
new, unknown structure. This is achieved by a six-dimensional search, in which the template is 
rotated and translated in three dimensions each. The Patterson functions of the amplitudes 
calculated from the known template structure and the amplitudes of the measured crystal correlate 
once the template model is successfully position. The phases calculated from the template in this 
orientation serve to calculate the initial electron density using the observed amplitudes of the new, 
unknown structure[125,127]. The model of the template structure is adapted to the sequence and 
electron density of the new, unknown protein, which in turn can be used to re-calculate phases. 
These improved phases are used to generate an optimized electron density map, to which the 
structure is further refined. This iterative cycle is performed until no further optimization is achieved. 
The quality of the structure is assessed via the R-factor[127], calculated as shown in Eq. 5: 
  𝑅 =    !| !!"# ! !!"#!   |!  |!!"#!|         (Eq. 5) 
  Fobs: measured amplitudes of the structure 
  Fcalc: calculated amplitudes of the structure model 
The Rfree factor is used for quality control, which is calculated using a subset (typically 5%) of the 
measured reflection that is not used for structure refinement to prevent over-fitting[131]. The R-factor 
is usually in the range of 0.2 for protein structures, depending on the resolution of the diffraction 
data[127].  
7.4.2 X-ray diffraction data collection 
Crystals were tested in-house for diffraction quality using a Bruker Microstar or Rigaku Micromax 
HF-007 rotating anode (operated at 45kV / 50mA and 40kV / 30mA, respectively) as x-ray source. 
Standard setup included cryo-cooling of the crystals to 100 K using an Oxford cryostat. Diffraction 
data was collected on mardtb image plate detectors. Test images and data sets were recorded with 
1˚ rotation and 3 to 10 min exposure time per image. Diffraction data of the crystal structures 
presented in this thesis was collected at X10SA beam line at the Swiss Light Source (SLS) at the 
Paul-Scherrer-Institute in Villigen, Switzerland on a Pilatus 6M detector (Dectris) (unless stated 
otherwise). Standard data collection settings not requiring anomalous signal for phasing was 0.25˚ 
rotation at 0.1s exposure time per image with a beam attenuated to 50% intensity and using the 
30µm aperture, resulting in a flux of 4x1011 ph/s at an wavelength of 1.0 Å (12.7keV). Customized 
strategies like fine slicing (0.1˚ rotation per image) or low-intensity high-redundancy data collection 
to obtain anomalous signal for heavy atoms in ligands have been applied if required. Indexing and 
strategy determination was carried out using iMosflm[132] and the automated processing pipeline[133] 
provided at the X10SA beam line utilizing mosflm[132], parts of XDS[134], cad (available through 
CCP4I[101]), Pointless[135], phenix.xtriage[136] and gnuplot[94].  
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7.4.3 Data reduction, phasing and structure building 
Diffraction data was indexed, integrated, and scaled using XDS and XSCALE, following to the 
conversion to mtz file format using XDSCONV, all part of the XDS program package[134]. The 
structures were solved via maximum likelihood Molecular Replacement using PhaserMR[137] from 
the Collaborative Computational Project No.4 program suite with interface (CCP4i)[135]. Structure 
refinement was carried out in iterative cycles of restrained refinement using refmac5[138] and coot[139] 
until no further convergence (reduction of the Rfree factor[131]) was observed.  
7.4.4 Structure validation 
Model validation was carried out using plugins implemented in coot[139] in parallel to the refinement, 
e.g. to check for Ramachandran outlier[140]. For further validation the program Molprobity[141] was 
used. The B-factors of the refined structure were extracted from the pdb-file using a script. 
Crystallographic statistics are summarized in the respective tables for each structure. Dimer 
analysis was carried out using the Secondary Structure Match (SSM) function implemented in 
coot[139]. Superimposing of the second monomer of two dimers, the kappa angle of the performed 
rotation (given in polar coordinates) describes the rotation of the dimer arrangement.  
7.4.5 Generation of ligand model restraints 
Models and corresponding chemical restraints of small molecule ligands, e.g. buffer components, 
are readily available at the HIC-UP data base[142] (http://xray.bmc.uu.se/hicup/). Models and 
restraints of novel ligands were created using ChemBioDraw[143] and eLBOW [144] of the Phenix 
suite (https://www.phenix-online.org/) [145].  
7.4.6 Illustration of crystal structures and annotating images 
All images of crystal structures were created using CCP4mg [93] and annotated using Gimp [4], if not 
stated otherwise.  
7.5  Biochemical Activity Assay  
Stefan Baumeister established a detergent-free activity assay system using esters of 8-
Hydroxypyrene-1,3,6-trisulfonic acid (HPTS) as substrate. 8-Octanoyloxypyrene-1,3,6-trisulfonic 
acid tri-sodium salt (OPTS) is the commercially available octanoyl ester that can be hydrolyzed by 
APT. The assay buffer contained 150 mM NaCl and 100mM K2HPO4, pH 7.4 without detergent and 
is suitable for concentrations of OPTS up to 500 mM at room temperature. 8-Palmitoyloxypyrene-
1,3,6-trisulfonic acid tri-sodium salt (PPTS) was a kind gift from Stefan Baumeister. Commercially 
available 8-Hydroxypyrene-1,3,6-trisulfonic acid tri-sodium salt (HPTS) was esterified with palmitic 
acid to create 8-Palmitoyloxypyrene-1,3,6-trisulfonic acid (PPTS). Reaction and product purification 
was performed by Stefan Baumeister. PPTS require a carrier to prevent (probably) tight micelle 
formation that inhibits hydrolysis by human APT1 at concentration higher than 20 µM. Fatty acid 
binding protein (FABP2, added in 10% molar ratio) was found to suite best without influencing 
activity of human APT1.  
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7.5.1 PPTS enzyme kinetics  
PPTS hydrolysis kinetics were measured from serial dilutions with a starting concentration of 
50.51 µM PPTS and 5.05 µM FABP2. Serial dilution of 99 µl PPTS-FABP2 solution in 99 µl assay 
buffer (see Chapter 7.5) were carried out directly in the 96 well assay plate, keeping the 10:1 molar 
ratio of PPTS to FABP2 constant in all conditions. The plate was briefly mixed using a microplate 
shaker before being transferred to an Infinite M200 microplate reader (Tecan). Fluorophore 
excitation was set to a wavelength of 415 nm and emission was detected at 520 nm. An initial 
fluorescence measurement was performed to check for a stable base line. Following the addition of 
1 µl of 500 nM protein (5 nM final protein concentration) and brief mixing of the microplate, 
fluorescence was measured in 45 s intervals for one hour at 27 ˚C. The fluorescence was corrected 
for auto-hydrolysis.  
7.5.2 Inhibitor IC50 determined in enzymatic activity assay using OPTS as substrate 
OPTS was used in the assay buffer (100 mM K2HPO4, pH 7.4 and 150 mM NaCl) as test substrate 
similarly to PPTS. OPTS has a better aqueous solubility and does not require an additional carrier. 
The assay can be used to test the potency of inhibitors and determine their IC50 towards human 
APT1, and analogously, the hexadecylated peptide was tested on its inhibitory effect using this 
protocol. First, the inhibitor in question was dissolved in assay buffer to a concentration of 1 mM, 
and 100 µl of this solution were added to the first column. The remaining columns were filled with 
50 µl of assay buffer. A serial dilution of the inhibitor was prepared by transferring 50 µl of the 
previous well using an automatic pipette, each step contained automatic mixing by pipetting a 
volume of 70 µl up and down three times. One column was left as control containing no inhibitor, 
and another contained no inhibitor or protein to measure autohydrolysis of the substrate. The 
DMSO stock solution of OPTS (100 mM) was diluted in assay buffer to a concentration of 255 µM, 
and 49 µl were added to each well. The protein was diluted to 500 nM in assay buffer, and 1 µl was 
added to each well, resulting in a final concentration of 5nM. The plate was briefly mixed using a 
microplate shaker and directly transferred to an Infinite M200 microplate reader (Tecan). Excitation 
wavelength and emission detection were set to 415 nm and 520 nm, respectively, and were 
measured in 45s intervals for 1 h.  
7.5.3 Analysis of the activity assay data 
Fluorescence was converted to concentration via a calibration curve covering the concentration 
range of HPTS formed upon complete substrate turnover. The slope of the linear range of the first 
180 s was calculated using Microsoft Excel and plotted against the concentration of PPTS and 
used to determine the Michaelis-Menten kinetics. Data was plotted and fitted using Origin Pro 9.0G.  
7.6 Stopped Flow  
The utilization of the tryptophan fluorescence as sensor for ligand binding to APT was investigated 
and established by Stefan Baumeister [unpublished results]. The intrinsic fluorescence of 
tryptophan is affected upon binding of ligands in close proximity. Human APT1 contains three 
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tryptophan residues. W32 is located on the surface at the shallow groove next to the active site; 
W67 is buried inside the protein core; and W140 forms the inner wall of the hydrophobic tunnel 
(compare Figure 10) The fluorescence of W32 and W140 change upon ligand binding next to the 
side chain at the groove and hydrophobic tunnel, respectively. Binding at either the tunnel or 
groove can be differentiated using the mutants containing the respective tryptophan while lacking 
the other. The change of fluorescence is the measured signal from which the binding rate constant 
kon can be determined.  
Standard procedure to determine the dissociation rate constant koff is a competition measurement, 
using a pre-formed complex of protein and fluorescent ligand that is competed off with a non-
labeled inhibitor used at higher concentration. As the binding sites of the protein contained the 
fluorescent label (tryptophan), equilibrium of the 2BP-protein complex was shifted using two 
different approaches. The first exploits the high affinity of 2BP towards CHAPS-micelles: by mixing 
a pre-formed hAPT1-2BP complex with a solution containing CHAPS-micelles, dissociated 2BP is 
rendered unavailable to APT by incorporation into the micelles, thereby shifting the equilibrium 
away from the complex to free APT at the rate of koff. However, koff from human APT1 could be 
affected by the interaction of APT with CHAPS micelles. In analogy to CHAPS micelles, both multi-
lamellar and uni-lamellar DOPC vesicles were used to bind free 2BP and shift the equilibrium from 
the 2BP-complex towards the free protein. The second approach is based on the competition for 
2BP with a non-fluorescent fatty acid binding protein. Trp-free human L-FABP was used in 14-fold 
excess to trap 2BP released from hAPT1 wt, shifting the equilibrium and measure the koff rate of the 
human APT1 - 2BP complex.  
7.6.1 Stopped Flow binding rate constant 
Binding rate constant kon of 2BP to human APT1 was determined at 298 K by measuring the 
change of the intrinsic tryptophan fluorescence of a 5 µM protein solution upon mixing with 50 µM 
2BP (respective final concentrations) using a Stopped Flow (Applied Photophysics). Standard gel 
filtration buffer containing 20 mM Tris-HCl pH 8.0, 30 mM NaCl, and 1 mM TCEP-HCl was used. 
DMSO concentration of protein and inhibitor solution was adjusted to 1% to prevent buffer mixing 
effects. The excitation wavelength was set to 280 nm and a 320 nm cut-off filter was used for 
detection. Photomultiplier voltage was adjusted individually for each experiment. Fluorescence was 
measured for 2 - 60 s.  
7.6.2 Stopped Flow dissociation rate constant 
A pre-formed complex of human APT1 (2.5 µM) and 2BP (10 µM), and non-fluorescent tryptophan-
free L-FABP (22.5 µM) were loaded into the respective syringes of the Stopped Flow. The 
dissociation of the human APT1 - 2BP complex upon mixing with L-FABP and consecutive L-FABP-
2BP complex formation was measured via the change of tryptophan fluorescence of human APT1. 
Alternatively, 1% v/v CHAPS or 1 mM DOPC vesicles were used as competitor. The excitation 
wavelength was set to 280 nm and a 320 nm cut-off filter was used for detection. Standard gel 
filtration buffer was used as for the measurement of the binding rate constant (see Chapter 7.6.1). 
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The DMSO content was adjusted to the same concentration in both syringes to prevent buffer 
mixing effects.  
7.6.3 DOPC Vesicles 
DOPC vesicles were created by freeze-thaw cycles as described before[146]. 157 µl of a DOPC 
stock solution (10 mg/ml in Trichloromethane) were dried in an Eppendorf tube in a Nitrogen steam 
and lyophilized over night. The dried DOPC was resuspended in 990 µl APT assay buffer 
containing 150 mM NaCl, 100 mM K2HPO4 at pH 7.4, resulting in a final concentration of 2 mM 
DOPC. The suspension was placed in an ultrasonic bath for 15 min, then flash-frozen in liquid 
nitrogen and thawed for 15 min five times before being sonicated for 5 min as the last step to create 
large multi-lamelar vesicles.  
7.6.4 Peptide Synthesis and Modification 
Peptides were synthesized by Philipp Cromm using standard Fmoc-strategy using a Rink Amide 
resin using a peptide synthesizer at the Department of Chemical Biology at the MPI Dortmund as 
described before[147]. The peptide mimics the first ten amino acids of the human APT1 N-terminus, 
which are palmitoylated at C2, (MC16CGNNMSTPL, 1290.71 Da, see Figure 113). A self-
synthesized building block of the hexadecylated cysteine was used. While the C-terminus is 
amidated, the N-terminus of the peptide is unmodified to significantly increase solubility. Following 
synthesis, the peptide was cleaved from the resin using a mixture of 95% TFA, 2.5% TIPSI and 
2.5% H2O as cleaving solution. The peptide was precipitated at -20 ˚C in acetone and the 
supernatant removed. The washed pellet was taken up in cleaving solution, which was transferred 
to a round bottom flask and lyophilized. Dried powder was taken up in DMF and purified via HPLC. 
The pure product was taken up in water and diluted to a concentration of 25 mM.  
7.7 Calculation of the free solvation energy using PISA 
PISA[97] (part of CCP4I suite[101]) is a program that calculates the theoretical entropy gained (free 
solvation energy, ΔG) upon complex formation of interfaces of macromolecular assemblies found in 
crystal structures, and provides a prediction of the stability in solution, and thus of the biological 
relevance of the respective interface. The free solvation energy is affected by multiple factors; 
some of these are the size of the interface area, surface charge and hydrophobicity, distance, and 
complementary of the surface shape[97].  
The standard setting of PISA is suitable to predict dimerization/oligomerization of APT via different 
crystal interfaces. For the calculation of the interaction strength of the lid-loop of different mutants of 
human APT1, the lid-loop needs to be treaded by PISA as a second molecule. Thus, the lid-loop 
was separated in silico from the core protein by deletion of amino acids D69 and D80 of the hinge 
region of human APT1 wild type and changing the chain ID.  
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Table 27: Tabular overview of the structures presented in this thesis. The structures of human APT1 M60S and 
human APT1 ΔM60 (both as apo form and 2BP complex) were solved and refined by Darius Bothe in his master 
thesis[100] under my supervision. 
Protein 
Space 
group 
Unit cell (a, b, 
c, [Å]) 
Unit cell (α, β, 
γ, [Å]) 
Monomers per 
asymmetric unit 
Resolution 
[Å] 
Yeast APT apo P212121  
44.70, 45.94, 
91.22 90, 90, 90 1 1.44 
Yeast APT + 
Palmostatin B P212121  
44.34 45.26 
90.21 90, 90, 90  1 1.70 
Yeast APT + 
Palmostatin M 
P42212 
145.6, 145.6, 
96.8 90, 90, 90 4 2.40 
Human APT1 + 
Cerulenin 
P42212 
91.15 91.15 
255.53 90, 90, 90 4 2.50 
Human APT1 + 2-
Bromopalmitate 
P21 
72.59 62.08 
114.67 90, 106.13, 90 4 1.60 
Human APT1 L171A P21 
76.88, 
55.50, 
101.55 
90, 112.05, 90 4 2.20 
Human APT1 L171V P1 38.5, 40.9, 71.9 
102.1,95.6, 
106.2 
2 1.28 
Human APT1 L58A C2 181.52, 79.73, 154.94 
90.00, 124.57, 
90.00 
8 2.62 
Human APT1 L73A P21 
35.65 57.41 
47.92 
90.00, 98.76 
90.00 1 1.60 
Human APT1 L73A + 
2BP 
P212121 
73.97, 109.70, 
109.79 90, 90, 90 4 1.85 
Human APT1 +LP P21 
36.37 59.44 
49.55 
90.0 100.03 
90.0 1 2.00 
Human APT1 
ΔL73S74 
C2 
106.57, 
105.23, 
143.74 
90.0, 92.88, 
90.0 8 2.55 
Human APT1 
ΔL73S74 + 2BP 
C2 139.37, 57.71, 64.33 
90.0, 92.71, 
90.0 2 1.62 
Human APT1 
ΔS74P75 
P21 
36.47, 58.46, 
49.63 
90.0, 100.96, 
90.0 1 1.85 
Human APT1 M60S 
apo P212121 
70.85, 77.83, 
143.55 
90.0, 90.0, 
90.0 4 1.95 
Human APT1 M60S 
+ 2BP 
P21 
72.17, 61.63, 
114.08 
90.0, 101.98, 
90.0 4 1.85 
Human APT1 ΔM60 
apo 
P1 39.66, 39.67, 69.70 
86.95, 88.91, 
63.95 2 1.34 
Human APT1 ΔM60 
+ 2BP 
P1 39.71, 39.76, 69.87 
89.07, 87.10, 
63.92 2 1.56 
Human APT1 
ΔM60+M202A 
(crystal1) 
P1 41.64, 68.18, 76.23 
112.15 104.31 
89.91 4 2.22 
Human APT1 
ΔM60+M202A 
(crystal2) 
C2 68.00, 41.46, 71.96 
90.00, 94.68, 
90.00 1 2.22 
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Table 28: List of programs used in this thesis 
Program Source Application 
iMosflm 
http://www.mrc-
lmb.cam.ac.uk/harry/imosflm/ver721/introd
uction.html [132] 
Data collection strategy 
XDS Package http://xds.mpimf-heidelberg.mpg.de/ [134] 
Diffraction data indexing, 
integration and reduction 
CCP4I package http://www.ccp4.ac.uk/ccp4i_main.php [101] 
Program suite for protein 
crystallography 
   PhaserMR http://www.ccp4.ac.uk/ccp4i_main.php [137] Phasing X-ray data 
   Refmac5 http://www.ccp4.ac.uk/ccp4i_main.php [138] Structure model refinement 
   PISA http://www.ebi.ac.uk/pdbe/pisa/ [97] Interface analysis 
Coot 
http://www2.mrc-
lmb.cam.ac.uk/personal/pemsley/coot/ [139]  
Structure refinement and 
validation 
Phenix package http://www.phenix-online.org/ [145]  
Program suite for protein 
crystallography 
   Xtriage http://www.phenix-online.org/ [136]  
Diffraction data quality 
analysis 
   eLBOW http://www.phenix-online.org/ [144]  
Generating geometry 
restraints for ligands 
ChemBioDraw PerkinElmer, Inc [143]  Chemical drawing 
MolProbity http://molprobity.biochem.duke.edu/ [141]  Structure validation 
CCP4mg http://www.ccp4.ac.uk/MG/ [93] Structure representation 
Gimp http://www.gimp.org/ [4] 
Image manipulation and 
annotation 
MagTran [92] Mass Spectrometry  
 
Table 29: List of webservers and data banks used in this thesis. 
Server / data bank name  Web address   
PISA http://www.ebi.ac.uk/pdbe/pisa/ [97] 
Analysis of protein interface in 
crystals 
Orientations of Proteins in 
Membranes (opm)  
http://opm.phar.umich.edu/ [102] 
Prediction of protein insertion into 
biomembranes 
Protein Data Bank (PDB)  http://www.wwpdb.org/ [148] 
Data bank for three-dimensional 
protein structures 
Hetero-compound Information 
Centre – Uppsala (HIC-Up) 
http://xray.bmc.uu.se/hicup/ [142] 
Structures of hetero compounds 
used in structural biology 
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Figure 116: Exemplary measurement of the dissociation rate of human APT1 wild type (5 µM) and 2BP (20 µM) 
using CHAPS (1%) as competitor. The data can be fitted using a single rate constant in the range of 34 s-1. The 
noise has a frequency of 50 Hz, unfortunately, the electrical consumer causing this interference is unknown. 
Screenshot of Pro-Data software (Applied Photophysics) used for data fitting of Stopped Flow measurements.  
 
Figure 117: Exemplary measurement of the dissociation rate of human APT1 wild type (5 µM) and 2BP (20 µM) 
using L-FABP (45 µM) as competitor. The higher dissociation rate constant was estimated in the range of koff = 50 
s-1 (probably corresponding to 2BP unspecifically bound next to W32 at the groove) compared to koff = 3 s-1 (2BP 
bound inside the tunnel), but has a smaller contribution to the overall signal (-0.32 versus -0.45, respectively). 
The noise has a frequency of 50 Hz, unfortunately, the electrical consumer causing this interference is unknown. 
Screenshot of Pro-Data software (Applied Photophysics) used for data fitting of Stopped Flow measurements.  
 
